



PARIS
17-20 SEPTEMBER 2025

PROGRAMME
BOOKLET

Editorial / Publisher

European Academy of Dermatology and Venereology (EADV)

Further information about the event

eadv.org

eadv.org/congress

Download the official app!

Get instant access to the full scientific programme, abstracts, ePosters, session surveys, industry sessions, and the latest news before, during and after the meeting! Interactions during sessions will be facilitated by the EADV app, allowing you to send questions, vote and evaluate.



On-demand content

Play all the scientific sessions on demand

Scientific programme

Access the full programme and create your own agenda

Abstracts and ePosters

Access the latest research

Certificates

Download your certificates

Session evaluations

Evaluate sessions and gain credits

Interactivity

Participate to sessions, answer polls and ask your questions

Learn more

eadv.org/congress/app/

Join the conversation

#EADVCongress



Table of contents

Table of contents.....	3
Welcome from the EADV President	4
Welcome from the EADV Scientific Programming Committee.....	5
The Academy.....	6
Continuing medical education – Continuing professional development (CME-CPD)	7
Abstract reviewers.....	8
Subspecialty and international societies	9
Scientific programme	10
Session tracks.....	10
Wednesday, 17 September 2025	12
Networking symposium	49
Thursday, 18 September 2025	50
Friday, 19 September 2025	84
Saturday, 20 September 2025.....	114
Practical workshops.....	142
Patient organisations area	145
General information.....	146
Internet access / Wi-Fi.....	146
Onsite facilities and opening hours	147
Official language.....	148
Scientific sessions.....	148
Abstracts and ePosters	149
Exhibition hall	149
Other services	150
Childcare facility	150
First aid room and emergency numbers	150
Privacy.....	151
The venue.....	152
Registration.....	156
EADV Congress ticket types	156
Press information for journalists and media representatives.....	157
Healthcare professional information and definition	158
Exhibition	159
Exhibitor list.....	160
Exhibition floor plan.....	161
Main sponsors.....	162
Acknowledgements.....	163

Welcome from the EADV President

Dear Colleagues, Friends, and Esteemed Members of the EADV Community,

It is with great pride and anticipation that I welcome you to the **EADV Congress 2025**, set against the vibrant backdrop of **Paris**—a city synonymous with elegance, culture, and innovation. As we gather at the Paris Convention Centre, we unite once again to celebrate the very best in dermatology and venereology.



This year's Congress promises to be our most dynamic yet. With **over 180 scientific sessions, 600+ expert speakers, 25+ dedicated subspecialty tracks, and 10 powerful plenary lectures**, our programme reflects the incredible depth and breadth of our field. We are especially excited to host **abstract-based free communications, late-breaking research highlights, and a residents-targeted session**, ensuring opportunities for every level of expertise and interest. And of course, we look forward to the **second edition of the EADV Games**, where science meets a fun rivalry.

Our robust scientific agenda is complemented by a vast exhibition area—an interactive space to explore cutting-edge technologies, treatments, and products that are shaping the future of patient care. It is here that science meets innovation, and where collaboration is born.

Importantly, this year marks a significant step forward in our **commitment to sustainability**. The EADV is proud to integrate eco-conscious initiatives throughout the Congress, from **recyclable materials and digital signage to sustainable catering and climate-focused scientific sessions**. In partnership with industry leaders and through thoughtful logistical planning—including **a transportation pass for all full-congress delegates**—we aim to reduce our environmental footprint and set new standards for responsible event management.

We invite all attendees to participate in our climate awareness survey and join the dialogue on how dermatology intersects with the changing global environment. Together, we are shaping not only the future of our specialty but contributing to a more sustainable world.

Whether you are attending your first EADV Congress or are a returning participant, I encourage you to make the most of every session, every conversation, and every opportunity this Congress offers. Let Paris inspire your curiosity, challenge your thinking, and reignite your passion for the work we do.

On behalf of the **EADV Executive Committee**, welcome to EADV Congress 2025. Let this gathering be a celebration of our shared purpose, a platform for progress, and a powerful testament to the strength of our global community.

With Warmest regards,

A handwritten signature in black ink, reading "Branka Marinović". The signature is fluid and cursive, with a large initial 'B'.

Prof. Branka Marinović
EADV President

Welcome from the EADV Scientific Programming Committee

Dear Colleagues,

We are excited to welcome you to the 34th EADV Congress in Paris! This year's event brings together science, clinical excellence, and innovation to shape the future of dermatology and venereology. With more than 600 expert speakers and record-breaking participation, the Congress promises to be a truly inspiring experience.

The scientific program features our core tracks, Updates, Training and Education, and Controversies, along with Focus on sessions dedicated to key global challenges: sexually transmitted infections, pigmentation disorders, and hair disorders. New topics this year include off-label use of medications, emerging viral infections, personalized approaches in clinical practice, global health, nutrition and dermatology, and a joint EADV/JDA session on faces of skin diseases from East to West.

Highlights include the second edition of the EADV GAMES, dedicated resident case presentations, and The Hot Seat, where residents challenge international experts. The plenary sessions will showcase advances in inflammatory skin diseases, genetics, infectious diseases, systemic therapies, and cutting-edge technologies such as robotics and artificial intelligence.

We are honored to open with a keynote lecture by Lucy Cooke, renowned zoologist, author, and broadcaster, who will share unique lessons from the natural world on behavior, evolution, and leadership.


With more than 5,300 abstract submissions, the latest research will be presented in Late-Breaking News sessions, Free Communications, and ePoster showcases. Hands-on Workshops, Subspecialty Sessions, and Controversies sessions will round out a diverse and stimulating program.

For those unable to attend in person, the Congress will be fully live-streamed, making it accessible worldwide.

Join us in Paris, or online, for what promises to be an unforgettable 34th EADV Congress.

With warm regards,

The EADV Scientific Programming Committee



Michel Gilliet

Chair of the Scientific Programming
Committee, EADV

EADV Scientific Programming Committee:

Michel Gilliet
Jo Lambert
Paola Pasquali
Lidia Rudnicka
Eli Sprecher
Thrasylvoulos Tzellos

The Academy



EADV is committed to building the international community that develops, shares, and adopts best practices within dermatology and venereology.

With over 13'000 members and an active community of more than 30'000 professionals around the world, our goal is to be the trusted source for proven scientific advancements and practices in the prevention, diagnosis, and treatment of skin and venereal diseases.

Skin and venereal diseases are continuously evolving, as are the science and practices for preventing, diagnosing, and treating them. Advancements are being made every day that have the potential to have a significant impact on the ongoing battle to improve skin and sexual health around the world. Enabling these advancements to be validated and ensuring all professionals adopt the best practices ultimately moves dermatology and venereology forward.

EADV and its international community of passionate professionals define and spread best practices in dermatology and venereology for the benefit of all. We are a true platform for collaboration and progress across borders and sub-specialties.

Expert task forces shape standards and develop best practice guidelines, while our events, publications, and educational courses share them with our members and the broader community so they can adopt them for maximum impact.

 **VISIT EADV.ORG**

Continuing medical education – Continuing professional development (CME-CPD)

The EADV Congress 2025 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **26.0 European CME credits (ECMEC®s)**. CME Credits Each medical specialist can claim only those hours of credit actually spent in the educational activity (as recorded by the scanning process or online access). Here below find the breakdown of credits per day:

Wednesday, 17 Sep 2025	6.5	<p>The accreditation system is based on 1 ECMEC per hour.</p> <p>No credits will be provided for the following sessions: industry sessions, subspecialty sessions, allied healthcare professionals workshop, ePoster showcases, Residents track and EADV Games.</p>
Thursday, 18 Sep 2025	6.5	
Friday, 19 Sep 2025	6.5	
Saturday, 20 Sep 2025	6.5	



Procedure to gain your credits

Scan your badge, complete the evaluation forms and download the CME-CPD Certificate.

The EADV offers individual CME-CPD participation through the scanning of the bar code and the speaker/session evaluation that will be available for a period of 3 months after the end of the Congress (until 31 December 2024).

1. Scan your badge as you pass through the entrance of each session hall (or access the session online, live or on-demand).
2. Complete the anonymous online evaluation form for each attended session. Access the evaluation system in the “My Congress” area on the online Congress platform.
3. Download your CME-CPD certificate and retain it for your personal records.

Evaluation data is essential to our statistics and is of considerable help in the choice of future topics and speakers. Your feedback and comments are greatly appreciated.

Conversion of credits

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at edhub.ama-assn.org/pages/applications

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Information regarding the conversion of EACCME® credits

Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at edhub.ama-assn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other healthcare professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority

Abstract reviewers

EADV is grateful to the following reviewers who have given their time and expertise in reviewing the submitted abstracts:

Badawi, Ashraf	Flohr, Carsten	Olszewska, Malgorzata
Balieva, Flora	Fritz, Klaus	Olteanu, Rodica
Basic, Marcela	Gelmetti, Carlo	Pereira, Manuel
Bata-Csorgo, Zsuzsanna	Gieler, Uwe	Pesqué, David
Bataille, Veronique	Giménez-Arnau, Ana	Peternel, Sandra
Bauer, Andrea	Hadj-Rabia, Smail	Pincelli, Carlo
Bauer, Johann	Hafner, Jürg	Podlipnik, Sebastian
Beliauskiene, Aiste	Heller-Vitouch, Claudia	Preto Gomes, Nuno Miguel
Bewley, Anthony	Hijnen, Dirk Jan	Reich, Adam
Bilgic, Aslı	Horvath, Barbara	Roque Ferreira, Bárbara
Bimbi, Cesar	Ioannides, Dimitrios	Sar-Pomian, Marta
Bobko, Svetlana	Iorizzo, Matilde	Schmuth, Matthias
Böhler, Kornelia	Kandolf-Sekulovic, Lidija	Simeonovski, Viktor
Calzavara-Pinton, Piergiacomo	Katoulis, Alexander	Simon, Dagmar
Carrascosa, Jose-Manuel	Kazandjieva, Jana	Siskou, Styliani
Carugno, Andrea	Kluger, Nicolas	Skerlev, Mihael
Chernyshov, Pavel	Kolyadenko, Kateryna	Soares de Almeida, Luis Miguel
Conde, Elena	Koumaki, Dimitra	Sollena, Pietro
Corrà, Alberto	Krastev, Dimitar	Soura, Efthymia
Crisan, Diana	Kuhn, Annegret	Srinivasan, Sundaramoorthy
Csoma, Zsanett Renáta	Laubach, Hans-Joachim	Stolz, Wilhelm
Dahmen, Robert Artur	Liakou, Aikaterini I.	Szepietowski, Jacek
Damiani, Giovanni	Liopyris, Konstantinos	Tasanen, Kaisa
Dessinioti, Clio	Lvov, Andrey	van der Zee, Hessel
Didona, Dario	Manolache, Liana Laurentia	Velthuis, Peter
Doss, Nejib	Marzano, Angelo Valerio	Vestergaard, Christian
Drenovska, Kossara	Mijakoski, Dragan	Vink, Liselot
El Hachem, May	Misery, Laurent	Vorobyev, Artem
Esdaile, Ben	Monnier, Jilliana	Warren, Richard B.
Faisal, Aheen	Moody, Brent	Wikonkal, Norbert
Fattore, Davide	Navarrete-Dechent, Cristian	Zink, Alexander
Fida, Monika	Neumann, H.A. Martino	Zuberbier, Torsten
Finlay, Andrew Y.	Nikkels, Arjen Fokko	
	Nisavic, Milos	

Subspecialty and international societies

The following societies develop and manage scientific sessions during the EADV Congress 2025 after approval from the EADV Scientific Programming Committee.

Each society has a specific focus on a dermatological topic and offers important insights into the latest developments in that field.

- ASDV - African Society of Dermatology and Venereology
- CILAD - Colegio Ibero-Latinoamericano de Dermatología
- EDS - Emirates Dermatology Society
- EDDs - Epidermal Differentiation Disorders Group
- Euromelanoma
- EHSF - European Hidradenitis Suppurativa Foundation
- ENS - European Nail Society
- ERN-Skin - European Reference Network
- ESCAD - European Society for Cosmetics and Aesthetic Dermatology
- ESDaP - European Society for Dermatology and Psychiatry
- ESLD - European Society for Lasers and Energy-Based Devices
- EURO-PDT - European Society for Photodynamic Therapy in Dermatology
- ESDP - European Society of Dermatopathology
- ESPD - European Society of Photodermatology
- ETFAD - European Task Force of Atopic Dermatitis
- EWDVS - European Women Dermatological and Venereological Society
- GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
- IADVL - Indian Association of Dermatologists, Venereologists and Leprologists
- IDS - International Dermoscopy Society
- IDEOM – International Dermatology Outcome Measures
- IEC - International Eczema Council
- IPS - International Peeling Society
- IPC - International Psoriasis Council
- ISD - International Society of Dermatology
- MEIDAM - Middle East International Dermatology and Aesthetic Medicine
- PALD - Pan Arab League of Dermatology
- SSDDS - Saudi Society of Dermatology and Dermatologic Surgery
- SPIN-FRT - Skin Inflammation & Psoriasis International Network, action of the Fondation René Touraine
- SOCS - Skin Of Color Society
- SFLD - Société Française des Lasers en Dermatologie
- SFED - Société Française d'Esthétique en Dermatologie
- WDS - Women's Dermatologic Society
- WDC - Worldwide Dermatology Collaboration

Scientific programme

The scientific programme has been organised on full or half-day tracks; each track has a specific topic and a structured programme. Entry will be made on a first-come, first-served basis.

Session tracks

Sessions of different formats will cover the important fields of dermatology and venereology. Subjects will be treated with different approaches and from different perspectives. The following session types will be scheduled throughout the duration of the Congress and are available to all registered participants.

- **Plenary sessions:** Plenary lectures are EADV show-case sessions and include key-note lectures delivered by eminent scientists and doctors.
- **Focus on:** These sessions aim at providing comprehensive in-depth coverage of a certain topic in dermatology. The talks will be included in sessions on pathophysiology / epidemiology, clinical challenges, or practical aspects of disease management and will provide the latest cutting-edge information.
- **Updates:** These sessions will enable participants to update their knowledge on a specific topic and hear about the most relevant and recent developments, guidelines and practical knowledge from the past year. The talks will summarize the current understanding of the subject, followed by an update on the most recent novelties with their impact on clinical practice.
- **Controversies:** Controversial topics in dermatology will be discussed from different points of view in the form of a debate, giving delegates extensive insights into the latest findings.
- **Training and education:** These lectures focus on a specific disease and include basic information about epidemiology, pathophysiology, diagnosis, management and prognosis. The target audience of these sessions is young dermatology trainees and residents, as well as dermatologists that want to refresh their basic knowledge on specific topics.
- **Free communications:** Authors of the most highly ranked abstracts assessed by a selected panel of abstract reviewers are invited to provide a 10-minute oral presentation.
- **Miscellaneous:** The miscellaneous track includes sessions organised and delivered by groups, task forces and committees other than the EADV Committee, such as the Project Proposal Review Committee, the Ethics Committee or the JEADV.

Scientific programme

-  **ePoster showcase:** A selection of the best ePosters made by the scientific programming committee will be orally presented in the ePoster Showcase (EPS) sessions. In addition to submitting their ePosters, the authors will have the possibility to present their findings to the audience in a 7-minutes oral presentation. Each of the six ePoster showcase sessions will be structured with a series of 12 ePoster oral presentations, followed by a final Q&A closure of 6 minutes.
-  **Subspecialty sessions:** Subspecialty and International Society meetings are scientific sessions developed and managed by the individual societies after approval from the EADV Scientific Programming Committee.
-  **EADV Games:** The EADV will host a quiz for residents during the congress, an event which will gather 18 European countries to compete against each other in a thrilling quiz focusing on various Dermatology topics.
-  **Workshops*:** Workshops are a great opportunity to immediately implement newly learned skills, to gain practical experience and quickly acquire knowledge on the subject. Workshops also promote interaction between instructors and participants.
-  **Allied healthcare professionals workshops:** A dedicated workshop series designed specifically for allied healthcare professionals. On Saturday, we will feature an entire track dedicated to Nurses, offering valuable insights, and opportunities for networking.

* All Workshops require a pre-registration and a pre-payment. Class sizes are limited to 35 places each and registrants are accepted on a first-paid, first-served basis. More info eadv.org/congress/scientific/workshops

Wednesday, 17 September 2025

Plenary	12:00 – 13:00	17:45 – 19:00
Paris Nord	Plenary Lectures A	Plenary session with keynote lecture

Room	08:30 – 10:00	10:15 – 11:45	14:15 – 15:45	16:00 – 17:30
Paris Nord			Late breaking news	Late breaking news
Paris Sud	European Task Force on Atopic Dermatitis (ETFAD)	European Society for Cosmetics and Aesthetic Dermatology (ESCAD)	Focus on STIs	Focus on STIs
N01	European Reference Network (ERN-Skin)	Epidermal Differentiation Disorders (EDDs) group	Psoriasis	Psoriasis
N04	International Psoriasis Council (IPC)	International Dermoscopy Society (IDS)	Acne	Hair disorders
N02	European Society for Lasers and energy based Devices (ESLD)	Skin Inflammation & Psoriasis International Network, action of the Fondation René Touraine (FRT-SPIN)	Oral diseases	Pregnancy and skin diseases
N03	Skin of Color Society (SOCS)	Women's Dermatologic Society (WDS)	JAK inhibitors	Vitiligo
S01	Pan Arab League of Dermatology (PALD)	Saudi Society of Dermatology and Dermatologic Surgery (SSDDS)	Dermatology in skin of colour patients	Dermatology in skin of colour patients
S02	Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)	European Nail Society (ENS)	Skin and systemic diseases	Rosacea
S03	European Society for Photodermatology (ESPD)	Latin American College of Dermatology (CILAD)	Emerging technologies and procedures	Emerging technologies and procedures
S04	Emirates Dermatology Society (EDS)	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)	Dermato-endocrinology	Vasculitis and vasculopathies
S05	African Society of Dermatology and Venereology (ASDV)	European Hidradenitis Suppurativa Foundation e.V. (EHSF)	Lasers and energy-based devices, Practical aspects of basics	Lasers and energy-based devices II: Advanced, including complications management
S06	European Society for Photodynamic Therapy (EURO-PDT)	Medical Excellence in Dermatology and Aesthetic Medicine (MEIDAM)	Skin ageing and rejuvenation	Geriatric dermatology
W05-W06	Euromelanoma	International Society of Dermatology (ISD)	Clinical-pathological correlation	Clinical-pathological correlation
W03-W04			Skin diseases in Latin America	Skin diseases named after pioneering French dermatologists
W07	[Workshop] Dermal Fillers		[Workshop] Allergology: skin environmental induced contact dermatitis and urticaria	
W08	[Workshop] STI diagnosis and treatment		[Workshop] Basics of ultrasound imaging in dermatology	
	ePoster showcase		ePoster showcase	

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **Paris Sud**

	European Task Force on Atopic Dermatitis (ETFAD) session Chairs: Magdalena Trzeciak (Gdansk, Poland) Andreas Wollenberg (Munich, Germany) Dirk Jan Hijnen (Rotterdam, Netherlands)
08:30	Atopic dermatitis and eczema of the elderly are distinct entities: Different patterns of patient history, clinical presentation, and diagnostic findings Susanne Radonjic (Bern, Switzerland)
08:37	Discussion Susanne Radonjic (Bern, Switzerland)
08:39	Chronic hand eczema is a type 2 disease: Evidence from integrated clinical trial and molecular profiling Marie Tauber (Pierre-Bénite, France)
08:46	Discussion Marie Tauber (Pierre-Bénite, France)
08:48	Abrocitinib treatment restores epidermal integrity and barrier function in atopic dermatitis Jan Hartmann (Kiel, Germany)
08:55	Discussion Jan Hartmann (Kiel, Germany)
08:57	Turnover of basement-membrane and epidermal associated collagens is increased in atopic dermatitis patients with inadequate response to dupilumab Magnus Kær Nørgaard Have (Copenhagen, Denmark)
09:04	Discussion Magnus Kær Nørgaard Have (Copenhagen, Denmark)
09:06	Effectiveness and safety of dupilumab versus tralokinumab in atopic dermatitis: A propensity score– matched analysis from the BioDay registry Lian van der Gang (Utrecht, Netherlands)
09:13	Discussion Lian van der Gang (Utrecht, Netherlands)
09:15	Patients with and without head-neck dermatitis treated with dupilumab in the TREATgermany population Annice Heratizadeh (Hannover, Germany)
09:22	Discussion Annice Heratizadeh (Hannover, Germany)
09:24	Successful dose reduction of Janus-kinase inhibitors in well-controlled atopic dermatitis: A prospective, multicenter, real-world study Anne Schlösser (Amsterdam, Netherlands)
09:31	Discussion Anne Schlösser (Amsterdam, Netherlands)

09:33	Association between novel systemic immunomodulatory medications and achievement of super-response in patients with moderate-to-severe atopic eczema: Results from the UK-Irish Atopic eczema Systemic Therapy Register (A-STAR) Carsten Flohr (London, United Kingdom)
09:40	Discussion Carsten Flohr (London, United Kingdom)
09:42	A DELphi survey on narrowband ultraviolet B phototherapy for ATopic Eczema (DEBATE): Consensus on clinical practices Eva Knöps (Amsterdam, Netherlands)
09:49	Discussion Eva Knöps (Amsterdam, Netherlands)
09:51	Analysis of the survey on the role of artificial intelligence in the management of atopic dermatitis Jean François Stalder (Nantes, France)
09:58	Discussion Jean François Stalder (Nantes, France)

Track: **Subspecialty**

Room **Paris Sud**

	European Society for Cosmetics and Aesthetic Dermatology (ESCAD): News in cosmetic and aesthetic dermatology Chairs: Peter Velthuis (Rotterdam, Netherlands) Miray Al-Mustafa (Oslo, Norway) Armanda Onderdijk (The Hague, Netherlands)
10:15	Filler complications protocols Peter Velthuis (Rotterdam, Netherlands)
10:30	New facts on calcium-hydroxyl-apatite fillers Zainab Akbar (Kuwait, Kuwait)
10:45	Vessels and fillers Sara Khoshnaw (Rotterdam, Netherlands)
11:00	Laser for hair growth Keyvan Nouri (Miami, United States)
11:15	Treatment methods in cosmetic dermatology many doctors do not know about Peter Velthuis (Rotterdam, Netherlands)
11:30	Science bites 2025: What's next in cosmetic dermatology —Tools, tech & translational frontiers Hema Sundaram (Rockville, United States)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **N01**

	European Reference Network (ERN-Skin): Rare, low prevalence and complex skin diseases Chairs: Christine Bodemer (Paris, France) Johann Bauer (Salzburg, Austria) May El Hachem (Rome, Italy)
08:30	ERN-Skin overview & best achievements Christine Bodemer (Paris, France)
08:40	Clinical cases on rare skin disorders not rarely seen in daily practice: (1) Ectodermal dysplasias and immune deficiency Johann Bauer (Salzburg, Austria)
08:47	Clinical cases on rare skin disorders not rarely seen in daily practice: (2) An unusual complication of a giant congenital melanocytic nevus Maya El Hachem (Rome, Italy)
08:54	Clinical cases on rare skin disorders not rarely seen in daily practice: (3) An unusual case of JEB with an evolution to a BP Biagio Didona (Rome, Italy)
09:01	Clinical cases on rare skin disorders not rarely seen in daily practice: (4) Severe pulmonary evolution in a paediatric case of TEN: A new therapeutic perspective Lea Jaume (Paris, France)
09:08	Rare skin diseases & sleep disorders Brigitte Faroux (Paris, France)
09:33	Rare skin diseases patient outcomes Marie-Claude Boiteux (France)
09:43	Test your knowledge on rare skin diseases: WCRSD26 free registration for the winner Johann Bauer (Salzburg, Austria)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **N01**

	Epidermal Differentiation Disorders (EDDs) group: From genes to clinics: The truth about EDDs in 90 minutes (ichthyosis, palmoplantar keratoderma, Darier disease, Hailey Hailey disease, CARD14) Chairs: Julia Maria Käthe Clabbers (Maastricht, Netherlands) Antoni Gostynski (Maastricht, Netherlands) Ángela Hernández-Martín (Madrid, Spain)
10:15	New EDD classification: Introduction and palmoplantar EDDs Edel O'Toole (London, United Kingdom)
10:25	New EDD classification: Non-syndromic EDDs and syndromic EDDs Judith Fischer (Freiburg, Germany)
10:35	Updated management guidelines for congenital ichthyosis Juliette Mazereeuw-Hautier (Toulouse Cedex 9, France)
10:45	New in EDD group: ATP2A2-nEDD (Darier disease) and ATP2C1-nEDD (Hailey-Hailey disease) Roni Dodiuk-Gad (Haifa, Israel)
10:55	Clinical and genetic characterization of palmoplantar EDDs Stine Bjørn Gram (Odense, Denmark)
11:05	Quality of life in EDDs and reproductive dilemmas Fauve van Veen (Maastricht, Netherlands)
11:15	Future therapies in EDDs Amy Paller (Chicago, IL, United States)
11:25	Summary of EDD expert meeting and future research agenda Eli Sprecher (Tel Aviv, Israel)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **N04**

	International Psoriasis Council (IPC): Psoriasis and its unique challenges Chairs: Mahira El Sayed (Cairo, Egypt) Jose-Manuel Carrascosa (Badalona, Spain)
08:30	Welcome and introduction Mahira El Sayed (Cairo, Egypt)
08:33	Overview of differential diagnosis Bruce Strober (Cromwell, CT, United States)
08:47	Case presentation: Differential diagnosis Lily Lyralin Tumalad (Manila, Philippines)
08:53	Addressing the itching and pain of psoriasis Martin Steinhoff (Doha, Qatar)
09:07	Case panel discussion: Psoriasis symptoms José Riera Monroig (Barcelona, Spain) Romina Contreras (Asuncion, Paraguay)
09:19	Psoriasis in darker skin tones Angela Maria Londoño-Garcia (Envigado, Colombia)
09:33	Psoriasis in the elderly Peter C.M. Van de Kerkhof (Eefde, Netherlands)
09:47	Case panel discussion: Special populations María Julia Cura (Buenos Aires, Argentina) Priscilla Angwenyi (Nairobi, Kenya)
09:59	Closing comments Jose-Manuel Carrascosa (Badalona, Spain)

Track: **Subspecialty**

Room **N04**

	International Dermoscopy Society (IDS): Session on dermoscopy Chairs: Caterina Longo (Modena, Italy) Zoe Apalla (Thessaloniki, Greece) John Paoli (Gothenburg, Sweden)
10:15	Melanoma and prognosis Aimilios Lallas (Thessaloniki, Greece)
10:35	RADICAL study: Practical implications Pascale Guitera (Wollstonecraft, Australia)
10:55	Lentigo maligna: IDS guidelines Ana-Maria Forsea (Bucharest, Romania)
11:15	My favourite dermoscopy topic Giuseppe Argenziano (Naples, Italy)
11:35	Discussion

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **N02**

	European Society for Lasers and energy based Devices (ESLD): Lasers and energy based devices updates 2025 Chairs: Ashraf Badawi (Oakville, Canada) Albert Wolkerstorfer (Amsterdam, Netherlands) Johan Snauwaert (Brasschaat, Belgium)
08:30	1064nm laser, what can be done in the periocular area Fouad Makhoul (Paris, France)
08:39	Laser light: Illuminating new paths in scars Louai Salah (Jeddah, Saudi Arabia)
08:48	Role of lasers in dermatological manifestations of immunological diseases Abeer Tawfik (Egypt)
08:56	10 years experience of laser assisted PDT in the treatment of skin cancer Johan Snauwaert (Brasschaat, Belgium)
09:05	Incorporating laser-assisted drug delivery into your clinical practice Merete Haedersdal (Copenhagen, Denmark)
09:14	Lasers in skin tumours, current evidence Ahmed Sadek (Cairo, Egypt)
09:23	The incredible evolution of Q- switched and picosecond lasers in dermatology: LIOB and beyond Leonardo Marini (Trieste, Italy)
09:32	Tips and tricks for managing dysmorphic concerns and reducing malpractice in laser clinics Cemre Turk (Rochester, United States)
09:41	I need to buy a laser or energy based device, how to decide which one should I buy? Ashraf Badawi (Oakville, Canada)
09:50	Selected cases from the ESLD forum Albert Wolkerstorfer (Amsterdam, Netherlands)

Track: **Subspecialty**

Room **N02**

	Skin Inflammation & Psoriasis International Network, action of the Fondation René Touraine (SPIN-FRT): A SPINning wheel - Immunoregulation in cutaneous inflammation Chairs: Wolf-Henning Boehncke (Geneva, Switzerland) Phyllis I. Spuls (Amstelveen, Netherlands)
10:15	SPIN – Who we are, and what is in there for you? Wolf-Henning Boehncke (Geneva, Switzerland)
10:25	Immune dysregulation in the pathophysiology of inflammation Graham Ogg (Oxford, United Kingdom)
10:45	Round table discussion: Evidence for immune dysregulation in cutaneous IMIDs Phyllis I. Spuls (Amstelveen, Netherlands)
11:00	Immunoregulation as a strategy to treat inflammation David Klatzmann (Paris, France)
11:20	A novel approach to treat vitiligo through immunomodulation Antonios Kolios (Zurich, Switzerland)
11:30	Round table discussion: New modes of action and new treatment goals in the management of cutaneous IMIDs Wolf-Henning Boehncke (Geneva, Switzerland)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **N03**

	Skin of Color Society (SOCS): Global perspectives in skin of color Chairs: Susan Taylor (Philadelphia, United States) Michelle Rodrigues (Mulgrave, Australia)
08:30	SOCS Presentation
08:35	Inflammatory dermatoses: Nuances in clinical presentation and advances in treatment Andrew F. Alexis (New York, United States)
08:49	Photoprotection in individuals with skin of color Henry Lim (Michigan, United States)
09:03	Unmasking facial hyperpigmentation in richly pigmented skin types Michelle Rodrigues (Mulgrave, Australia)
09:17	Scarring alopecia: Diagnostic clues and nuances Susan Taylor (Philadelphia, United States)
09:31	From factory to follicle: The chemical footprint of synthetic hair Ncoza Dlova (Durban, South Africa)
09:45	Q&A

Track: **Subspecialty**

Room **N03**

	Women's Dermatologic Society (WDS): WDS Parade of Roses Chair: Cheryl Rosen (Toronto, Canada)
10:15	Welcome Cheryl Rosen (Toronto, Canada)
10:20	Drug induced bullous eruptions Aikaterini Patsatsi (Thessaloniki, Greece)
10:35	New therapies for atopic dermatitis Melinda Gooderham (Peterborough, ON, Canada)
10:50	Gums to gut: Oral manifestations of inflammatory bowel disease Katherine Bodiford (Jacksonville, United States)
11:05	Wounds (and things that look like them) David Croitoru (Toronto, Canada)
11:20	Plaquenil cutaneous toxicity Cheryl Rosen (Toronto, Canada)
11:35	Q&A + Network

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **S01**

	Pan Arab League of Dermatology (PALD): Diagnostic and therapeutic update in inflammatory and autoimmune skin diseases Chairs: Ibrahim Galadari (Dubai, United Arab Emirates) Mohamed Bengazil (Tripoli, Libya) Nejib Doss (Tunis, Tunisia)
08:30	Application of adipose tissue derived stem cells (ADSCs) and their exosomes in scar prevention and treatment Heba Saeed Mohamed Adly Abdelrazek (Cairo, Egypt)
08:40	Beyond JAK inhibitors: What's next in alopecia areata management? Roxanna Sadoughifar (Tehran, Iran)
08:50	New generation hairloss treatment: When and which? Ulaş Güvenç (Mersin, Türkiye)
09:00	Unmet needs and treatment guidelines of vitiligo Gamal Duweb (Benghazi, Libya)
09:10	Tinea capitis: A new unusual presentation Khalil Alhamdi (Basra, Iraq)
09:20	Molecular identification of the species that cause leprosy Leonardo Mayorga-Garibaldi (Jalisco, Mexico)
09:30	Picosecond laser for pigmented lesions in Maghrebian skin Siham Dikhaye (Oudja, Morocco)
09:40	Hidradenitis suppurativa in Libyan patients Ibrahim Almukahhal (Benghazi, Libya)
09:50	The place of lasers in oncodermatology Mohammed Rachid Hamlaoui (Algiers, Algeria)

Track: **Subspecialty**

Room **S01**

	Saudi Society of Dermatology and Dermatologic Surgery (SSDDS) Chair: Abdullah Alakeel (Riyadh, Saudi Arabia) Maysa Tariq Eshmawi (Saudi Arabia) Dana Alessa (Riyadh, Saudi Arabia)
10:15	Hidradenitis suppurativa in special population Nouf Almuhanna (Riyadh, Saudi Arabia)
10:27	Management of post surgical scars Najla Al Dawsari (Dhahran, Saudi Arabia)
10:39	From diagnosis to treatment: Tackling challenging cases in hair dermatology Abdullah Al Muqrin (Skaka, Saudi Arabia)
10:51	What are we doing differently? Challenging cases Faten Albukhari (Riyadh, Saudi Arabia)
11:03	Tips for lasers in skin of color; My 30 years experience Ahmed Alissa (Riyadh, Saudi Arabia)
11:15	Scarring alopecia; Updates on management Ruaa Al Harithy (Riyadh, Saudi Arabia)
11:27	Q&A and discussion

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **S02**

	Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) session Chairs: Kiran Vasant Godse (Navi Mumbai, India)
08:30	JAK inhibitors in the treatment of vitiligo Vinay Keshava Murthy (Chandigarh, India)
08:39	An underexplored variant of retrograde alopecia: Insights from a 30 patient case series Naveen Thomas (Kochi, India)
08:48	Comparative study of the efficacy of azathioprine, dapsone, and NB-UVB phototherapy as steroid-sparing modalities in generalised lichen planus Mithra S (Tamil Nadu, India)
08:57	Oral and topical minoxidil combination therapy for alopecia Kiran Vasant Godse (Navi Mumbai, India)
09:06	Newer non ablative laser for SOC, scar Mukta Sachdev (Bangalore, India)
09:15	Mycobacteria other than tuberculosis: An emerging threat with myriad presentation Parul Verma (Lucknow, India)
09:24	Global migration, key lessons with regard to leprosy and other neglected tropical diseases Santoshdev Pitambarbhai Rathod (Ahmedabad, India)
09:33	Decoding electronic skin – A novel technology in the world of wearable skin devices Sushmitha Dharani Sankar (Puducherry, India)
09:42	Advances in topical management of atopic dermatitis: Current pipeline and future directions Sk Shahriar Ahmed (Kolkata, India)
09:51	“Nail peels” - An innovative treatment option for various nail disorders Shraddha Ingole (Nagpur, India)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **S02**

	European Nail Society (ENS) Annual Meeting Chair: Bertrand Richert (Brussels, Belgium) Matilde Iorizzo (Lugano, Switzerland) Nilton Gioia Di Chiacchio (Sao Paulo, Brazil)
10:15	Introduction
10:20	Terbinafine resistance: Why we should worry Pauline Lecerf (Brussels, Belgium)
10:30	Nail clippings: When and why Adam Rubin (New York, United States)
10:40	Clinical Case Julio Jasso Olivares (Quebec, Canada)
10:45	Clinical Case Charlotte Arnal (Nancy, France)
10:50	Periungual warts: Treatment algorithm Bianca Maria Piraccini (Bologna, Italy)
11:00	Clinical Case Kashif Bhatti (Leeds, United Kingdom)
11:05	What's new in inflammatory nail disorders Axel Villani (Lyon, France)
11:15	Pincer nail: Tips and tricks on treatment Juan Jimenez Cauhe (Madrid, Spain)
11:25	Clinical Case Christin Pelzer (Winterthur, Switzerland)
11:30	Clinical Case Adriana Matter (Curitiba, Brazil)
11:35	Q&A
11:40	Conclusion/ announcements

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **S03**

	European Society for Photodermatology (ESPD): Photodermatology Chairs: Piergiacomo Calzavara-Pinton (Brescia, Italy) Yolanda Gilaberte (Zaragoza, Spain) Lesley Rhodes (Manchester, United Kingdom)
08:30	Ian Magnus lecture: A realistic positioning of phototherapy today Piergiacomo Calzavara-Pinton (Brescia, Italy)
08:55	Personalized photoprotection Salvador González Rodríguez (Madrid, Spain)
09:10	Daylight phototherapy of vitiligo Dilek Seckin (Istanbul, Türkiye)
09:25	The aryl hydrocarbon receptor in environmentally induced cancers Thomas Haarmann-Stemmann (Germany)
09:40	Comparison of photoprotection habits and preferences of patients with cutaneous immune-mediated inflammatory diseases (IMID) Zita Alvarez Bobillo (Zaragoza, Spain)
09:50	Comparison of the efficacy and safety of narrowband UVB alone versus narrowband UVB combined with topical tazarotene in the treatment of psoriasis Esra Nur Kiraz Çırakoğlu (Istanbul, Türkiye)

Track: **Subspecialty**

Room **S03**

	Latin American College of Dermatology (CILAD): Phototype is not immunity: Challenges in skin cancer among Latin American populations Chair: Miguel Olmos Perez (Bogota, Colombia) Emilia Cohen Sabban (Buenos Aires, Argentina)
10:15	Introduction Miguel Olmos Perez (Bogota, Colombia) Emilia Cohen Sabban (Buenos Aires, Argentina)
10:20	Pigmented Bowen disease: Dermoscopic features in the Ibero-Latin American population Rosario Peralta (Chubut, Argentina)
10:32	Brown skin natural protection? Reality of non-melanoma skin cancer in Latin America Patricia Lopez Olmos (Guadalajara, Mexico)
10:44	Latin American stories of Mohs surgery: A surgeon's perspective Miguel Olmos Perez (Bogota, Colombia)
10:56	Keratinocytic cancer in transplant patients Ivonne Arellano Mendoza (Ciudad de Mexico, Mexico)
11:08	Update on cutaneous T-cell lymphoma Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic)
11:20	First Latin American initiative for clinical practice guidelines in subungual melanoma Fernando Bulla Alcalá (Bogota, Colombia)
11:32	Skin cancer and the exposome: A new frontier in dermatologic oncology Yolanda Gilaberte (Zaragoza, Spain)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **S04**

	Emirates Dermatology Society (EDS) session Chairs: Fatima Albreiki (Al Ain, United Arab Emirates) Ayman Alnaeem (RAK, United Arab Emirates) Muna Al Murrawi (Abu Dhabi, United Arab Emirates)
08:30	Consensus recommendations for the management of atopic dermatitis in the United Arab Emirates Ayman Alnaeem (RAK, United Arab Emirates)
08:40	Management strategies for recalcitrant dermatological diseases: Advances and challenges Muna Al Murrawi (Abu Dhabi, United Arab Emirates)
08:50	Similar rashes different diagnosis Ahmed Ameen (Abu Dhabi, United Arab Emirates)
09:00	Genodermatoses without borders: From DNA to daily practice in the era of precision dermatology Alia Galadari (Dubai, United Arab Emirates)
09:10	Signal to Solution: The Evolving Role of JAK in Dermatology Huda Rajab Ali (Abu Dhabi, United Arab Emirates)
09:20	Clinical photography in dermatology Meera Aladawi (United Arab Emirates)
09:30	GRWM, Fads and everything in Bet'TWEENS Sahar Al-Nowais (Abu Dhabi, United Arab Emirates)
09:40	Tiny patients, timeless lessons: Clinical pearls from paediatric dermatology cases Sara Aljanahi (Abu Dhabi, United Arab Emirates)
09:50	Standard patch test: Pitfalls and limitation Ashraf Reda (Dubai, United Arab Emirates)

Track: **Subspecialty**

Room **S04**

	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Psoriasis and psoriatic arthritis Chair: Joseph F. Merola (Dallas, United States) April Armstrong (Los Angeles, United States)
10:15	Psoriatic arthritis for the dermatologist: Emerging therapies 2025 Joseph F. Merola (Dallas, United States)
10:30	GLP-1 agonists in psoriatic disease: Weight loss, inflammation, and disease control Kenneth B. Gordon (Milwaukee, United States)
10:40	Pixels and plaques: Artificial Intelligence in psoriasis April Armstrong (Los Angeles, United States)
10:50	Addressing mental health in psoriatic disease: Challenges and opportunities for the dermatologist Laura Jane Savage (Leeds, United Kingdom)
11:00	PsA screening and MSK symptoms in psoriasis: Novel outcome measures and ultrasound for the derm Alice B. Gottlieb (New York, United States)
11:10	Treating PPP and palmoplantar disease in 2025: Data-driven approach Bruce Strober (Cromwell, United States)
11:20	Y-GRAPPA update: What's next for the next generation? Dimitri Luz Felipe Da Silva (Campinas, Brazil)
11:30	Open faculty Q&A and panel discussion

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **S05**

	African Society of Dermatology and Venereology (ASDV): Dermatology in skin of colour patients Chairs: Nouredine Litaïem (Tunis, Tunisia) Asmahane Souissi (Ghazela Ariana, Tunisia) Ncoza Dlova (Durban, South Africa)
08:30	Atopic dermatitis on pigmented skin Samira Zobiri (Algiers, Algeria)
08:38	Acne keloidalis nuchae: Cases and updates Awatef Kelati (Casablanca, Morocco)
08:46	Frontal fibrosing alopecia amongst black South African women Ncoza Dlova (Durban, South Africa)
08:54	Diagnosis and management of mycosis fungoides in paediatric patients with skin of colours Soumaya Gara (Bizerte, Tunisia)
09:02	Squamous cell carcinoma associated with the cosmetic skin bleaching among Senegalese women Fatimata Ly (Dakar, Senegal)
09:10	Skin cancer in skin of colour Nomphelo Gantsho (Cape Town, South Africa)
09:18	Scalp discoid lupus erythematosus in skin of colour Asmahane Souissi (Ghazela Ariana, Tunisia)
09:26	Hyperpigmentation on the African skin Abel Onunu (Benin City, Nigeria)
09:34	Energy based skin rejuvenation in skin of colour Mwatsveruka Munhutu (Harare, Zimbabwe)
09:42	Infections in skin of colour patient: Updates Ibrahima Traore (Conakry, Guinea)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **S05**

	European Hidradenitis Suppurativa Foundation e.V. (EHSF): Hidradenitis suppurativa: What's new in research and treatment? Chair: Christos C. Zouboulis (Dessau, Germany) Gregor Borut Jemec (Roskilde, Denmark) Thrasyvoulos Tzellos (Bodø, Norway)
10:15	Introduction Christos C. Zouboulis (Dessau, Germany)
10:16	The role of shear wave elastography in the evaluation of hidradenitis suppurativa lesions and analysis of its relationship with clinical findings Yusuf Can Edek (Ankara, Türkiye)
10:24	Using images to guide patient management in hidradenitis suppurativa Michelle Raupelyté Reiersen (France)
10:32	Prevalence of hidradenitis suppurativa in patients with pilonidal sinus disease Lucas Klepfish (Lyon, France)
10:40	Spatial transcriptome sequencing reveals the formation and development of sinus tract epithelium in hidradenitis suppurativa Qiang Ju (Shanghai, China)
10:52	Mapping early immune landscapes in hidradenitis suppurativa via integrated spatial transcriptomics Youngin Lee (Seoul, South Korea)
11:04	The role of fat and adipocytes in hidradenitis suppurativa patients: Serum analysis of lipid profiles of a multicenter cohort of patients Flavia Manzo Margiotto (Pisa, Italy)
11:12	Hidradenitis suppurativa updates and weight loss management Aysha Almoosa (Manama, Bahrain)
11:20	3D Seboskin model of hidradenitis suppurativa: Insights into antibiotic response Georgia Vradeli (Dessau-Roßlau, Germany)
11:28	The study of virulence and resistance of bacterial species colonizing hidradenitis suppurativa lesions Mara Madalina Mihai (Bucharest, Romania)
11:36	Long term efficacy and safety of upatacitinib in hidradenitis suppurativa patients Gianmarco Silvi (Florence, Italy)
11:44	Conclusion Gregor Borut Jemec (Roskilde, Denmark)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **S06**

	European Society for Photodynamic Therapy (EURO-PDT): What is new in dermatological PDT for 2025 Chairs: Lasse R. Braathen (Oberhofen, Switzerland) Colin Morton (Perthshire, United Kingdom) Rolf-Markus Szeimies (Recklinghausen, Germany)
08:30	Welcome and Introduction Lasse R. Braathen (Oberhofen, Switzerland)
08:35	Times are changing – on incubation and irradiation procedures Maria Concetta Fargnoli (Rome, Italy)
08:48	Use of PDT in the clinic in 2025 – European perspective Colin Morton (Perthshire, United Kingdom)
09:01	Use of PDT in the clinic in 2025 – US perspective Maria M. Tsoukas (Chicago, United States)
09:14	PDT for actinic cheilitis Elena Sotiriou (Thessaloniki, Greece)
09:27	PDT in transplant patients Günther Hofbauer (Wetzikon, Switzerland)
09:40	PDT for aesthetic purposes Rolf-Markus Szeimies (Recklinghausen, Germany)
09:53	Discussion & summary Lasse R. Braathen (Oberhofen, Switzerland)

Track: **Subspecialty**

Room **S06**

	Medical Excellence in Dermatology and Aesthetic Medicine (MEIDAM) association session Chair: Khaled Al Nuaimi (Dubai, United Arab Emirates) Husain Juma (Manama, Bahrain) Ruaa Al Harithy (Riyadh, Saudi Arabia)
10:15	NAD shots May El Samahy (Cairo, Egypt)
10:35	Contact dermatitis: Recent advances and clinical updates Aisha Al Ali (Muscat, Oman)
10:50	Algorithm for longitudinal melanonychia Sana Mokni (Sousse, Tunisia)
11:05	Hidradenitis suppurativa updates from my practice Aysha Al-Moosa (Manama, Bahrain)
11:20	Hidradenitis and its comorbidities: Key insights for practice Sarah Alsukait (Riyadh, Saudi Arabia)
11:35	Q&A & closing remarks Saad Alsogair (Khobar, Saudi Arabia)

Wednesday, 17 September 2025

Track: **Subspecialty**

Room **W05-W06**

	Euromelanoma session: Skin cancer prevention Chairs: Del Marmol Veronique (Brussels, Belgium) Josep Malvehy (Barcelona, Spain) Mariano Suppa (Brussels, Belgium)
08:30	Welcome & introduction Del Marmol Veronique (Brussels, Belgium)
08:40	Update on the EUSCAP database Katharina Wunderlich (Brussels, Belgium)
08:50	Impact of regular skin cancer screening on melanoma Breslow thickness Katharina Wunderlich (Brussels, Belgium)
09:00	Artificial Intelligence in melanoma screening: From mobile apps to total body dermoscopy Josep Malvehy (Barcelona, Spain)
09:20	Shaping the future of prevention: Key priorities ahead Mariano Suppa (Brussels, Belgium)
09:40	Outlook on the next EADO/Euromelanoma campaign Philippe Pendaries (London, United Kingdom)
09:50	Q&A and conclusions Del Marmol Veronique (Brussels, Belgium)

Track: **Subspecialty**

Room **W05-W06**

	International Society of Dermatology (ISD): Pearls from around the world Chair: Leopoldo Santos (Sao Paulo, Brazil) Martin Kassir (Dallas, United States)
10:15	Opening remarks Leopoldo Santos (Sao Paulo, Brazil)
10:20	PASH syndrome (Pyoderma gangrenosum, Acne, and Suppurative Hidradenitis) Ina Sotiri (Tirana, Albania)
10:32	ISD mentorship experience and dermoscopy diagnosis of melanocytic lesions in melanoma Thais Bello di Giacomo (Sao Paulo, Brazil)
10:44	Pemphigus foliaceus and variants A. Razzaque Ahmed (Boston, United States)
10:56	Management of frontal fibrosing alopecia Ncoza Dlova (Durban, South Africa)
11:08	Acquired dermal macular hyperpigmentation/ Lichen planus pigmentosus Vinay Keshava Murthy (Chandigarh, India)
11:20	Q&A
11:35	Closing remarks and certificates

Wednesday, 17 September 2025

Track: ePoster Showcase

Room E01-E03

EPS01		E-Poster showcase 1 Chair: Andrea Carugno (Varese, Italy)
EPS01.1	08:30	Successful Management of Hidradenitis Suppurativa Using CO₂ Laser Deroofing Dimitrios Motsios (Athens, Greece)
EPS01.2	08:37	Modified Fanning Technique for Better Biostimulant Distribution in Aesthetic Medicine Anna Grodecka (Krakow, Poland)
EPS01.3	08:44	The Major Challenge in Nail Unit Biopsies: Clinical and Dermatopathological Correlation – A Series of 111 Cases Sevgi Özensel Özel (Ankara, Türkiye)
EPS01.4	08:51	Increased Incidence and Risk of Hair Loss with GLP-1 Agonists: A Real-World Multicenter Cohort Study Yagiz Matthew Akiska (Washington, United States)
EPS01.5	08:58	Access to dermatologic care among indigenous peoples in Palawan, Philippines: A community project Maria Vinna Nicodemus Crisostomo (Manila, Philippines)
EPS01.6	09:05	Evaluation of a teledermatological store-and-forward application - analysis of patient care and attitudes in Germany Marina Otten (Hamburg, Germany)
EPS01.7	09:12	Factors Affecting Career Advancement in Academic Dermatology in the US Allen Shih (Boston, United States)
EPS01.8	09:19	Patient-Led Teledermatology for Skin Lesion assessment in Primary Care – A real world experience Filip Mijovic (London, United Kingdom)
EPS01.9	09:26	Efficacy and Safety of Imiquimod 5% for Lentigo Maligna of the Head, Neck & Face: A Systematic Review and Meta-analysis Laura Ghanem (Beirut, Lebanon)
EPS01.10	09:33	NUDT15 and TPMT Pharmacogenomic Testing for Azathioprine-Induced Adverse Reactions in Immune-mediated Skin Diseases Koramon Phuwaraks (Bkk, Thailand)
EPS01.11	09:40	Treatment of Toxic Epidermal Necrolysis by Plasmapheresis: A Prospective Study Lamis Elyamani (Oujda, Morocco)
EPS01.12	09:47	The Dermatology Life Quality Index (DLQI) in 27 guidelines and 38 registries- a systematic review involving 45 countries: The International Standard of Care. Jeffrey Johns (Cardiff, United Kingdom)
	09:54	Q&A

Wednesday, 17 September 2025

Track: ePoster Showcase

Room E01-E03

EPS02		E-Poster showcase 2 Chair: Artem Vorobyev (Luebeck, Germany)
EPS02.1	10:15	“Scars of Life”: Assessment of the Determinants of Bullying in Atopic Dermatitis Delphine Kerob (Levallois Perret, France)
EPS02.2	10:22	Recurrence of basal cell carcinoma after different treatment modalities: A nationwide study with up to 9 years follow-up Johan Sieborg (Copenhagen, Denmark)
EPS02.3	10:29	Remibrutinib-treated patients with CSU who achieve well-controlled disease activity reach this by week 3 in the majority of patients: Results from REMIX-1/-2 studies Martin Metz (Berlin, Germany)
EPS02.4	10:36	Efficacy of remibrutinib in patients with CSU by demographics and baseline characteristics: Pooled analysis from REMIX-1/-2 studies Bin Yang (China)
EPS02.5	10:43	Temporal trends in the course and management of chronic urticaria at a tertiary care center in Denmark Clara Østergaard (Copenhagen, Denmark)
EPS02.6	10:50	Diagnostic pitfalls and clinical mimics of subacute cutaneous lupus erythematosus Neda Delic (Belgrade, Serbia)
EPS02.7	10:57	Impact of Early vs Late Biologic Treatment Initiation on Health Care Resource Utilization in Patients With Chronic Spontaneous Urticaria: Results From a United States Claims Database Study Merin Kuruvilla (Atlanta, United States)
EPS02.8	11:04	Monitoring of nail psoriasis with optical coherence tomography under treatment with Tildrakizumab for 52 weeks Sarah Hobelsberger (Dresden, Germany)
EPS02.9	11:11	Barzolvolimab Treatment Improves Urticaria Activity in Patients with Chronic Spontaneous Urticaria Regardless of Baseline IgE Levels Martin Metz (Berlin, Germany)
EPS02.10	11:18	Innovative industrial 3D-Scanning and 3D-Printing Technologies allow for a Reintroducing of three-dimensional Wax Replicas “Moulages” in Dermatology Alexander Schneller (Augsburg, Germany)
EPS02.11	11:25	Germline predisposition in early onset melanoma: A study of a Greek patient cohort Eftychia Chatziioannou (Tübingen, Germany)
EPS02.12	11:32	Safety and efficacy of bruton’s tyrosine kinase inhibitors for the treatment of chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials Martin Cevallos Cueva (Quito, Ecuador)
EPS02.1	10:15	“Scars of Life”: Assessment of the Determinants of Bullying in Atopic Dermatitis Delphine Kerob (Levallois Perret, France)
	11:39	Q&A

Wednesday, 17 September 2025

Track: **Plenary**

Room **Paris Nord**

	Plenary Lectures A Chairs: Martin Röcken (Tübingen, Germany) Lidia Rudnicka (Warsaw, Poland)
12:00	Crosstalk between skin, gut and brain Richard L. Gallo (San Diego, United States)
12:20	Vexas syndrome Cedric Lenormand (Strasbourg, France)
12:40	Will we cure chronic inflammatory skin diseases? Christopher E. M. Griffiths (Manchester, United Kingdom)

Wednesday, 17 September 2025

Track: **Updates**

Room **Paris Nord**

DIT1.1		Late Breaking News Chairs: Cristina Has (Freiburg, Germany) Menno de Rie (Breukelen, Netherlands)
DIT1.1A	14:15	Long-term efficacy and complete scalp hair regrowth in patients with alopecia areata receiving ritlecitinib 50 mg QD up to 3 years in the ALLEGRO clinical trial program Brett King (Fairfield, United States)
DIT1.1B	14:30	Baricitinib in the treatment of adults with pyoderma gangrenosum: A phase II open label trial Alex Ortega Loayza (Portland, United States)
DIT1.1C	14:45	Povorcitinib for moderate to severe Hidradenitis Suppurativa: Week 24 interim phase 3 results Martina L Porter (Boston, United States)
DIT1.1D	15:00	Efficacy and safety of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: Week 16 results from a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Kim A. Papp (Waterloo, Canada)
DIT1.1E	15:15	IL-22RA1 antagonism with temtokibart provides significant early and sustained improvements in atopic dermatitis: Results from a phase 2b dose-finding trial Stephan Weidinger (Bridgewater, Germany)
DIT1.1F	15:30	Temtokibart, an IL-22RA1 monoclonal antibody broadly dampens gene expression markers of activated immune pathways in Atopic Dermatitis: Results from a Phase 2b Trial subgroup analysis Ester Del Duca (New York, United States)

Track: **Updates**

Room **Paris Nord**

DIT1.2		Late Breaking News Chairs: Erkan Alpsoy (Antalya, Türkiye) Margarida Gonçalo (Coimbra, Portugal)
DIT1.2A	16:00	Efficacy and safety of Ruxolitinib cream in patients with Prurigo Nodularis: Pooled results from the phase 3 TRuE-PN1 and TRuE-PN2 randomized, vehicle-controlled studies Sonja Ständer (Münster, Germany)
DIT1.2B	16:15	Maintenance of response With Icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults (Weeks 24-52) and continuous treatment in adolescents (through week 52) from the phase 3, ICONIC-LEAD trial Jennifer Soung (Santa Ana, United States)
DIT1.2C	16:30	Balinatunfib, the first oral selective inhibitor of TNFR1 signalling, in plaque psoriasis: A double-blind, randomized, placebo-controlled phase 2b study Fernando Valenzuela (Santiago, Chile)
DIT1.2D	16:45	First-in-Class FASN inhibitor Denifanstat achieved all endpoints in the treatment of acne vulgaris: Results from a phase III randomised placebo controlled trial Flora Xiang (Shanghai, China)
DIT1.2E	17:00	Bimekizumab efficacy and safety through 3 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and their open-label extension BE HEARD EXT John R. Ingram (Cardiff, United Kingdom)
DIT1.2F	17:15	KT-621, an oral, once daily, targeted STAT6 degrader: First-in-human phase 1a safety, pharmacokinetics, pharmacodynamics and Th2 biomarker effects Mahta Mortezaei (Watertown, United States)

Wednesday, 17 September 2025

Track: **Focus on**

Room **Paris Sud**

DIT2.1		Focus on STIs Chairs: Claudia Heller-Vitouch (Vienna, Austria) Nicolas Dupin (Paris, France)
DIT2.1A	14:15	Epidemiological trends Sébastien Fouéré (Paris, France)
DIT2.1B	14:35	STIs in sexually abused children Claudia Heller-Vitouch (Vienna, Austria)
DIT2.1C	14:55	Complications of syphilis in men and women Nicolas Dupin (Paris, France)
DIT2.1D	15:15	STIs during pregnancy Valeska Padovese (Msida, Malta)
DIT2.1E	15:35	Discussion, Q&A

Track: **Focus on**

Room **Paris Sud**

DIT2.2		Focus on STIs Chairs: Electra Nicolaidou (Athens, Greece) Henry John Christiaan De Vries (Amsterdam, Netherlands)
DIT2.2A	16:00	Therapeutical challenges of gonococcal and non gonococcal urethritis Electra Nicolaidou (Athens, Greece)
DIT2.2B	16:20	Atypical presentations of syphilis Henry John Christiaan De Vries (Amsterdam, Netherlands)
DIT2.2C	16:40	Doxy PEP and HIV PREP Simona Saluzzo (Vienna, Austria)
DIT2.2D	17:00	Vaccines Georg Stry (Vienna, Austria)
DIT2.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **N01**

DIT3.1		Psoriasis Chairs: Denis Jullien (Lyon, France) Richard B. Warren (Manchester, United Kingdom)
DIT3.1A	14:15	Understanding endotypes Denis Jullien (Lyon, France)
DIT3.1B	14:35	Towards a cure: Hit early, hit hard Andrew Blauvelt (Portland, United States)
DIT3.1C	14:55	Oral treatments Richard B. Warren (Manchester, United Kingdom)
DIT3.1D	15:15	Diet and psoriasis Wendy Hall (London, United Kingdom)
DIT3.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **N01**

DIT3.2		Psoriasis Chairs: Lone Skov (Hellerup, Denmark) Julia-Tatjana Maul (Zurich, Switzerland)
DIT3.2A	16:00	Treatment resistance Lone Skov (Hellerup, Denmark)
DIT3.2B	16:20	Preventing and management of comorbidities Álvaro González-Cantero (Madrid, Spain)
DIT3.2C	16:40	Update on therapy pipeline Bruce Strober (Cromwell, United States)
DIT3.2D	17:00	Special focus: Women Julia-Tatjana Maul (Zurich, Switzerland)
DIT3.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Training and education**

Room **N04**

DIT4.1		Acne Chairs: Vicente Torres Lozada (Atizapan, Mexico) Benedicte Oules (Paris, France)
DIT4.1A	14:15	Pathogenesis Dae Hun Suh (Seoul, South Korea)
DIT4.1B	14:35	Surgical management Vicente Torres Lozada (Atizapan, Mexico)
DIT4.1C	14:55	Treatment algorithm Margarita Larralde (Buenos Aires, Argentina)
DIT4.1D	15:15	How to use Isotretinoin Benedicte Oules (Paris, France)
DIT4.1E	15:35	Discussion, Q&A

Track: **Training and education**

Room **N04**

DIT4.2		Hair disorders Chairs: Anastasia Therianou (London, United Kingdom) Sergio Vaño-Galván (Madrid, Spain)
DIT4.2A	16:00	Androgenetic alopecia Anastasia Therianou (London, United Kingdom)
DIT4.2B	16:20	Alopecia areata Anna Waskiel-Burnat (Warsaw, Poland)
DIT4.2C	16:40	Lichen planopilaris Sergio Vaño-Galván (Madrid, Spain)
DIT4.2D	17:00	Hair loss in systemic diseases Ana Filipa Pedrosa (Porto, Portugal)
DIT4.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **N02**

DIT5.1		Oral diseases Chairs: Thomas Rustemeyer (Amsterdam, Netherlands) Mahtab Samimi (Tours, France)
DIT5.1A	14:15	Aphthosis and ulcers Jane Setterfield (London, United Kingdom)
DIT5.1B	14:35	Leukoplakia Raimonds Karls (Daugmale, Latvia)
DIT5.1C	14:55	Hyperpigmented lesions Thomas Rustemeyer (Amsterdam, Netherlands)
DIT5.1D	15:15	Burning mouth Mahtab Samimi (Tours, France)
DIT5.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **N02**

DIT5.2		Pregnancy and skin diseases Chairs: Robert Muellegger (Vienna, Austria) Sara Pruneddu (London, United Kingdom)
DIT5.2A	16:00	Polymorphic eruption of pregnancy Robert Muellegger (Vienna, Austria)
DIT5.2B	16:20	Pustular eruptions in pregnancy Brigitte Stephan (Hamburg, Germany)
DIT5.2C	16:40	Biologics in pregnancy Jenny Murase (San Francisco, United States)
DIT5.2D	17:00	Management of pruritus in pregnancy Sara Pruneddu (London, United Kingdom)
DIT5.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **N03**

DIT6.1		JAK inhibitors Chairs: Jean David Bouaziz (Paris, France) Alexa B. Kimball (Boston, United States)
DIT6.1A	14:15	Approved drugs and their indications Kamran Ghoreschi (Berlin, Germany)
DIT6.1B	14:35	Off-label use Curdin Conrad (Lausanne, Switzerland)
DIT6.1C	14:55	Short and long term monitoring Jean David Bouaziz (Paris, France)
DIT6.1D	15:15	Pipeline of systemic and topical JAKs Alexa B. Kimball (Boston, United States)
DIT6.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **N03**

DIT6.2		Vitiligo Chairs: Albert Wolkerstorfer (Amsterdam, Netherlands) Thierry Passeron (Nice, France)
DIT6.2A	16:00	Understanding the disease Reinhart Speeckaert (Gent, Belgium)
DIT6.2B	16:20	Disease mimickers Albert Wolkerstorfer (Amsterdam, Netherlands)
DIT6.2C	16:40	New and emerging treatments Thierry Passeron (Nice, France)
DIT6.2D	17:00	Special focus: Children Karan Lal (Scottsdale, United States)
DIT6.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **S01**

DIT7.1		Dermatology in skin of colour patients Chairs: Ophelia Entsir Dadzie (London, United Kingdom) Ibrahima Traore (Conakry, Guinea)
DIT7.1A	14:15	Recognising common inflammatory skin diseases Ophelia Entsir Dadzie (London, United Kingdom)
DIT7.1B	14:35	Hyper- and Hypo-pigmented conditions Esperanza Welsh (Monterrey, Mexico)
DIT7.1C	14:55	Challenges in detecting skin cancer Ibrahima Traore (Conakry, Guinea)
DIT7.1D	15:15	Acne and keloids Andrew F. Alexis (New York, United States)
DIT7.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **S01**

DIT7.2		Dermatology in skin of colour patients Chairs: Daudi Mavura (Moshi, Tanzania) Susan Taylor (Philadelphia, United States)
DIT7.2A	16:00	Dermoscopy in darker skin types Daudi Mavura (Moshi, Tanzania)
DIT7.2B	16:20	Strategies and consequences of depigmentation Susan Taylor (Philadelphia, United States)
DIT7.2C	16:40	Hair disorders Nicolas Kluger (Helsinki, Finland)
DIT7.2D	17:00	Infections Omar Lupi (Rio De Janeiro, Brazil)
DIT7.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **S02**

DIT8.1		Skin and systemic diseases Chairs: Asja Prohić (Sarajevo, Bosnia and Herzegovina) Jan Gutermuth (Brussels, Belgium)
DIT8.1A	14:15	Granulomatous diseases Bill Damsky (New Haven, United States)
DIT8.1B	14:35	Diabetic skin manifestations Jan Gutermuth (Brussels, Belgium)
DIT8.1C	14:55	Haematological diseases associated signs Juan Torre-Castro (Madrid, Spain)
DIT8.1D	15:15	Paraneoplastic skin signs Asja Prohić (Sarajevo, Bosnia and Herzegovina)
DIT8.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **S02**

DIT8.2		Rosacea Chairs: Martin Steinhoff (Doha, Qatar) Anna Di Nardo (Rome, Italy)
DIT8.2A	16:00	Understanding subtypes Martin Steinhoff (Doha, Qatar)
DIT8.2B	16:20	Managing subtypes Linda Stein Gold (Michigan, United States)
DIT8.2C	16:40	Management of Rhinophyma Florian Anzengruber (Chur, Switzerland)
DIT8.2D	17:00	New treatments Anna Di Nardo (Rome, Italy)
DIT8.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **S03**

DIT9.1		Emerging technologies and procedures Chairs: Mariano Suppa (Brussels, Belgium) Mohamad Goldust (Baltimore, United States)
DIT9.1A	14:15	LC-OCT Mariano Suppa (Brussels, Belgium)
DIT9.1B	14:35	Robotics for hair transplantation Alba Gómez-Zubiaur (Madrid, Spain)
DIT9.1C	14:55	3D printing Mohamad Goldust (Baltimore, United States)
DIT9.1D	15:15	Ex-vivo reflectance confocal microscopy Javiera Perez-Anker (Barcelona, Spain)
DIT9.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **S03**

DIT9.2		Emerging technologies and procedures Chairs: Johann Bauer (Salzburg, Austria) James G. Krueger (New York, United States)
DIT9.2A	16:00	Stem cells and exosomes in regenerative dermatology Aseem Sharma (Mumbai, India)
DIT9.2B	16:20	Cellular therapy, including CART cells Antonios Kolios (Zurich, Switzerland)
DIT9.2C	16:40	CRISPR and genetic technologies Johann Bauer (Salzburg, Austria)
DIT9.2D	17:00	Multi-cell engagers and multi-specific antibodies James G. Krueger (New York, United States)
DIT9.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **S04**

D1T10.1		Dermato-endocrinology Chairs: Selim Aractingi (Paris, France) Shyam Verma (Vadodara, India)
D1T10.1A	14:15	Steroids and the skin: From Cushing syndrome to Addison's disease Selim Aractingi (Paris, France)
D1T10.1B	14:35	Facial acanthosis nigricans Shyam Verma (Vadodara, India)
D1T10.1C	14:55	Skin-thyroid link Ralf Paus (Miami, United States)
D1T10.1D	15:15	Obesity and the skin Emilie Sbidian (Créteil, France)
D1T10.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **S04**

D1T10.2		Vasculitis and vasculopathies Chairs: Emek Kocatürk Göncü (Istanbul, Türkiye) Cord Sunderkoetter (Halle, Germany)
D1T10.2A	16:00	Small vessel vasculitis Francois Chasset (Paris, France)
D1T10.2B	16:20	Urticarial vasculitis Emek Kocatürk Göncü (Istanbul, Türkiye)
D1T10.2C	16:40	Cutaneous Polyarteritis nodosa Cord Sunderkoetter (Halle, Germany)
D1T10.2D	17:00	Livedoid vasculopathy and alike Marie Jachiet (Paris, France)
D1T10.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **S05**

DIT11.1		Lasers and energy-based devices: Practical aspects of basics Chair: Assi Levi (Mevaseret Zion, Israel)
DIT11.1A	14:15	Vascular lasers Daniel Brualla Palazón (Barcelona, Spain)
DIT11.1B	14:35	Pigmented lasers Kristine Heidemeyer (Bern, Switzerland)
DIT11.1C	14:55	Ablative lasers and energy based devices Mukta Sachdev (Bangalore, India)
DIT11.1D	15:15	Avoiding potential side effects Assi Levi (Mevaseret Zion, Israel)
DIT11.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **S05**

DIT11.2		Lasers and energy-based devices II: Advanced, including complications management Chair: Ashraf Badawi (Oakville, Canada)
DIT11.2A	16:00	Laser treatment of vascular lesions Pablo Boixeda (Madrid, Spain)
DIT11.2B	16:20	Photodynamic therapy and fractional laser Johan Snauwaert (Brasschaat, Belgium)
DIT11.2C	16:40	Laser practice rules for skin of colour Ahmed Sadek (Cairo, Egypt)
DIT11.2D	17:00	Challenges in laser and energy based practice Ashraf Badawi (Oakville, Canada)
DIT11.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room-S06

DIT12.1		Skin ageing and rejuvenation Chairs: Lidiya Todorova (Plovdiv, Bulgaria) Natasha Mesinkovska (Irvine, United States)
DIT12.1A	14:15	Hormonal treatments Beata Bergler-Czop (Katowice, Poland)
DIT12.1B	14:35	Metformin and semaglutide Natasha Mesinkovska (Irvine, United States)
DIT12.1C	14:55	PRP, adipose tissue and stem cells Evgenia Makrantonaki (Wildeshausen, Germany)
DIT12.1D	15:15	Topicals: What is the evidence? Lidiya Todorova (Plovdiv, Bulgaria)
DIT12.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **S06**

DIT12.2		Geriatric dermatology Chairs: Gürkan Kaya (Geneva, Switzerland) Paola Pasquali (Cambrils, Spain)
DIT12.2A	16:00	Novel anti-ageing strategies in the skin Gürkan Kaya (Geneva, Switzerland)
DIT12.2B	16:20	Management of skin cancer Paola Pasquali (Cambrils, Spain)
DIT12.2C	16:40	Pruritus: Causes and management Emilie Brenaut (Brest, France)
DIT12.2D	17:00	Hair and nail changes Michela Starace (Bologna, Italy)
DIT12.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Updates**

Room **W05-W06**

DIT13.1		Clinical-pathological correlation Chairs: Catherine M. Stefanato (London, United Kingdom) Maria del Mar Llamas Velasco (Madrid, Spain)
DIT13.1A	14:15	CTCL vs atopic eczema Reuven Bergman (Haifa, Israel)
DIT13.1B	14:35	Scarring alopecia: Lupus vs Lichen planopilaris Catherine M. Stefanato (London, United Kingdom)
DIT13.1C	14:55	Ulcers: Pyoderma gangrenosum vs vasculitis Daniela Kroshinsky (Durham, United States)
DIT13.1D	15:15	Lobular panniculitis: Subcutaneous lymphoma vs lupus panniculitis Maria del Mar Llamas Velasco (Madrid, Spain)
DIT13.1E	15:35	Discussion, Q&A

Track: **Updates**

Room **W05-W06**

DIT13.2		Clinical-pathological correlation Chair: Antoni Gostynski (Maastricht, Netherlands) Bernard Cribier (Strasbourg, France)
DIT13.2A	16:00	Granulomatous diseases: Infectious vs non-infectious Bernard Cribier (Strasbourg, France)
DIT13.2B	16:20	Erythemato-squamous diseases: PRP vs psoriasis Antoni Gostynski (Maastricht, Netherlands)
DIT13.2C	16:40	Lichen sclerosus vs Lichen planus Eleonora Leoni (Locarno, Switzerland)
DIT13.2D	17:00	Melanoma vs Spitzoid lesions Raymond Barnhill (Paris, France)
DIT13.2E	17:20	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Miscellaneous**

Room **W03-W04**

D1T14.1		Skin diseases in Latin America Chairs: Omar Lupi (Rio De Janeiro, Brazil) José Manuel Ríos-Yuil (Ciudad de Panama, Panama) María Ivonne Arellano Mendoza (Mexico, Mexico)
D1T14.1A	14:15	Introduction
D1T14.1B	14:20	Diagnosing ectoparasitoses with dermoscopy Horacio Cabo (Buenos Aires, Argentina)
D1T14.1C	14:30	Tungiasis Emilia Cohen Sabban (Buenos Aires, Argentina)
D1T14.1D	14:40	Leishmaniasis: An update José Manuel Ríos-Yuil (Ciudad de Panama, Panama)
D1T14.1E	14:50	Disseminated cutaneous histoplasmosis Carlos Fernando Gatti (Buenos Aires, Argentina)
D1T14.1F	15:00	Clinical aspects of Larva migrans in LATAM María Ivonne Arellano Mendoza (Mexico, Mexico)
D1T14.1G	15:10	Sporotrichosis: The perfect storm Omar Lupi (Rio De Janeiro, Brazil)
D1T14.1G	15:20	Superficial mycoses: Diagnosis and management Maria Goreti Baião Catorze (Lisboa, Portugal) Antonio G. Massa (Porto, Portugal)
D1T14.1H	15:30	Discussion, Q&A

Wednesday, 17 September 2025

Track: **Miscellaneous**

Room **W03-W04**

DIT14.2		Skin diseases named after pioneering French dermatologists Chair: Daniel Wallach (Paris, France) Manuelle Viguiet (Reims, France)
DIT14.2A	16:00	Dowling-Degos Daniel Wallach (Paris, France)
DIT14.2B	16:10	Darier's disease Bruno Halioua (Paris, France)
DIT14.2C	16:20	Acrodermatitis continua suppurativa Hallopeau Manuelle Viguiet (Reims, France)
DIT14.2D	16:30	Fournier's gangrene Jean Noël Dauendorffer (Paris, France)
DIT14.2E	16:40	Favre-Racouchot Michel Janier (Paris, France)
DIT14.2F	16:50	Confluent reticulated papillomatosis Gougerot Carteaud Antoine David Petit (Paris, France)
DIT14.2G	17:10	Bazin's disease Bernard Cribier (Strasbourg, France)

Wednesday, 17 September 2025

Track: ePoster Showcase

Room E01-E03

EPS03		E-Poster showcase 3 Chair: Norbert Wikonkal (Budapest, Hungary)
EPS03.1	14:15	Patient-Reported Impact of Dermatological Diseases and Mental Health Allison Fitzgerald (Ottawa, Canada)
EPS03.2	14:22	Dose and time dependent efficacy of vilobelimab on wound healing outcomes in patients with ulcerative pyoderma gangrenosum – findings from a Phase 2 trial Afsaneh Alavi (Rochester, United States)
EPS03.3	14:29	The role of the dermatologist in gender-affirming care Madeleine Haynes (London, United Kingdom)
EPS03.4	14:36	Efficacy of secukinumab uptitration from every 4 weeks to every 2 weeks dosing in week 52 HiSCR non-responder patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE extension trial Afsaneh Alavi (Rochester, United States)
EPS03.5	14:43	A mixed-methods study of the factors influencing sunscreen use in conflict settings Sari Taha (Nablus, Palestine)
EPS03.6	14:50	Qualitative examination of Skindex-16 questionnaire in adult patients with atopic dermatitis Eszter Szlavicz (Pécs, Hungary)
EPS03.7	14:57	Prevalence and Risk Factors of Suicidal Ideation in Atopic Eczema: Insights from the Scars of Life Study Delphine Kerob (Levallois Perret, France)
EPS03.8	15:04	Real-World Evaluation of the Effectiveness and Safety of Dupilumab in Chronic Urticaria: An Ambispective Multicenter Case Series Nidia Planella Fontanillas (Barcelona, Spain)
EPS03.9	15:11	Scars of Life: How Atopic Dermatitis Shapes Educational Paths, Career Choices, and Social Lives from Childhood to Adulthood Delphine Kerob (Levallois Perret, France)
EPS03.10	15:18	Impact of atopic eczema on life choices and destiny: a global study Delphine Kerob (Levallois Perret, France)
EPS03.11	15:25	Genetically proxied inhibition of lipid pathways and risk of atopic dermatitis: a multi-ancestry Mendelian randomisation study John Tetteh (Manchester, United Kingdom)
EPS03.12	15:32	Treatment with delgocitinib cream is associated with a reduction of Staphylococcus aureus density and pain in patients with mild to severe Chronic Hand Eczema Daniel Elenius Madsen (Ballerup, Denmark)
	15:39	Q&A

Wednesday, 17 September 2025

Track: ePoster Showcase

Room E01-E03



EPS04		E-Poster showcase 4 Chair: Dario Didona (Rome, Italy)
EPS04.1	16:00	Adapting Therapeutic Education Programs for Chronic Dermatological Diseases: A Systematic Review and Framework Proposal for the United Arab Emirates Healthcare Context Shaikha Alhaj (Dubai, United Arab Emirates)
EPS04.2	16:07	Mental Health Burden in Prurigo Nodularis: Results from the PN- paTient Reported burdEn of sickNess (PN-TREK) EU Real-World Study Donia Bahloul (Chilly-Mazarin, France)
EPS04.3	16:14	Prospective observational study on the use of confocal microscopy in defining pre-operative surgical margins of Non melanoma skin cancers of the head and neck treated with Mohs Surgery Federico Venturi (Bologna, Italy)
EPS04.4	16:21	Skin Pain in Patients with Prurigo Nodularis: Results from the Real-World Patient Survey: PN-TREK EU Study Donia Bahloul (Chilly-Mazarin, France)
EPS04.5	16:28	Pruritus in Pregnancy: Is There a Link to Iron Deficiency? Kerem Balan (Ankara, Türkiye)
EPS04.6	16:35	Early Real-World Experience of Ritlecitinib in the Treatment of Severe Alopecia Areata in British Patients: A Single-Centre Case Series Tang N Shim (Coventry, United Kingdom)
EPS04.7	16:42	Safe Switching from Originator Ustekinumab to FYB202 Ustekinumab Biosimilar in subjects with Moderate-to-severe Plaque Psoriasis: Efficacy, Safety and Immunogenicity data following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study Antonio Costanzo (Milan, Italy)
EPS04.8	16:49	Vilobelimab induced C5a suppression correlates with clinical benefit and pain reduction in patients with ulcerative pyoderma gangrenosum Afsaneh Alavi (Rochester, United States)
EPS04.9	16:56	“Scars of Life”: The Burden of Pruritus in Atopic Dermatitis – A Global Analysis of Its Impact on Quality of Life Delphine Kerob (Levallois Perret, France)
EPS04.10	17:03	Patient Reported Impact and Satisfaction With Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: 12-month Results of the PsABIOnD Observational Study Laure Gossec (Paris, France)
EPS04.11	17:10	Clinically meaningful and sustained itch and skin responses in the OLYMPIA open-label extension nemolizumab study in patients with prurigo nodularis: An interim analysis up to 100 weeks Martin Metz (Berlin, Germany)
EPS04.12	17:17	Real-world efficacy and safety of dupilumab in prurigo nodularis: 52-week results from the BioDay registry Lian van der Gang (Utrecht, Netherlands)
	17:24	Q&A

Wednesday, 17 September 2025

	Plenary session with keynote lecture Chairs: Branka Marinovic (Zagreb, Croatia) Michel Gilliet (Lausanne, Switzerland)
17:45	Welcome from the EADV President Branka Marinovic (Zagreb, Croatia)
17:55	Welcome from the President of the French Society of Dermatology Saskia Oro (Créteil, France)
18:05	Keynote speaker introduction Michel Gilliet (Lausanne, Switzerland)
18:10	Live like a sloth, think like an octopus: Lessons from nature's greatest survivors Lucy Cooke (Hastings, United Kingdom)
18:45	Discussion, Q&A

Networking symposium

Join us to celebrate the start of the 2025 EADV Congress and participate in the first plenary lecture of this year's edition

<p>Following the enriching first plenary session, we invite you to join us for a networking reception to celebrate the start of the 2025 EADV Congress and connect with colleagues and speakers in a relaxed setting.</p>	 
Wednesday, 17 September	
STARTING AT 19:00	
LOCATION: Foyer 7.2.1 – Level 2	

Thursday, 18 September 2025

Programme at a glance

Plenary					12:00 – 13:00
Paris Nord					Plenary Lectures B
Room	08:30 – 10:00	10:15 – 11:45	14:15 – 15:45	16:00 – 17:30	
Paris Nord	Focus on hair disorders: Diagnosis	Focus on hair disorders: Management	Late Breaking News	Late Breaking News	
Paris Sud	Atopic dermatitis	Atopic dermatitis	Nail disorders	Nail disorders	
N01	Paediatric dermatology	Paediatric dermatology	Hidradenitis suppurativa	Hidradenitis suppurativa	
N04	Contact eczema	Chronic hand eczema	Chronic Urticaria in honour of Marcus Maurer	Drug reactions	
N02	Melanoma	Melanoma	Basal cell carcinoma	Squamous cell carcinoma	
N03	Dermatosurgery	Dermatosurgery	Mohs surgery	Off-label use	
S01	Non-genetic rare diseases	Immediate type allergies	Sclerotic skin diseases	Genital diseases	
S02	Controversies I	Controversies II	Controversies III	Controversies IV	
S03	Basal cell carcinoma	Squamous cell carcinoma	Melanoma	Melanoma	
S04	Drug reactions	Urticaria	Atopic dermatitis	Non-atopic eczema	
S05	Fillers I, Basics	Fillers II, Advanced	Botulinum Toxin I, Basics	Fibroblast as a target for rejuvenation	
S06	Autoimmune bullous diseases	Bullous diseases	Imported and emerging viral infections	Infestations and parasitic infections	
W05-W06	Free Communications 1 (Psoriasis)	Free Communications 2 (Psoriasis)	Free Communications 3 (Pigmentary disorders)	Free Communications 4 (Autoimmune disorders)	
W03-W04	AI and social media strategies in dermatological practice	EADV Research funding and Fellowships	Ethics, diversity and Inclusion	Best of Dermatology papers 2025: a panoramic view	
W07	[Workshop] Playing with AI in Dermatology		[Workshop] Dermoscopy – practical and conceptual		
W08	[Workshop] Wound Healing		[Workshop] Confocal Microscopy and LC-OCT		
	ePoster showcase				

Thursday, 18 September 2025

Track: **Focus on**

Room **Paris Nord**

D2T1.1		Focus on hair disorders: Diagnosis Chairs: Alexander Katoulis (Athens, Greece)
D2T1.1A	08:30	Trichoscopy and other non-invasive techniques Lidia Rudnicka (Warsaw, Poland)
D2T1.1B	08:50	Mimickers of androgenetic alopecia in women Ozlem Dicle (İstanbul, Türkiye)
D2T1.1C	09:10	Mimickers of alopecia areata Alexander Katoulis (Athens, Greece)
D2T1.1D	09:30	Pseudopelade Maryanne M. Senna (Burlington, United States)
D2T1.1E	09:50	Discussion, Q&A

Track: **Focus on**

Room **Paris Nord**

D2T1.2		Focus on hair disorders: Management Chairs: Jerry Shapiro (New York, United States) Awatef Kelati (Casablanca, Morocco)
D2T1.2A	10:15	Androgenetic alopecia in children and adults Luis Sanchez (Guadalajara, Mexico)
D2T1.2B	10:35	Alopecia areata in children and adults David Saceda Corralo (Madrid, Spain)
D2T1.2C	10:55	Lichen planopilaris and frontal fibrosing alopecia Jerry Shapiro (New York, United States)
D2T1.2D	11:15	Dissecting cellulitis and folliculitis decalvans Awatef Kelati (Casablanca, Morocco)
D2T1.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Plenary**

Room **Paris Nord**

	Plenary lectures B Chairs: Carmen Maria Salavastru (Bucharest, Romania) Georg Stry (Vienna, Austria)
12:00	New ways of approaching global skin health Lucinda Claire Fuller (London, United Kingdom)
12:20	5-alpha reductase inhibitors "Facts and Myths" Ramon Grimalt (Barcelona, Spain)
12:40	Robotics in dermatology Martin Kassir (Dallas, United States)

Thursday, 18 September 2025

Track: **Updates**

Room **Paris Nord**

D2T1.3		Late breaking news Chairs: Yolanda Gilaberte Calzada (Zaragoza, Spain) Markus Vincent Starink (Amstelveen, Netherlands)
D2T1.3A	14:15	Molecular and clinical effects of oral ATI-2138, an ITK/JAK3 inhibitor, in moderate-to-severe Atopic Dermatitis: Sub-study of a phase 2a open-Label, single-arm trial Jessica Beaziz Tordjman (NY, United States)
D2T1.3B	14:30	DELTA TEEN phase 3 trial: Efficacy and safety of Delgocitinib cream in adolescents with moderate to severe chronic hand eczema Sonja Molin (Berlin, Germany)
D2T1.3C	14:45	Efficacy and safety of Rezpegaldesleukin, a selective Regulatory T-Cell-inducing interleukin-2 conjugate, in the treatment of Atopic Dermatitis: Final results from the 16-week induction of a randomized phase 2b study (REZOLVE AD) Jonathan I. Silverberg (Washington, United States)
D2T1.3D	15:00	Rocatinlimab With concomitant topical therapy significantly improved clinical signs and symptoms of atopic dermatitis in adults: Results from the phase 3 ROCKET-SHUTTLE trial Eric Simpson (Portland, United States)
D2T1.3E	15:15	Safety of delgocitinib cream in adult patients with Chronic Hand Eczema (CHE): pooled analysis of five phase 2b and phase 3 trials Robert Bissonnette (Montreal, Canada)
D2T1.3F	15:30	Whole genome sequencing analysis of generalized pustular psoriasis samples from a global clinical study Sandra Smieszek (DC, United States)

Track: **Updates**

Room **Paris Nord**

D2T1.4		Late breaking news Chairs: Georg Stary (Vienna, Austria) Paola Pasquali (Cambrils (TA), Spain)
D2T1.4A	16:00	Demonstration of early proof-of-concept for STAR-0310, a long-acting OX40 receptor antagonist: Initial safety, PK, and PD results from a phase 1a trial Stephan Weidinger (Kiel, Germany)
D2T1.4B	16:15	JAK3/TEC inhibition is safe and effective in cicatricial alopecias: Evidence from a prospective trial Anusha Pasumarthi (New York, United States)
D2T1.4C	16:30	Predictive factors for early super response to Bimekizumab in 341 patients with psoriasis - A 24 week short term multicenter real life experience Tubanur Cetinarslan (Manisa, Türkiye)
D2T1.4D	16:45	Phase 1 clinical data of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody with potential for once-yearly dosing in plaque psoriasis James Krueger (New York, United States)
D2T1.4E	17:00	Dose reduction of IL-17 and IL-23 inhibitors in patients with plaque psoriasis is non-inferior to usual care: an international pragmatic randomized controlled trial – The BeNeBio study Juil van den Reek (Nijmegen, Netherlands)
D2T1.4F	17:15	Long-term holistic management in psoriatic disease: Tildrakizumab achieves sustained control of skin manifestations, psychological well-being, and partner quality of life - The POSITIVE study Ulrich Mrowietz (Kiel, Germany)

Thursday, 18 September 2025

Track: **Updates**

Room **Paris Sud**

D2T2.1		Atopic dermatitis Chairs: Laura Maintz (Bonn, Germany) Carsten Flohr (London, United Kingdom)
D2T2.1A	08:30	Understanding endotypes Patrick Brunner (New York, United States)
D2T2.1B	08:50	Comorbidities Delphine Staumont Salle (Lille, France)
D2T2.1C	09:10	How can we stop atopic march in children? Laura Maintz (Bonn, Germany)
D2T2.1D	09:30	Special focus: Children Carsten Flohr (London, United Kingdom)
D2T2.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **Paris Sud**

D2T2.2		Atopic dermatitis Chairs: Emma Guttman-Yassky (New York, United States) Matthias Schmuth (Innsbruck, Austria)
D2T2.2A	10:15	New and upcoming treatments Emma Guttman-Yassky (New York, United States)
D2T2.2B	10:35	Role of environment and allergens in AD flares Matthias Schmuth (Innsbruck, Austria)
D2T2.2C	10:55	Super responders and disease modification Eric Simpson (Portland, United States)
D2T2.2D	11:15	Difficult to treat and treatment-resistant AD Thomas Bieber (Bonn, Germany)
D2T2.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **Paris Sud**

D2T2.3		Nail disorders Chairs: Matilde Iorizzo (Lugano, Switzerland) Bertrand Richert (Brussels, Belgium)
D2T2.3A	14:15	Nail psoriasis Matilde Iorizzo (Lugano, Switzerland)
D2T2.3B	14:35	Drug-induced nail changes Tomer Goldsmith (Tel Aviv, Israel)
D2T2.3C	14:55	Lichen planus Bertrand Richert (Brussels, Belgium)
D2T2.3D	15:15	Special focus: Children Lourdes Navarro Campoamor (Madrid, Spain)
D2T2.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **Paris Sud**

D2T2.4		Nail disorders Chairs: Luc Thomas (Pierre-Bénite, France) Begoña Echeverria Garcia (Fuenlabrada, Spain)
D2T2.4A	16:00	Dermoscopy of nail pigmentation Luc Thomas (Pierre-Bénite, France)
D2T2.4B	16:20	Ultrasound Begoña Echeverria Garcia (Fuenlabrada, Spain)
D2T2.4C	16:40	Biopsy techniques and surgery Andre Lencastre (Alcabideche, Portugal)
D2T2.4D	17:00	Laser and PDT Michela Starace (Bologna, Italy)
D2T2.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **N01**

D2T3.1		Paediatric dermatology Chairs: Neil Rajan (Newcastle upon Tyne, United Kingdom) Ulrike Blume-Peytavi (Berlin, Germany)
D2T3.1A	08:30	New advances in genodermatoses Neil Rajan (Newcastle upon Tyne, United Kingdom)
D2T3.1B	08:50	New mosaic skin diseases Pierre Vabres (Dijon, France)
D2T3.1C	09:10	New hair and nail diseases Ulrike Blume-Peytavi (Berlin, Germany)
D2T3.1D	09:30	Ancillary testing clues for challenging paediatric cases Minia Campos (Madrid, Spain)
D2T3.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N01**

D2T3.2		Paediatric dermatology Chairs: Cristina Has (Freiburg, Germany) Martin Theiler (Zurich, Switzerland)
D2T3.2A	10:15	JAK inhibitors for children Andreas Wollenberg (Augsburg, Germany)
D2T3.2B	10:35	Biologic therapy in children Amy Paller (Chicago, United States)
D2T3.2C	10:55	Treatment of genetic skin diseases Cristina Has (Freiburg, Germany)
D2T3.2D	11:15	Difficult to treat paediatric diseases Martin Theiler (Zurich, Switzerland)
D2T3.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **N01**

D2T3.3		Hidradenitis suppurativa Chairs: Ruta Ganceviciene (Vilnius, Lithuania) Lukasz Matusiak (Wroclaw, Poland)
D2T3.3A	14:15	Understanding disease forms Gregor Borut Jemec (Roskilde, Denmark)
D2T3.3B	14:35	Comorbidities Lukasz Matusiak (Wroclaw, Poland)
D2T3.3C	14:55	Modifying disease progression Axel Villani (Lyon, France)
D2T3.3D	15:15	Special focus: Women Ruta Ganceviciene (Vilnius, Lithuania)
D2T3.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **N01**

D2T3.4		Hidradenitis suppurativa Chairs: Francesca Prignano (Florence, Italy) Thrasyvoulos Tzellos (Bodø, Norway)
D2T3.4A	16:00	Assessing disease severity Francesca Prignano (Florence, Italy)
D2T3.4B	16:20	Management of HS in 2025 Christos C. Zouboulis (Dessau, Germany)
D2T3.4C	16:40	Surgical approach Antonio Martorell Calatayud (Valencia, Spain)
D2T3.4D	17:00	Upcoming treatments Thrasyvoulos Tzellos (Bodø, Norway)
D2T3.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **N04**

D2T4.1		Contact eczema Chairs: Claus Zachariae (Hellerup, Denmark) Jana Kazandjieva (Sofia, Bulgaria)
D2T4.1A	08:30	Understanding contact allergies Claus Zachariae (Hellerup, Denmark)
D2T4.1B	08:50	New contact allergens in 2025 Jonathan White (Brussel, Belgium)
D2T4.1C	09:10	Metal allergies: Skin and beyond Peter Thomas (Munich, Germany)
D2T4.1D	09:30	Special focus: Children Jana Kazandjieva (Sofia, Bulgaria)
D2T4.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N04**

D2T4.2		Chronic hand eczema Chairs: Marie-Louise Schuttelaar (Groningen, Netherlands) David Pesqué (Barcelona, Spain)
D2T4.2A	10:15	What exactly is CHE? Sonja Molin (Berlin, Germany)
D2T4.2B	10:35	Diagnostic workup of CHE David Pesqué (Barcelona, Spain)
D2T4.2C	10:55	New treatments Marie-Louise Schuttelaar (Groningen, Netherlands)
D2T4.2D	11:15	Special focus: Workers Maria Pesonen (Helsinki, Finland)
D2T4.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **N04**

D2T4.3		Chronic urticaria in honour of Marcus Maurer Chairs: Martin Metz (Berlin, Germany) Margarida Gonçalo (Coimbra, Portugal)
D2T4.3A	14:15	Understanding chronic spontaneous urticaria Martin Metz (Berlin, Germany)
D2T4.3B	14:35	Understanding chronic inducible urticaria Mojca Bizjak (Golnik, Slovenia)
D2T4.3C	14:55	Diagnostic workup Margarida Gonçalo (Coimbra, Portugal)
D2T4.3D	15:15	New treatments Ana Giménez-Arnau (Barcelona, Spain)
D2T4.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **N04**

D2T4.4		Drug reactions Chairs: Maja Mockenhaupt (Freiburg, Germany) Saskia Oro (Créteil, France)
D2T4.4A	16:00	Understanding and managing AGEP vs GPP Maja Mockenhaupt (Freiburg, Germany)
D2T4.4B	16:20	Understanding and managing DRESS syndrome Vincent Descamps (Paris, France)
D2T4.4C	16:40	Understanding and managing epidermal necrolysis Elizabeth Phillips (Nashville, United States)
D2T4.4D	17:00	Special focus: Oncologic patients Saskia Oro (Créteil, France)
D2T4.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **N02**

D2T5.1		Melanoma Chairs: Eduardo Nagore (Valencia, Spain) Danica Tiodorovic (Nis, Serbia)
D2T5.1A	08:30	Screening and prevention campaigns: Are they delivering? Veronique del Marmol (Brussels, Belgium)
D2T5.1B	08:50	Total body and lesion-directed imaging Danica Tiodorovic (Nis, Serbia)
D2T5.1C	09:10	Sentinel lymph node biopsy: Is it still useful? Eduardo Nagore (Valencia, Spain)
D2T5.1D	09:30	Identifying high risk groups Ana-Maria Forsea (Bucharest, Romania)
D2T5.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N02**

D2T5.2		Melanoma Chairs: Simone Ribero (Turin, Italy) Lukas Flatz (Tübingen, Germany)
D2T5.2A	10:15	Immunotherapy and targeted therapy Nikolas Haas (Woolloongabba, Australia)
D2T5.2B	10:35	Adjuvant and neoadjuvant therapies Simone Ribero (Turin, Italy)
D2T5.2C	10:55	Cellular therapy Lukas Flatz (Tübingen, Germany)
D2T5.2D	11:15	Special focus: Pregnancy Marek Pásek (Prague, Czech Republic)
D2T5.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **N02**

D2T5.3		Basal cell carcinoma Chairs: Caterina Longo (Modena, Italy) Celeste Lebbe (Paris, France)
D2T5.3A	14:15	Beyond sun exposure: Role of the exposome Almudena Nuno Gonzalez (Madrid, Spain)
D2T5.3B	14:35	Imaging for diagnosis and follow-up Caterina Longo (Modena, Italy)
D2T5.3C	14:55	Minimally invasive treatment Christopher Bower (Exeter, United Kingdom)
D2T5.3D	15:15	Treatment of advanced tumours Celeste Lebbe (Paris, France)
D2T5.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **N02**

D2T5.4		Squamous cell carcinoma Chairs: Kiarash Khosrotehrani (Ascot, Australia) Alexander Stratigos (Athens, Greece)
D2T5.4A	16:00	Identifying and managing high risk groups Kiarash Khosrotehrani (Ascot, Australia)
D2T5.4B	16:20	Non-invasive treatment Alexander Stratigos (Athens, Greece)
D2T5.4C	16:40	Treatment of advanced tumours Emily Ruiz (Boston, United States)
D2T5.4D	17:00	Special focus: Outdoor workers Sven Malte John (Osnabrück, Germany)
D2T5.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **N03**

D2T6.1		Dermatosurgery Chairs: John Paoli (Gothenburg, Sweden) Judith Ulla Ostertag (Maastricht, Netherlands)
D2T6.1A	08:30	Surgical margins for melanoma Cristian Navarrete-Dechent (Santiago, Chile)
D2T6.1B	08:50	Surgical margins for BCC and SCC John Paoli (Gothenburg, Sweden)
D2T6.1C	09:10	Reconstruction tips in geriatric patients Judith Ulla Ostertag (Maastricht, Netherlands)
D2T6.1D	09:30	Laser treatments for surgical scars Khaled Turki (Nabeul, Tunisia)
D2T6.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N03**

D2T6.2		Dermatosurgery Chairs: Severin Lächli (Zurich, Switzerland) John Paoli (Gothenburg, Sweden)
D2T6.2A	10:15	Reconstructions: Nose I Stanislav Tolkachjov (Lewisville, United States)
D2T6.2B	10:25	Reconstructions: Nose II Michael Mühlstädt (Geneva, Switzerland)
D2T6.2C	10:35	Reconstructions: Scalp / ear I Ally-Khan Somani (Orland Park, United States)
D2T6.2D	10:45	Reconstructions: Scalp / ear II Pedro Redondo Bellon (Madrid, Spain)
D2T6.2E	10:55	Reconstructions: Lower face I Olivier Cogrel (Bordeaux, France)
D2T6.2F	11:05	Reconstructions: Lower face II Antoni Bennàssar Vicens (Palma de Mallorca, Spain)
D2T6.2G	11:15	Reconstructions: Trunk and extremities I Goran van Rooijen (Haarlem, Netherlands)
D2T6.2H	11:25	Reconstructions: Trunk and extremities II Elena Rossi (Modena, Italy)
D2T6.2I	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **N03**

D2T6.3		Mohs surgery Chairs: Severin Läuchli (Zurich, Switzerland) Joseph Alcalay (Tel Aviv, Israel)
D2T6.3A	14:15	Mohs surgery in Europe Severin Läuchli (Zurich, Switzerland)
D2T6.3B	14:35	Mohs surgery for lentigo maligna Agustín Toll (Barcelona, Spain)
D2T6.3C	14:55	Mohs surgery for Dermatofibrosarcoma protuberans Brent Moody (Nashville, United States)
D2T6.3D	15:15	Neoadjuvant treatments in Mohs surgery Joseph Alcalay (Tel Aviv, Israel)
D2T6.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **N03**

D2T6.4		Off-label use Chairs: Diamant Thaçi (Luebeck, Germany) Marjolein de Bruin-Weller (Utrecht, Netherlands)
D2T6.4A	16:00	JAK inhibitors and PDE4 inhibitors Brett King (New Haven, United States)
D2T6.4B	16:20	Anti-Th17 biologics Diamant Thaçi (Luebeck, Germany)
D2T6.4C	16:40	Anti-Th2 biologics Marjolein de Bruin-Weller (Utrecht, Netherlands)
D2T6.4D	17:00	Botulinum toxin Oliver Kreyden (Muttens, Switzerland)
D2T6.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **S01**

D2T7.1		Non-genetic rare diseases Chairs: Giampiero Girolomoni (Verona, Italy) Dagmar Simon (Bern, Switzerland)
D2T7.1A	08:30	Eosinophilic cellulitis and folliculitis Dagmar Simon (Bern, Switzerland)
D2T7.1B	08:50	Pityriasis lichenoides (PLC and PLEVA) Giampiero Girolomoni (Verona, Italy)
D2T7.1C	09:10	Mucinosi and systemic amyloidosis Franco Rongioletti (Milan, Italy)
D2T7.1D	09:30	Figurate erythemas Alexander Böhner (Munich, Germany)
D2T7.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **S01**

D2T7.2		Immediate type allergies Chairs: Peter Schmid-Grendelmeier (Zurich, Switzerland) Luca Stingeni (Corciano, Italy)
D2T7.2A	10:15	Food allergens Torsten Zuberbier (Berlin, Germany)
D2T7.2B	10:35	Aero-allergens Peter Schmid-Grendelmeier (Zurich, Switzerland)
D2T7.2C	10:55	Protein contact dermatitis Luca Stingeni (Corciano, Italy)
D2T7.2D	11:15	Desensitisation (immunotherapy) Thomas Kuendig (Zurich, Switzerland)
D2T7.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **S01**

D2T7.3		Sclerotic skin diseases Chairs: Aleksandra Dańczak-Pazdrowska (Poznan, Poland) Franco Rongioletti (Milan, Italy)
D2T7.3A	14:15	Understanding sclerosing diseases Bartosz Miziołek (Katowice, Poland)
D2T7.3B	14:35	Management of systemic sclerosis Marija Geroldinger-Simic (Linz, Austria)
D2T7.3C	14:55	Localised scleroderma Aleksandra Dańczak-Pazdrowska (Poznan, Poland)
D2T7.3D	15:15	Sclerosing diseases as a manifestation of haematological malignancies Franco Rongioletti (Milan, Italy)
D2T7.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **S01**

D2T7.4		Genital diseases Chairs: Christopher Barry Bunker (London, United Kingdom) Mariana Jimena Martinez (Mendoza, Argentina)
D2T7.4A	16:00	Lichen sclerosus Christopher Barry Bunker (London, United Kingdom)
D2T7.4B	16:20	Vulvodynia Mariana Jimena Martinez (Mendoza, Argentina)
D2T7.4C	16:40	Intraepithelial neoplasia Vincenzo De Giorgi (Florence, Italy)
D2T7.4D	17:00	Zoon plasma cell balanitis and vulvitis Rafael Pasternack (Tampere, Finland)
D2T7.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Controversies**

Room **S02**

D2T8.1		Controversies I Chairs: Michel Gilliet (Lausanne, Switzerland) Alexander Zink (Munich, Germany)
D2T8.1A	08:30	Introduction Alexander Zink (Munich, Germany)
D2T8.1B	08:35	Will ChatGPT improve patient management? YES Laura Serra (Barcelona, Spain)
D2T8.1C	08:50	Will ChatGPT improve patient management? NO Josep Malvehy (Barcelona, Spain)
D2T8.1D	09:05	Discussion, Q&A
D2T8.1E	09:15	Introduction Michel Gilliet (Lausanne, Switzerland)
D2T8.1F	09:20	Will molecular based approach replace morphological diagnosis? YES Kilian Eyerich (Freiburg, Germany)
D2T8.1G	09:35	Will molecular based approach replace morphological diagnosis? NO Christian Posch (Vienna, Austria)
D2T8.1H	09:50	Discussion, Q&A

Track: **Controversies**

Room **S02**

D2T8.2		Controversies II Chairs: Nicole Jeanne Jouan (Brest, France) Margarida Gonçalves (Coimbra, Portugal)
D2T8.2A	10:15	Introduction Margarida Gonçalves (Coimbra, Portugal)
D2T8.2B	10:20	Toxic epidermal necrolysis - supportive treatment Elizabeth Phillips (Nashville, United States)
D2T8.2C	10:35	Toxic epidermal necrolysis - immune modulation Michael Arden-Jones (Southampton, United Kingdom)
D2T8.2D	10:50	Discussion, Q&A
D2T8.2E	11:00	Introduction Nicole Jeanne Jouan (Brest, France)
D2T8.2F	11:05	Diet in treatment of acne? YES Brigitte Dréno (Nantes, France)
D2T8.2G	11:20	Diet in treatment of acne? NO Clio Dessinioti (Athens, Greece)
D2T8.2H	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Controversies**

Room **S02**

D2T8.3		Controversies III Chairs: Peter Wolf (Graz, Austria) Jo Lambert (Ghent, Belgium)
D2T8.3A	14:15	Introduction Jo Lambert (Ghent, Belgium)
D2T8.3B	14:20	GLP-1 agonist for dermatological conditions? YES Jose-Manuel Carrascosa (Badalona, Spain)
D2T8.3C	14:35	GLP-1 agonist for dermatological conditions? NO Jacek Szepietowski (Wroclaw, Poland)
D2T8.3D	14:50	Discussion, Q&A
D2T8.3E	15:00	Introduction Peter Wolf (Graz, Austria)
D2T8.3F	15:05	Is there still a place for phototherapy in psoriasis? YES Henry W. Lim (Grosse Pointe, MI, United States)
D2T8.3G	15:20	Is there still a place for phototherapy in psoriasis? NO Wolfgang Weger (Graz, Austria)
D2T8.3H	15:35	Discussion, Q&A

Track: **Controversies**

Room **S02**

D2T8.4		Controversies IV Chairs: Antonio Torrelo (Madrid, Spain) Lidia Rudnicka (Warsaw, Poland)
D2T8.4A	16:00	Introduction Lidia Rudnicka (Warsaw, Poland)
D2T8.4B	16:05	Platelet-rich plasma for alopecia: YES Daniel Asz Sigall (Mexico City, Mexico)
D2T8.4C	16:20	Platelet-rich plasma for alopecia: NO Adriana Rakowska (Warsaw, Poland)
D2T8.4D	16:35	Discussion, Q&A
D2T8.4E	16:45	Introduction Antonio Torrelo (Madrid, Spain)
D2T8.4F	16:50	Molluscum contagiosum and warts in children - To treat Luca Bianchi (Rome, Italy)
D2T8.4G	16:55	Molluscum contagiosum and warts in children - Not to treat Sébastien Barbarot (Nantes, France)
D2T8.4H	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Training and education**

Room **S03**

D2T9.1		Basal cell carcinoma Chairs: François Kuonen (Lausanne, Switzerland) Elvira Moscarella (Naples, Italy)
D2T9.1A	08:30	Diagnosing subtypes Elvira Moscarella (Naples, Italy)
D2T9.1B	08:50	Treatment of non-high risk tumours Eva Backman (Gothenburg, Sweden)
D2T9.1C	09:10	Treatment of high-risk tumours Rafael Botella-Estrada (Valencia, Spain)
D2T9.1D	09:30	Systemic therapy François Kuonen (Lausanne, Switzerland)
D2T9.1E	09:50	Discussion, Q&A

Track: **Training and education**

Room **S03**

D2T9.2		Squamous cell carcinoma Chairs: David Moreno-Ramirez (Sevilla, Spain) Caroline Gaudy-Marqueste (Marseille, France)
D2T9.2A	10:15	Diagnosing subtypes Iris Zalaudek (Trieste, Italy)
D2T9.2B	10:35	Treatment of low risk tumours Veronique Bataille (Hemel Hempstead, United Kingdom)
D2T9.2C	10:55	Treatment of high-risk tumours David Moreno-Ramirez (Sevilla, Spain)
D2T9.2D	11:15	Novel and upcoming systemic therapy Caroline Gaudy-Marqueste (Marseille, France)
D2T9.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Training and education**

Room **S03**

D2T9.3		Melanoma Chairs: Giulia Briatico (Naples, Italy) Martin Röcken (Tübingen, Germany)
D2T9.3A	14:15	Management of early stage Giulia Briatico (Naples, Italy)
D2T9.3B	14:35	Biopsy and excision margins Christoffer Gebhardt (Hamburg, Germany)
D2T9.3C	14:55	New prognostic biomarkers Martin Röcken (Tübingen, Germany)
D2T9.3D	15:15	Follow up after diagnosis Petr Arenberger (Prague, Czech Republic)
D2T9.3E	15:35	Discussion, Q&A

Track: **Training and education**

Room **S03**

D2T9.4		Melanoma Chairs: Cristina Carrera (Barcelona, Spain) Thomas Eigentler (Berlin, Germany)
D2T9.4A	16:00	Adjuvant treatment Cristina Carrera (Barcelona, Spain)
D2T9.4B	16:20	Neoadjuvant treatment Simone Ribero (Turin, Italy)
D2T9.4C	16:40	Management of immune related adverse events Aram Boada (Badalona, Spain)
D2T9.4D	17:00	Combination of mRNA vaccines and immunotherapy Thomas Eigentler (Berlin, Germany)
D2T9.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Training and education**

Room **S04**

D2T10.1		Drug reactions Chairs: Annick Barbaud (Paris, France) Wolfram Hoetzenecker (Linz, Austria)
D2T10.1A	08:30	Immediate drug reactions Marie Tauber (Pierre-Bénite, France)
D2T10.1B	08:50	Severe drug reactions Annick Barbaud (Paris, France)
D2T10.1C	09:10	Maculopapular exanthema: Virus, drug or both? Wolfram Hoetzenecker (Linz, Austria)
D2T10.1D	09:30	SDRIFE and fixed drug eruption Roni Dodiuk-Gad (Haifa, Israel)
D2T10.1E	09:50	Discussion, Q&A

Track: **Training and education**

Room **S04**

D2T10.2		Urticaria Chairs: Emek Kocatürk Göncü (Istanbul, Türkiye) Hilde Lapeere (Ghent, Belgium)
D2T10.2A	10:15	Classification Angèle Soria (Paris, France)
D2T10.2B	10:35	Diagnostic workup Hilde Lapeere (Ghent, Belgium)
D2T10.2C	11:15	Treatment Andac Salman (Istanbul, Türkiye)
D2T10.2D	10:55	Urticaria vasculitis Emek Kocatürk Göncü (Istanbul, Türkiye)
D2T10.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: Training and education

Room S04

D2T10.3		Atopic dermatitis Chairs: Mette Sondergaard Deleuran (Aarhus, Denmark) Magdalena Trzeciak (Gdansk, Poland)
D2T10.3A	14:15	Pathophysiology comorbidities Melinda Gooderham (Peterborough, Canada)
D2T10.3B	14:35	Phenotypes Mette Sondergaard Deleuran (Aarhus, Denmark)
D2T10.3C	14:55	Conventional systemic treatments Magdalena Trzeciak (Gdansk, Poland)
D2T10.3D	15:15	Biologics and JAK inhibitors Teresa Løvold Berents (Oslo, Norway)
D2T10.3E	15:35	Discussion, Q&A

Track: Training and education

Room S04

D2T10.4		Non-atopic eczema Chairs: Annarita Antelmi (Malmö, Sweden) Dimitrios Ioannides (Thessaloniki, Greece)
D2T10.4A	16:00	Hand eczema and its subtypes Richard Brans (Osnabrück, Germany)
D2T10.4B	16:20	Allergic contact dermatitis Katharina Hansel (Perugia, Italy)
D2T10.4C	16:40	Photoallergic contact dermatitis Annarita Antelmi (Malmö, Sweden)
D2T10.4D	17:00	Seborrheic eczema Dimitrios Ioannides (Thessaloniki, Greece)
D2T10.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **S05**

D2T11.1		Fillers I, Basics Chair: Berthold Rzany (Wien, Austria)
D2T11.1A	08:30	Filler for beginners Oliver Kreyden (Muttensz, Switzerland)
D2T11.1B	08:50	Smart filling with 1 to 2 ml Daisy Kopera (Graz, Austria)
D2T11.1C	09:10	Full face approach with 3 and more ml Luis Uva (Lisbon, Portugal)
D2T11.1D	09:30	Adverse events and how to manage them Berthold Rzany (Wien, Austria)
D2T11.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **S05**

D2T11.2		Fillers II, Advanced Chairs: Pierre Andre (Paris, France)
D2T11.2A	10:15	Ultrasound in aesthetic dermatology Hugues Cartier (Arras, France)
D2T11.2B	10:35	The periocular region: How can it be improved? Wayne Carey (Montreal, Canada)
D2T11.2C	10:55	How to manage complications of non permanent fillers? Pierre Andre (Paris, France)
D2T11.2D	11:15	How to prevent, detect and treat vascular compromise after filler injections? Tanja Fischer (Potsdam, Germany)
D2T11.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **S05**

D2T11.3		Botulinum Toxin I, Basics Chair: Andreas Katsambas (Athens, Greece)
D2T11.3A	14:15	How to achieve natural results Ines Verner Rashkovsky (Savyon, Israel)
D2T11.3B	14:35	Meso-botox Peter Velthuis (Rotterdam, Netherlands)
D2T11.3C	14:55	Tips and tricks for mid and lower face Andreas Katsambas (Athens, Greece)
D2T11.3D	15:15	Scar prevention and wound healing Leonardo Marini (Trieste, Italy)
D2T11.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **S05**

D2T11.4		Fibroblast as a target for rejuvenation Chair: Hans-Joachim Laubach (Geneva, Switzerland)
D2T11.4A	16:00	Fibroblasts in different ethnicities and skin types Emanuel Carneiro Marques (Prague, Czech Republic)
D2T11.4B	16:00	Senescent fibroblasts in ageing skin Sadaf Sanii (Lausanne, Switzerland)
D2T11.4C	16:40	Injectables to stimulate fibroblasts Muriel Creusot (Plancenoit, Belgium)
D2T11.4D	17:00	EBDs to stimulate fibroblasts Hans-Joachim Laubach (Geneva, Switzerland)
D2T11.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **S06**

D2T12.1		Autoimmune bullous diseases Chairs: Luca Borradori (Bern, Switzerland) Dédée Murrell (Sydney, Australia)
D2T12.1A	08:30	Clinical and diagnostic approach to pemphigoid Luca Borradori (Bern, Switzerland)
D2T12.1B	08:50	New and emerging treatments of pemphigoid Frederic Caux (Bobigny, France)
D2T12.1C	09:10	Clinical and diagnostic approach to pemphigus Dédée Murrell (Sydney, Australia)
D2T12.1D	09:30	New and emerging treatments of pemphigus Pascal Joly (Rouen, France)
D2T12.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **S06**

D2T12.2		Bullous diseases Chairs: Carmen Maria Salavastru (Bucharest, Romania) Barbara Horvath (Groningen, Netherlands)
D2T12.2A	10:15	Herpetiform dermatitis Agnieszka Zebrowska (Lodz, Poland)
D2T12.2B	10:35	Epidermolysis bullosa acquisita Barbara Horvath (Groningen, Netherlands)
D2T12.2C	10:55	Bullae in other skin diseases Emiliano Antiga (Florence, Italy)
D2T12.2D	11:15	Special focus: Children Carmen Maria Salavastru (Bucharest, Romania)
D2T12.2E	11:35	Discussion, Q&A

Thursday, 18 September 2025

Track: **Updates**

Room **S06**

D2T12.3		Imported and emerging viral infections Chairs: Vincent Piguet (Toronto, Canada) Diana Rojas Alvarez (Geneva, Switzerland)
D2T12.3A	14:15	Zika and West Nile Vincent Piguet (Toronto, Canada)
D2T12.3B	14:35	Dengue and Chikungunya Virus Omar Lupi (Rio De Janeiro, Brazil)
D2T12.3C	14:55	Oropouche fever Diana Rojas Alvarez (Geneva, Switzerland)
D2T12.3D	15:15	M-pox Claire Dewsnap (Sheffield, United Kingdom)
D2T12.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **S06**

D2T12.4		Infestations and parasitic infections Chairs: Patricia Daps (Vitoria, Brazil) Gianluca Nazzaro (Milan, Italy)
D2T12.4A	16:00	Cutaneous leishmaniasis Patricia Daps (Vitoria, Brazil)
D2T12.4B	16:20	Larva migrans Guadalupe Estrada-Chavez (Acapulco, Mexico)
D2T12.4C	16:40	Cutaneous myiasis Gianluca Nazzaro (Milan, Italy)
D2T12.4D	17:00	Scabies and lice Anne-Marte Henriksen (Tromsø, Norway)
D2T12.4E	17:20	Discussion, Q&A

Thursday, 18 September 2025

Track: Free communication

Room W05-W06

FC01		Free Communication 1 (Psoriasis) Chairs: Lidija Kandolf-Sekulovic (Belgrade, Serbia) Laurent Misery (Brest, France)
FC01.1A	08:30	Pregnancy related-outcomes in women with moderate-to-severe psoriasis: Analysis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), on behalf of the BADBIR study group Oras Alabas (Manchester, United Kingdom)
FC01.1B	08:40	Exploring super responders who remained treatment-free for more than 3 years after guselkumab withdrawal: Insights from the phase 3b GUIDE trial in psoriasis Knut Schäkel (Heidelberg, Germany)
FC01.1C	08:50	Psoriasis management after autologous stem cell transplantation: Clinical and immunologic insights from IL-17 Inhibition Roberto Bueno Filho (Ribeirão Preto, Brazil)
FC01.1D	09:00	Zasocitinib (TAK-279), an oral, allosteric, highly selective TYK2 inhibitor, reduced PASI body region and individual component scores in a phase 2b trial in moderate-to-severe plaque psoriasis Melinda Gooderham (Peterborough, Canada)
FC01.1E	09:10	Healthcare resource utilization for patients with generalized pustular psoriasis (GPP) from a French claims database Denis Jullien (Lyon, France)
FC01.1F	09:20	Efficacy and safety of Guselkumab for the treatment of moderate-to-severe psoriasis: A systematic review and meta-analysis of randomized placebo-controlled trials Laura Ghanem (Beirut, Lebanon)
FC01.1G	09:30	Icotrokinra demonstrated superior responses compared with placebo and Deucravacitinib in the treatment of moderate-to-severe plaque psoriasis: Results through week 24 of the phase 3 ICONIC-ADVANCE 1&2 studies Linda Stein Gold (Michigan, United States)
FC01.1H	09:40	Understanding psoriasis care costs and the impact of comorbidities: A time-driven activity-based costing analysis in an integrated practice unit Emma Vyvey (Ghent, Belgium)
FC01.1I	09:50	Serious infection risk with systemic treatments for psoriasis: A cohort study using British Association of Dermatologists Biologic and Immunomodulators Register Heber Rew Bright Bright (Manchester, United Kingdom)

Thursday, 18 September 2025

FC02		Free Communication 2 (Psoriasis) Chairs: Anna Balato (Napoli, Italy) Dimitra Koumaki (Heraklion, Crete, Greece)
FC02.1A	10:15	Subclinical synovitis in patients with psoriasis: A systematic review and meta-analysis Grace Xiong (Hamilton, Canada)
FC02.1B	10:25	Choice of a systemic treatment for psoriasis: Data from the German Psoriasis Registry PsoBest Kühl Laura (Hamburg, Germany)
FC02.1C	10:35	Long-term integrated analysis of clinical trial data to evaluate the safety of Risankizumab in patients with psoriatic disease Kenneth B. Gordon (Milwaukee, United States)
FC02.1D	10:45	The impact of climate change on chronic inflammatory skin diseases: A focus on eczema and psoriasis Shakhzoda Uchkunkhonova (Tashkent, Uzbekistan)
FC02.1E	10:55	High Body Mass Index (BMI) psoriasis is associated with higher prevalence of cardiometabolic disease, psoriatic arthritis, and systemic inflammation. Joseph F. Merola (Dallas, United States)
FC02.1F	11:05	Early intervention with guselkumab is associated with greater efficacy and higher rates of complete skin clearance independent of super responder status: The phase 3b GUIDE trial in psoriasis Andreas Pinter (Frankfurt am Main, Germany)
FC02.1G	11:15	VISIBLE: Guselkumab impact on psoriatic arthritis through week 48 in participants with moderate-to-severe psoriasis across all skin tones Joseph F. Merola (Dallas, United States)
FC02.1H	11:25	Efficacy and safety of Icotrokinra, a novel targeted oral peptide (IL-23R-inhibitor), in adolescents with moderate-to-severe plaque psoriasis: Subgroup analyses from a phase-3, randomized, double-blind, placebo-controlled study (ICONIC-LEAD) Lawrence Eichenfield (San Diego, United States)
FC02.1I	11:35	EVERLAST-A: A phase 2a study design of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody for plaque psoriasis Andrew Blauvelt (Portland, United States)

Thursday, 18 September 2025

Track: **Free communication**

Room **W05-W06**

FC03		Free Communication 3 (Pigmentary disorders) Chairs: Ashraf Badawi (Oakville, Canada) Kornelia Böhler (Vienna, Austria)
FC03.1A	14:15	Low-dose Interleukin-2 restores immune tolerance and drives rapid repigmentation in vitiligo by enhancing Regulatory T Cell function Antonios Kolios (Zurich, Switzerland)
FC03.1B	14:25	Prevalence of immune-mediated inner ear disease in non-segmental vitiligo: A cross-sectional study Helena Marchioro (Piraquara, Brazil)
FC03.1C	14:35	Metabolic dysregulation and immune activation in vitiligo: Unveiling the mitochondrial and inflammatory imprint of disease pathogenesis Barbara Bellei (Rome, Italy)
FC03.1D	14:45	Cohort study of vitiligo activity markers Arij Danden (Saint-Petersburg, Russian Federation)
FC03.1E	14:55	Efficacy and tolerability of topical timolol for reducing infraorbital bruising following mesotherapy for periorbital hyperpigmentation: A double-blinded randomized controlled trial Houriah Nukaly (Montreal, Saudi Arabia)
FC03.1F	15:05	Bidirectional association between vitiligo and melasma: A large-scale population-based study Shany Sherman (Tel Aviv, Israel)
FC03.1G	15:15	Prevalence and clinical characteristics of vitiligo-associated hearing loss among patients enrolled in a phase 2 clinical trial of Povorcitinib Leandro L. Santos (Wilmington, United States)
FC03.1H	15:25	Afamelanotide: A novel promising treatment for vitiligo case studies from the randomized CUV105 clinical trial Antoine Bertolotti (Saint Pierre, Reunion)
FC03.1I	15:35	Ex vivo organ culture model of vitiligo skin acts as preclinical research platform demonstrating Ruxolitinib's anti-inflammatory and pigmentation-promoting responses Janin Edelkamp (Münster, Germany)

Thursday, 18 September 2025

Track: **Free communication**

Room **W05-W06**

FC04		Free Communication 4 (Autoimmune disorders) Chairs: Carlo Pincelli (Modena, Italy) Kossara Drenovska (Sofia, Bulgaria)
FC04.1A	16:00	Cell-free DNA profiles of dermatomyositis and its potential role in discriminating phenotypes Zhuangli Tang (Hangzhou, China)
FC04.1B	16:10	Correlation of clinical and histopathological features with anti-desmoglein antibody profile in pemphigus patients Hitaishi Mehta (Chandigarh, India)
FC04.1C	16:20	Differential risks of venous thromboembolic events in pemphigus and pemphigoid diseases: A large-scale retrospective cohort study Ralf Ludwig (Lübeck, Germany)
FC04.1D	16:30	Topical gluconolactone induces immune tolerance in cutaneous lupus erythematosus in human and mice Antonios Kolios (Zurich, Switzerland)
FC04.1E	16:40	Bullous pemphigoid and hematologic malignancies: Clarifying the debatable association by a large-scale population-based study Khalaf Kridin (Poriya, Israel)
FC04.1F	16:50	Rapid improvement of cutaneous dermatomyositis with Brepocitinib: A 12-week open-label trial Aaron Mangold (Scottsdale, United States)
FC04.1G	17:00	A retrospective analysis of clinical presentations in anti-SAE subtype dermatomyositis: A case series from India Urmila Yellamelli (Vellore, India)
FC04.1H	17:10	When urticarial-like lesions do not represent common urticaria: A case report of McDuffie syndrome Gabriela Fiorese (Santos, São Paulo, Brazil)
FC04.1I	17:20	Comorbidity burden and demographics of patients across subtypes of cutaneous lupus erythematosus from a large US electronic health record database study Joseph F. Merola (Dallas, United States)

Thursday, 18 September 2025

Track: **Miscellaneous**

Room **W03-W04**

D2T14.1		AI and social media strategies in dermatological practice Chairs: Tammi Shipowick (Ottawa, Canada) Aleksandra Lesiak (Lodz, Poland) Catherine van Montfrans (Rotterdam, Netherlands)
D2T14.1A	08:30	Welcome by chairs Catherine van Montfrans (Rotterdam, Netherlands) Tammi Shipowick (Ottawa, Canada), Aleksandra Lesiak (Lodz, Poland)
D2T14.1B	08:35	Can AI provide reliable treatment and care advice? Kenneth Thomsen (Aarhus, Denmark) Susanna Palkonen (Brussels, Belgium)
D2T14.1C	08:55	Is social media a source of misinformation? Ana Maria Molina Ruiz (Madrid, Spain) África Luca de Tena (Madrid, Spain)
D2T14.1C	09:15	To be or not to be on social media? Magdalena Antoszewska (Gdansk, Poland) Karin Veldman ('s Hertogenbosch, Netherlands)
D2T14.1D	09:35	Next generation dermatology: From one-size-fits-all to high-tech personalised skin care Robert Rissmann (Leiden, Netherlands) Ilse van Ee (Leusden, Netherlands)
D2T14.1E	09:35	Closing remarks

Track: **Miscellaneous**

Room **W03-W04**

D2T14.2		EADV research funding and fellowships Chairs: Veronique del Marmol (Brussels, Belgium) Hok Bing Thio (Rotterdam, Netherlands) Emmanuella Guenova (Lausanne, Switzerland)
D2T14.2A	10:15	Introduction Veronique del Marmol (Brussels, Belgium)
D2T14.2B	10:25	Characterisation of European dermatophyte antifungal resistance Ditte Marie L. Saunte (Virum, Denmark)
D2T14.2C	10:40	Rare coding variants in NOX4 link high superoxide levels to psoriatic arthritis mutilans Isabel Tapia (Stockholm, Sweden)
D2T14.2D	10:55	Hidradentitis suppurativa phenotypes: Validation and implementation of a latent class model to identify specific clusters of patients Vincenzo Bettoli (Ferrara, Italy)
D2T14.2E	11:10	Intratumoural CMP-001 in association with nivolumab in patients with high-risk resectable melanoma Florent Amatore (Marseille, France)
D2T14.2F	11:20	Clonal competition and mutation burden: Role in skin carcinogenesis and implication in effectiveness of immune checkpoint inhibitors Lea Dousset (Bordeaux, France)
D2T14.2G	11:30	Mohs center: Department of Dermatology, Fundación Instituto Valenciano de Oncología Ruggero Moro (València, Spain)
D2T14.2H	11:35	Clinical fellowship experience at the Erasme Hospital, Bruxelles, Belgium Sofia Labbouz (Brussels, Belgium)
D2T14.2I	11:40	Discussion, Q&A

Thursday, 18 September 2025

Track: **Miscellaneous**

Room **W03-W04**

D2T14.3		Ethics, diversity and inclusion Chairs: Elizabeth Lazaridou (Thessaloniki, Greece) Dédée Murrell (Sydney, Australia)
D2T14.3A	14:15	Artificial intelligence in dermatology: Navigating ethics and equity Jui Vyas (Cardiff, United Kingdom)
D2T14.3B	14:35	Global health inequalities in the treatment of paediatric atopic dermatitis Bisola Laguda (London, United Kingdom)
D2T14.3C	14:55	Gender equity in academic dermatology and basic research Dédée Murrell (Sydney, Australia)
D2T14.3D	15:15	Diversity and skin colour in dermatology: A historical look at selected dermatoses Antoine David Petit (Paris, France)
D2T14.3E	15:35	Discussion, Q&A

Track: **Miscellaneous**

Room **W03-W04**

D2T14.4		Best of dermatology papers 2025: A panoramic view Chairs: Carle Paul (Toulouse, France) Erwin Tschachler (Vienna, Austria)
D2T14.4A	16:00	Welcome and introduction Carle Paul (Toulouse, France)
D2T14.4B	16:05	Best papers of the year from JAAD Dirk Elston (Charleston, United States)
D2T14.4C	16:25	Best papers of the year from JID Erwin Tschachler (Vienna, Austria)
D2T14.4D	16:45	Best papers of the year from BJD Carsten Flohr (London, United Kingdom)
D2T14.4E	17:05	Best papers of the year from JEADV Carle Paul (Toulouse, France)
D2T14.4F	17:25	General discussion

Thursday, 18 September 2025

Track: ePoster Showcase

Room E01-E03

EPS05		E-Poster showcase 5 Chair: Sandra Peternel (Rijeka, Croatia)
EPS05.1	08:30	CRKL amplification regulates YAP expression and synergizes with mechanical stress-induced signaling to dually activate YAP oncogenic pathways, driving plantar acral melanoma progression Yeqiang Liu (Shanghai, China)
EPS05.2	08:37	A randomized phase 2 proof-of-concept study to evaluate the efficacy and safety of topical bimiralisib application in patients suffering from actinic keratosis on the face and/or scalp and/or back of hands over a 2 and 4-week treatment period Olivier Gaide (Lausanne, Switzerland)
EPS05.3	08:44	Secondary intention healing achieves better long-term aesthetic and functional outcomes than full thickness skin graft following functional nail surgery: a retrospective multicenter study. Joan Ceravalls (Barcelona, Spain)
EPS05.4	08:51	Cardiometabolic Comorbidities in Psoriasis and Hidradenitis Suppurativa: Insights From a Multicenter Cohort Flavia Manzo Margiotta (Pisa, Italy)
EPS05.5	08:58	Comparative Efficacy of Omalizumab, Dupilumab, and Remibrutinib in Chronic Spontaneous Urticaria: A Network Meta-Analysis of Randomized Control Trials Grace Xiong (Hamilton, Canada)
EPS05.6	09:05	External validation of the WHO skin NTDs App's artificial intelligence algorithms for diagnosing leprosy and leprosy reactions Patricia Duarte Deps (Brazil)
EPS05.7	09:12	Late-stage mycosis fungoides is more associated with the presence of Bartonella spp. DNA in the skin than early-stage mycosis fungoides. Elisa Nunes Secamilli (Piracicaba, Brazil)
EPS05.8	09:19	Sleep Disturbance and Quality of Life Impact in Patients with Prurigo Nodularis in Europe: Results from the PN – paTient Reported burdEn of sicKness (PN-TREK) Study Donia Bahloul (Chilly-Mazarin, France)
EPS05.9	09:26	Eosinophilic Fasciitis: Lack of Consensus in the Management of a Rare Disease Sofiia Tymchuk (Saint-Petersburg, Russian Federation)
EPS05.10	09:33	Recommendations on diagnosis and treatment of adult-onset IgA Vasculitis proposed by the European IgA Vasculitis Study Group: focus on skin involvement Marie Jachiet (Paris, France)
EPS05.11	09:40	Avapritinib Durably Improves Cutaneous Involvement of Indolent Systemic Mastocytosis in Patients Treated in the PIONEER Study Stéphane Barete (Paris, France)
EPS05.12	09:47	Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT" Gabriele Rocuzzo (Turin, Italy)
	09:54	Q&A

Thursday, 18 September 2025

Track: ePoster Showcase

Room E01-E03

EPS06		E-Poster showcase 6 Chair: Jilliana Monnier (Marseille, France)
EPS06.1	10:15	Innovate Triple Co-Localization Using Super-Magnified Dermoscopy, LC-OCT and Dermoscopy Christian Dorado Cortez (Saint-Etienne, France)
EPS06.2	10:22	Kaposiform haemangioendothelioma: a case report of sirolimus as monotherapy Shihab Siddiquee (Tiwi, Australia)
EPS06.3	10:29	Evaluation of Artificial Intelligence Chatbots in Assisting Genetic Counselors in Genodermatology Ethan Bendayan (Montreal, Canada)
EPS06.4	10:36	Tildrakizumab significantly improves clinical outcomes in patients with psoriasis in high impact areas: 52-week interim data of the phase IV ZODIPSO study Ines Zaraa (Paris, France)
EPS06.5	10:43	GLP-1RA and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a global cohort study Ralf Ludwig (Lübeck, Germany)
EPS06.6	10:50	Single-cell RNA sequencing reveals transcriptomic landscape and potential targets for giant congenital melanocytic nevi Wei Tan (Shanghai, China)
EPS06.7	10:57	Pediatric Lichen Sclerosus: A Self-Limited Disease? A Long-Term Follow-Up Case Series Carlos Nogueira (Braga, Portugal)
EPS06.8	11:04	Psoriasis is Associated with an Increased Risk of Age-Related Macular Degeneration: Results from a Retrospective Observational Cohort Study Alison Treichel (Rochester, United States)
EPS06.9	11:11	Residual disease in adult psoriasis-treated patients: frequency, clinical aspects, and management. A survey among dermatologists Emmanuel Mahe (Argenteuil, France)
EPS06.10	11:18	Moving towards value-based healthcare: defining outcomes that matter to people living with psoriasis Emma Vyvey (Ghent, Belgium)
EPS06.11	11:25	Real-world use of deucravacitinib in high-impact areas: interim data from a 5-year, multicenter, prospective study in patients with moderate to severe plaque psoriasis in Germany (DELPHIN) Ralph von Kiedrowski (Selters, Germany)
EPS06.12	11:32	Photoprotection in Children: Knowledge, Practices, and Risk Perception Hiba Kherbach (Agadir, Morocco)
	11:39	Q&A

Friday, 19 September 2025

Programme at a glance

Room	08:30 – 10:00	10:15 – 11:45	14:15 – 15:45	16:00 – 17:30
Paris Nord	Focus on pigmentary disorders: Hyperpigmentation	Focus on pigmentary disorders: Hypopigmentation	Late breaking news	Late breaking news
Paris Sud	Dermoscopy for non-melanoma skin cancer	Dermoscopy for melanoma and melanocytic naevi	Nail and hair dermoscopy	Dermoscopy: Beyond tumours
N01	Personalised approaches for clinical practice	Social media in my daily practice	Merkel cell carcinoma and cutaneous sarcomas	Cutaneous lymphomas
N04	Genetic diseases	Neutrophilic diseases	Lupus erythematosus	Dermatomyositis
N02	Scars and keloids	Wound healing	Adverse events in new anti-cancer therapy and their management	Non-infectious granulomatous diseases
N03	Top advances in 2025 presented by ESDR	Hot topics in Dermatology selected by the EADV President	Best of European and American Dermatology	Best of European and American Dermatology
S01	Body art and dermatology		Lichen planus	HIV
S02	Controversies V	Controversies VI	Controversies VII	Controversies VIII
S03	New and emerging diagnostic technologies	New and emerging treatment technologies	Psoriasis	Autoimmune disorders
S04	Bullous diseases	Surgical therapy	Genetics for the clinician	Immunology for the clinician
S05	Peeling	Combination treatments in aesthetic dermatology	Scars	Skin tightening and rejuvenation
S06	Bacterial skin infections	Fungal skin infections	Skin microbiome	Migrant dermatology
W05-W06	Free communications 5 (Hair and nail disorders)	Free communications 6 (Acne and related disorders)	Free Communications 7 (Inflammatory skin diseases)	Free Communications 8 (Atopic dermatitis / Eczema)
W03-W04	Gearing up your talents in: Presenting	Gearing up your talents in: Writing	Gearing up your talents in: Photography	
W07	[Workshop] Dermoscopy – practical and conceptual		[Workshop] Phlebology for Beginners	
W08	[Workshop] Surgery – Beginners		[Workshop] Surgery – Intermediate	
E01-E03				EADV Games

Friday, 19 September 2025

Track: **Focus on**

Room **Paris Nord**

D3T1.1		Focus on pigmentary disorders: Hyperpigmentation Chairs: Antoine David Petit (Paris, France) Fatimata Ly (Dakar, Senegal)
D3T1.1A	08:30	Melasma Antoine David Petit (Paris, France)
D3T1.1B	08:50	Post-inflammatory hyperpigmentation Fatimata Ly (Dakar, Senegal)
D3T1.1C	09:10	Linked to systemic diseases belena Stojkovic-Filipovic (Belgrade, Serbia)
D3T1.1D	09:30	Genetic syndromes Lilia Bekel (Paris, France)
D3T1.1E	09:50	Discussion, Q&A

Track: **Focus on**

Room **Paris Nord**

D3T1.2		Focus on pigmentary disorders: Hypopigmentation Chairs: Mauro Picardo (Rome, Italy) Khaled Ezzedine (Créteil, France)
D3T1.2A	10:15	Hypomelanosis Mauro Picardo (Rome, Italy)
D3T1.2B	10:35	Vitiligo and vitiligo-like syndromes Madhulika Mhatre (Mumbai, India)
D3T1.2C	10:55	Drug-induced hypopigmentation Liesbeth Delbaere (Gent, Belgium)
D3T1.2D	11:15	Genetic syndromes Khaled Ezzedine (Créteil, France)
D3T1.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **Paris Nord**

D3T1.3		Late breaking news Chairs: Antonio Torrelo (Madrid, Spain) Nicole Jeanne Jouan (Brest, France)
D3T1.3A	14:15	Arginine undecylenate, a novel viral entry inhibitor, for the topical treatment of Herpes Zoster and associated pain: A first-in-patient, randomized, double-blind, placebo-controlled phase Ib study Alyce Mayfosh (Geelong, Australia)
D3T1.3B	14:30	EVO756, an oral MRGPRX2 inhibitor, demonstrates robust treatment effect in chronic inducible urticaria Edward (Ted) Lain (Pflugerville, United States)
D3T1.3C	14:45	Remibrutinib decreases specific IgG autoantibody levels in patients with chronic spontaneous urticaria Martin Metz (Berlin, Germany)
D3T1.3D	15:00	Safety, pharmacokinetics, and pharmacodynamics of LAD191, an IL-1RAP-targeting monoclonal antibody, in adults with hidradenitis suppurativa: Results from part 3 of a phase I study Esther García Gil (Barcelona, Spain)
D3T1.3E	15:15	Nemolizumab suppressed multiaxial inflammatory pathways and improved barrier protein signatures in skin and blood proteomic analysis of patients with moderate-to-severe AD Daniel Liu (New York, United States)
D3T1.3F	15:30	Initial "super response" to Tralokinumab leads to stable long-term response in patients with moderate-to-severe atopic dermatitis: Responder and predictor analysis from the ECZTRA 3 & ECZTEND trials Andrew Blauvelt (Portland, United States)

Track: **Updates**

Room **Paris Nord**

D3T1.4		Late Breaking News Chairs: Gudrun Ratzinger (Innsbruck, Austria) Bertrand Richert (Brussels, Belgium)
D3T1.4A	16:00	APG777, a novel, half-life extended anti-IL-13 antibody, demonstrates safety and efficacy in moderate-to-severe atopic dermatitis: 16-week results from the phase 2 APEX study Emma Guttman-Yassky (New York, United States)
D3T1.4B	16:15	Molecular design and characterization of GTX-B001: A bispecific antibody targeting c-Kit/CD203c for selective mast cell silencing Orla Cunningham (Boston, United States)
D3T1.4C	16:30	Comparative efficacy of an investigational oral Minoxidil extended-release tablet versus existing Minoxidil formulations in androgenetic alopecia: A blinded retrospective IGA analysis Jerry Shapiro (United States)
D3T1.4D	16:45	Evaluating the efficacy and safety of Deucravacitinib in refractory Lichen Planopilaris: A single-center retrospective pilot study Wenyu Wu (Shanghai, China)
D3T1.4E	17:00	Molecular profiling of inflammatory palmoplantar disorders for diagnosis and treatment optimization Teofila Caplanusi (Lausanne, Switzerland)
D3T1.4F	17:15	Efficacy and safety of a selective oral TYK2/JAK1 inhibitor, AC-201, in patients with plaque psoriasis: A phase II, randomized, double-blinded, placebo-controlled trial Xing-Hua Gao (Shenyang, China)

Friday, 19 September 2025

Track: **Updates**

Room **Paris Sud**

D3T2.1		Dermoscopy for non-melanoma skin cancer Chairs: Harald Kittler (Vienna, Austria) Joanna Ludzik (Cracow, Poland)
D3T2.1A	08:30	Precancerous lesions Harald Kittler (Vienna, Austria)
D3T2.1B	08:50	Basal cell carcinoma and squamous cell carcinoma Katarzyna Korecka (Poznan, Poland)
D3T2.1C	09:10	Other non-melanoma malignant tumours Claudio Conforti (Rome, Italy)
D3T2.1D	09:30	Monitoring tumour treatment Joanna Ludzik (Cracow, Poland)
D3T2.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **Paris Sud**

D3T2.2		Dermoscopy for melanoma and melanocytic naevi Chairs: Monika Arenbergerova (Prague, Czech Republic) Bengü Nisa Akay (Ankara, Türkiye)
D3T2.2A	10:15	Indicators of melanoma in pigmented lesions Giuseppe Argenziano (Naples, Italy)
D3T2.2B	10:35	Lentigo maligna Jilliana Monnier (Marseille, France)
D3T2.2C	10:55	Spitzoid lesions Bengü Nisa Akay (Ankara, Türkiye)
D3T2.2D	11:15	Pigmented lesions of the oral and genital mucosa Monika Arenbergerova (Prague, Czech Republic)
D3T2.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **Paris Sud**

D3T2.3		Nail and hair dermoscopy Chairs: Michela Starace (Bologna, Italy) Adriana Rakowska (Warsaw, Poland)
D3T2.3A	14:15	Focal alopecia Aimilios Lallas (Thessaloniki, Greece)
D3T2.3B	14:35	Diffuse alopecia Adriana Rakowska (Warsaw, Poland)
D3T2.3C	14:55	Inflammatory nail diseases Michela Starace (Bologna, Italy)
D3T2.3D	15:15	Tumours of the nail apparatus Bianca Maria Piraccini (Bologna, Italy)
D3T2.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **Paris Sud**

D3T2.4		Dermoscopy: Beyond tumours Chairs: Ecem Bostan (Ankara, Türkiye) Giuseppe Micali (Catania, Italy)
D3T2.4A	16:00	Melasma and other hyperpigmentations Ecem Bostan (Ankara, Türkiye)
D3T2.4B	16:20	Inflammatory diseases Pedro Zaballos (Taragona, Spain)
D3T2.4C	16:40	Infestations Giuseppe Micali (Catania, Italy)
D3T2.4D	17:00	Challenges in skin of colour Emmanouil Karampinis (Larissa, Greece)
D3T2.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **N01**

D3T3.1		Personalised approaches for clinical practice Chairs: Michel Gilliet (Lausanne, Switzerland) Jo Lambert (Ghent, Belgium)
D3T3.1A	08:30	Molecular profiling Michel Gilliet (Lausanne, Switzerland)
D3T3.1B	08:50	Personalised drug dosing Jo Lambert (Ghent, Belgium)
D3T3.1C	09:10	Team medicine approach Kåre Steinar Tveit (Bergen, Norway)
D3T3.1D	09:30	Shared decision making Helene Aubert Wastiaux (Nantes, France)
D3T3.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N01**

D3T3.2		Social media in my daily practice Chairs: Alexander Zink (Munich, Germany) Karlijn Clarysse (Paris, France)
D3T3.2A	10:15	Impact of social media on patient care Alexander Zink (Munich, Germany)
D3T3.2B	10:35	How to be a successful derm influencer Karlijn Clarysse (Paris, France)
D3T3.2C	10:55	Successful podcasts Hassan Galadari (Dubai, United Arab Emirates)
D3T3.2D	11:15	The don'ts in social media Alia Ahmed (London, United Kingdom)
D3T3.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **N01**

D3T3.3		Merkel cell carcinoma and cutaneous sarcomas Chairs: Mahtab Samimi (Tours, France) Stephan Grabbe (Mainz, Germany)
D3T3.3A	14:15	Merkel cell carcinoma Mahtab Samimi (Tours, France)
D3T3.3B	14:35	Kaposi sarcoma Stefano Piaserico (Padua, Italy)
D3T3.3C	14:55	Dermatofibrosarcoma protuberans Stephan Grabbe (Mainz, Germany)
D3T3.3D	15:15	Angiosarcoma Thomas Vogt (Homburg, Germany)
D3T3.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **N01**

D3T3.4		Cutaneous lymphomas Chairs: Adele de Masson (Paris, France) Robert Gniadecki (Copenhagen, Denmark)
D3T3.4A	16:00	T-cell lymphomas Adele de Masson (Paris, France)
D3T3.4B	16:20	B-cell lymphomas Rein Willemze (Leiden, Netherlands)
D3T3.4C	16:40	Mimickers Robert Gniadecki (Copenhagen, Denmark)
D3T3.4D	17:00	Advanced treatment Emmanuella Guenova (Lausanne, Switzerland)
D3T3.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **N04**

D3T4.1		Genetic diseases Chairs: Eli Sprecher (Tel Aviv, Israel) Jemima Mellerio (London, United Kingdom)
D3T4.1A	08:30	Keratoderma Eli Sprecher (Tel Aviv, Israel)
D3T4.1B	08:50	Ichthyosis Ángela Hernández-Martín (Madrid, Spain)
D3T4.1C	09:10	Epidermolysis bullosa Jemima Mellerio (London, United Kingdom)
D3T4.1D	09:30	Genetic hair disorders Alexandros Onoufriadis (Thessaloniki, Greece)
D3T4.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N04**

D3T4.2		Neutrophilic diseases Chairs: Angelo Valerio Marzano (Milan, Italy) Maria del Mar Llamas Velasco (Madrid, Spain)
D3T4.2A	10:15	Vexas syndrome Thibault Mahevas (Paris, France)
D3T4.2B	10:35	Sweet syndrome and pyoderma gangrenosum Angelo Valerio Marzano (Milan, Italy)
D3T4.2C	10:55	Pustular dermatosis Maria del Mar Llamas Velasco (Madrid, Spain)
D3T4.2D	11:15	Neutrophilic dermatoses in children Antonio Torrelo (Madrid, Spain)
D3T4.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **N04**

D3T4.3		Lupus erythematosus Chairs: Miloš Nikolić (Belgrade, Serbia) Branka Marinovic (Zagreb, Croatia)
D3T4.3A	14:15	Chronic discoid lupus Jörg Wenzel (Bonn, Germany)
D3T4.3B	14:35	Subacute cutaneous lupus erythematosus Miloš Nikolić (Belgrade, Serbia)
D3T4.3C	14:55	Systemic lupus erythematosus Branka Marinovic (Zagreb, Croatia)
D3T4.3D	15:15	Novel and emerging cellular and systemic treatments Claudia Günther (Dresden/Tübingen, Germany)
D3T4.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **N04**

D3T4.4		Dermatomyositis Chairs: Petra De Haes (Leuven, Belgium) Victoria Werth (Wynnewood, United States)
D3T4.4A	16:00	Serology and risk assessment Axel De Greef (Brussels, Belgium)
D3T4.4B	16:20	Misdiagnosis Petra De Haes (Leuven, Belgium)
D3T4.4C	16:40	Treatment Victoria Werth (Wynnewood, United States)
D3T4.4D	17:00	Special focus: Children Aleksandra Lesiak (Lodz, Poland)
D3T4.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **N02**

D3T5.1		Scars and keloids Chairs: Klaus Fritz (Landau, Germany) Alison Layton (York, United Kingdom)
D3T5.1A	08:30	Prevention of scars Klaus Fritz (Landau, Germany)
D3T5.1B	08:50	Pharmacological treatment of scars Alison Layton (York, United Kingdom)
D3T5.1C	09:10	Laser and cryosurgery Ivan Peev (Sofia, Bulgaria)
D3T5.1D	09:30	Surgery and radiotherapy Klaus Eisendle (Bolzano, Italy)
D3T5.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N02**

D3T5.2		Wound healing Chairs: Marco Romanelli (Pisa, Italy) Catherine van Montfrans (Rotterdam, Netherlands)
D3T5.2A	10:15	Understanding wound healing Catherine van Montfrans (Rotterdam, Netherlands)
D3T5.2B	10:35	Chronic ulcer Valentina Dini (Pisa, Italy)
D3T5.2C	10:55	Diabetic foot management Matthias Augustin (Hamburg, Germany)
D3T5.2D	11:15	New treatments Marco Romanelli (Pisa, Italy)
D3T5.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **N02**

D3T5.3		Adverse events in new anti-cancer therapy and their management Chairs: Zoe Apalla (Thessaloniki, Greece) Vincent Sibaud (Toulouse, France)
D3T5.3A	14:15	Immune checkpoint inhibitors Azael Freites Martinez (Madrid, Spain)
D3T5.3B	14:35	Targeted therapy Zoe Apalla (Thessaloniki, Greece)
D3T5.3C	14:55	CAR T-cell therapy Vincent Sibaud (Toulouse, France)
D3T5.3D	15:15	Radiation therapy Davide Fattore (Napoli, Italy)
D3T5.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **N02**

D3T5.4		Non-infectious granulomatous diseases Chairs: Enzo Errichetti (Udine, Italy) Anna Gabriel (Vienna, Austria)
D3T5.4A	16:00	Granuloma annulare Enzo Errichetti (Udine, Italy)
D3T5.4B	16:20	Interstitial granulomatous dermatitis Afsaneh Alavi (Rochester, United States)
D3T5.4C	16:40	Sarcoidosis Anna Gabriel (Vienna, Austria)
D3T5.4D	17:00	Necrobiosis lipoidica Francesco Borgia (Messina, Italy)
D3T5.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: Updates

Room N03

D3T6.1		Top advances in 2025 presented by ESDR Chairs: Beatrice Dyring-Andersen (Copenhagen, Denmark) Knut Schäkel (Heidelberg, Germany)
D3T6.1A	08:30	Precision diagnostics for genodermatoses Alexandros Onoufriadis (Thessaloniki, Greece)
D3T6.1B	09:30	Beyond the plaque: Genetic insights into the link between psoriasis and its comorbidities Ravi Ramessur (London, United Kingdom)
D3T6.1C	09:10	Drug repurposing for genodermatoses: From understanding the pathogenesis to disease relief Dimitra Kiritsi (Thessaloniki, Greece)
D3T6.1D	08:50	Advances in hidradenitis suppurativa Kelsey van Straalen (Rotterdam, Netherlands)
D3T6.1E	09:50	Discussion, Q&A

Track: Updates

Room N03

D3T6.2		Hot topics in dermatology selected by the EADV President Chairs: Branka Marinovic (Zagreb, Croatia) Marie-Aleth Richard (Marseille, France) Martin Röcken (Tübingen, Germany)
D3T6.2A	10:15	How to reach unity in dermatology Seemal R Desai (Plano, United States)
D3T6.2B	10:40	CAR T-cell therapy in autoimmune diseases Marc Scherlinger (Strasbourg, France)
D3T6.2C	11:05	From tolerance to therapy: Harnessing inducible regulatory T-cells for precision control of autoimmune disease Masayuki Amagai (Tokyo, Japan)
D3T6.2D	11:30	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **N03**

D3T6.3		Best of European and American Dermatology Chairs: Michel Gilliet (Lausanne, Switzerland) Robert Kirsner (Miami, United States)
D3T6.3A	14:15	Chronic Prurigo Sonja Ständer (Münster, Germany)
D3T6.3B	14:45	Approaching patients with 'recalcitrant' dermatoses: Lessons learned from 5 decades of practice Jeffrey Callen (Louisville, United States)
D3T6.3C	15:15	Melanoma immunotherapy: Innovations and challenges Rolland Gyulai (Szeged, Hungary)

Track: **Updates**

Room **N03**

D3T6.4		Best of European and American Dermatology Chairs: Michel Gilliet (Lausanne, Switzerland) Robert Kirsner (Miami, United States)
D3T6.4A	16:00	New and emerging infectious diseases Kenneth Tomecki (Cleveland, United States)
D3T6.4B	16:30	Atopic dermatitis: Latest advances and insights Thomas Bieber (Bonn, Germany)
D3T6.4C	17:00	Improving dermatology - Gaps in knowledge and practice Erik Stratman (Marshfield, United States)

Friday, 19 September 2025

Track: **Updates**

Room **S01**

D3T7.1		Body art and dermatology Chairs: Nicolas Kluger (Helsinki, Finland) Christa de Cuyper (Bruges, Belgium)
D3T7.1A	08:30	Monitoring moles in tattoos Nicolas Kluger (Helsinki, Finland)
D3T7.1B	08:50	Tattoo complications Aneta Szczerkowska Dobosz (Gdansk, Poland)
D3T7.1C	09:10	Piercings complications Christa de Cuyper (Bruges, Belgium)
D3T7.1D	09:30	Tattoo removal Hugues Cartier (Arras, France)
D3T7.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **S01**

D3T7.3		Lichen planus Chairs: Johann Gudjonsson (Ann Arbor, United States) Malgorzata Olszewska (Warsaw, Poland)
D3T7.3A	14:15	Understanding lichen planus and its forms Johann Gudjonsson (Ann Arbor, United States)
D3T7.3B	14:35	Nail lichen planus Matilde Iorizzo (Lugano, Switzerland)
D3T7.3C	14:55	Mucosal lichen planus Malgorzata Olszewska (Warsaw, Poland)
D3T7.3D	15:15	New and upcoming treatments Aaron Mangold (Scottsdale, United States)
D3T7.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **S01**

D3T7.4		HIV Chairs: Andrew Winter (Glasgow, United Kingdom) Alba Catala (Barcelona, Spain)
D3T7.4A	16:00	Epidemiology in Europe and beyond Andrew Winter (Glasgow, United Kingdom)
D3T7.4B	16:20	Anti retroviral therapy Morgan Krekels (Bochum, Germany)
D3T7.4C	16:40	PREP Carmen Lisboa Silva (Porto, Portugal)
D3T7.4D	17:00	Dermatological manifestations Alba Catala (Barcelona, Spain)
D3T7.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Controversies**

Room **S02**

D3T8.1		Controversies V Chairs: Richard Weller (Edinburgh, United Kingdom) Marie-Aleth Richard (Marseille, France)
D3T8.1A	08:30	Introduction Richard Weller (Edinburgh, United Kingdom)
D3T8.1B	08:35	Sunscreens: Friend or foe? (Friend) Thierry Passeron (Nice, France)
D3T8.1C	08:50	Sunscreens: Friend or foe? (Foe) Amaya Viros (Manchester, United Kingdom)
D3T8.1D	09:05	Discussion, Q&A
D3T8.1E	09:15	Introduction Marie-Aleth Richard (Marseille, France)
D3T8.1F	09:20	Actinic keratoses: Are we over treating? YES Alexander Stratigos (Athens, Greece)
D3T8.1G	09:30	Actinic keratoses: Are we over treating? NO Eggert Stockfleth (Bochum, Germany)
D3T8.1H	09:35	Discussion, Q&A

Track: **Controversies**

Room **S02**

D3T8.2		Controversies VI Chairs: Derek Freedman (Dublin, Ireland) Errol Prens (Rotterdam, Netherlands)
D3T8.2A	10:15	Introduction Errol Prens (Rotterdam, Netherlands)
D3T8.2B	10:20	Is there a place for a HPV vaccine after treatment of genital warts? YES Peter Greenhouse (Bristol, United Kingdom)
D3T8.2C	10:30	Is there a place for a HPV vaccine after treatment of genital warts? NO Maarten Schim van der Loeff (Amsterdam, Netherlands)
D3T8.2D	10:45	Discussion, Q&A
D3T8.2E	11:00	Introduction Derek Freedman (Dublin, Ireland)
D3T8.2F	11:05	Prevention with doxycycline: A game-changer? John White (Limavady, United Kingdom)
D3T8.2G	11:20	Prevention with doxycycline: A risky gamble? Guillaume Conort (Bordeaux cedex, France)
D3T8.2H	10:15	Discussion, Q&A

Friday, 19 September 2025

Track: **Controversies**

Room **S02**

D3T8.3		Controversies VII Chairs: Eduardo Nagore (Valencia, Spain) Giuseppe Argenziano (Naples, Italy)
D3T8.3A	14:15	Introduction Eduardo Nagore (Valencia, Spain)
D3T8.3B	14:20	Do we need sentinel lymph node biopsy for the management of melanoma? YES David Moreno-Ramirez (Sevilla, Spain)
D3T8.3C	14:35	Do we need sentinel lymph node biopsy for the management of melanoma? NO Monika Arenbergerova (Prague, Czech Republic)
D3T8.3D	15:15	Discussion, Q&A
D3T8.3E	15:35	Introduction Giuseppe Argenziano (Naples, Italy)
D3T8.3F	15:05	Over diagnosis of melanoma. Does it exist? YES Harald Kittler (Vienna, Austria)
D3T8.3G	15:20	Over diagnosis of melanoma. Does it exist? NO Aimilios Lallas (Thessaloniki, Greece)
D3T8.3H	15:35	Discussion, Q&A

Track: **Controversies**

Room **S02**

D3T8.4		Controversies VIII Chairs: Andreas Wollenberg (Augsburg, Germany) Maarten Vermeer (Leiden, Netherlands)
D3T8.4A	16:00	Introduction Andreas Wollenberg (Augsburg, Germany)
D3T8.4B	16:05	Should we use JAK inhibitors before biologics in atopic dermatitis? YES Magdalena Trzeciak (Gdansk, Poland)
D3T8.4C	16:20	Should we use JAK inhibitors before biologics in atopic dermatitis? NO Christian Vestergaard (Skoedstrup, Denmark)
D3T8.4D	16:35	Discussion, Q&A
D3T8.4E	16:45	Introduction Maarten Vermeer (Leiden, Netherlands)
D3T8.4F	16:50	AD and lymphoma: Is there a link? YES Marie Beylot-Barry (Bordeaux, France)
D3T8.4G	17:05	AD and lymphoma: Is there a link? NO Ulrike Wehkamp (Hamburg, Germany)
D3T8.4H	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Training and education**

Room **S03**

D3T9.1		New and emerging diagnostic technologies Chairs: Giovanni Pellacani (Rome, Italy) Kilian Eyerich (Freiburg, Germany)
D3T9.1A	08:30	LC-OCT Margot Fontaine (Brussels, Belgium)
D3T9.1B	08:50	Confocal microscopy Giovanni Pellacani (Rome, Italy)
D3T9.1C	09:10	Digital pathology Helmut Beltraminelli (Bellinzona, Switzerland)
D3T9.1D	09:30	Molecular approaches Kilian Eyerich (Freiburg, Germany)
D3T9.1E	09:50	Discussion, Q&A

Track: **Training and education**

Room **S03**

D3T9.2		New and emerging treatment technologies Chairs: Lluís Puig (Barcelona, Spain) Su Lwin (London, United Kingdom)
D3T9.2A	10:15	Multi specific antibodies and cell engagers Lluís Puig (Barcelona, Spain)
D3T9.2B	10:35	Cell therapies Su Lwin (London, United Kingdom)
D3T9.2C	10:55	Gene therapy Cristina Has (Freiburg, Germany)
D3T9.2D	11:15	Peptides and small molecules Wayne Gulliver (St. John's, Canada)
D3T9.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Training and education**

Room **S03**

D3T9.3		Psoriasis Chairs: Paolo Gisondi (Verona, Italy) Nina Magnolo (Muenster, Germany)
D3T9.3A	14:15	Pathophysiology Tiago Torres (Porto, Portugal)
D3T9.3B	14:35	Clinical phenotypes Luca Potestio (Naples, Italy)
D3T9.3C	14:55	Comorbidities Paolo Gisondi (Verona, Italy)
D3T9.3D	15:15	Treatment Nina Magnolo (Muenster, Germany)
D3T9.3E	15:35	Discussion, Q&A

Track: **Training and education**

Room **S03**

D3T9.4		Autoimmune disorders Chairs: Erkan Alpsoy (Antalya, Türkiye) Stefan Beissert (Dresden, Germany)
D3T9.4A	16:00	Systemic sclerosis Francesco Del Galdo (Leeds, United Kingdom)
D3T9.4B	16:20	Behçet disease Erkan Alpsoy (Antalya, Türkiye)
D3T9.4C	16:40	Lupus erythematosus Carle Paul (Toulouse, France)
D3T9.4D	17:00	Dermatomyositis Stefan Beissert (Dresden, Germany)
D3T9.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Training and education**

Room **S04**

D3T10.1		Bullous diseases Chair: May El Hachem (Rome, Italy)
D3T10.1A	08:30	Pemphigus Dario Didona (Marburg, Germany)
D3T10.1B	08:50	Pemphigoid Jose Manuel Mascaro (Barcelona, Spain)
D3T10.1C	09:10	Other acquired bullous diseases Enno Schmidt (Lübeck, Germany)
D3T10.1D	09:30	Inherited bullous diseases May El Hachem (Rome, Italy)
D3T10.1E	09:50	Discussion, Q&A

Track: **Training and education**

Room **S04**

D3T10.2		Surgical therapy Chairs: Marta Sar-Pomian (Warsaw, Poland) Myrto-Georgia Trakatelli (Thessaloniki, Greece)
D3T10.2A	10:15	Biopsy techniques Marta Sar-Pomian (Warsaw, Poland)
D3T10.2B	10:35	Cryosurgery Paola Pasquali (Cambrils, Spain)
D3T10.2C	10:55	Paediatric surgery Juan Carlos López-Gutiérrez (Madrid, Spain)
D3T10.2D	11:15	Nail surgery Myrto-Georgia Trakatelli (Thessaloniki, Greece)
D3T10.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Training and education**

Room **S04**

D3T10.3		Genetics for the clinician Chairs: Alain Hovnanian (Paris, France) Jan Cezary Sitek (Oslo, Norway)
D3T10.3A	14:15	Principles Alain Hovnanian (Paris, France)
D3T10.3B	14:35	Modern genetic techniques Judith Fischer (Freiburg, Germany)
D3T10.3C	14:55	Genetic counseling Jan Cezary Sitek (Oslo, Norway)
D3T10.3D	15:15	Therapeutic approaches Yuval Ramot (Jerusalem, Israel)
D3T10.3E	15:35	Discussion, Q&A

Track: **Training and education**

Room **S04**

D3T10.4		Immunology for the clinician Chairs: Christoph Schlapbach (Bern, Switzerland) Katia Boniface (Bordeaux, France)
D3T10.4A	16:00	Principles Christoph Schlapbach (Bern, Switzerland)
D3T10.4B	16:20	Laboratory techniques Katia Boniface (Bordeaux, France)
D3T10.4C	16:40	Skin tests and interpretation Jean-François Nicolas (Pierre-Benite, France)
D3T10.4D	17:00	Therapeutic approaches Tea Rosovic (Opatija, Croatia)
D3T10.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **S05**

D3T11.1		Peeling Chair: Oliver Kreyden (Muttenez, Switzerland)
D3T11.1A	08:30	Superficial chemical peeling: What can be successfully treated? Claudia Borelli (Tübingen, Germany)
D3T11.1B	08:50	Difficult to treat melasma Fotini Bageorgou (Athens, Greece)
D3T11.1C	09:10	The risk of phenol peeling Oliver Kreyden (Muttenez, Switzerland)
D3T11.1D	09:30	Deep peels without phenol Felipe Ribeiro (São Paulo, Brazil)
D3T11.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **S05**

D3T11.2		Combination treatments in aesthetic dermatology Chairs: Leonardo Marini (Trieste, Italy) Christopher Zachary (Irvine, United States)
D3T11.2A	10:15	Microdosing biostimulators Christopher Zachary (Irvine, United States)
D3T11.2B	10:35	Combination strategies for difficult to treat vascular lesions Leonardo Marini (Trieste, Italy)
D3T11.2C	10:55	Combination treatments for skin ageing Suzanne Kilmer (Sacramento, United States)
D3T11.2D	11:15	Clinical cases
D3T11.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **S05**

D3T11.3		Scars Chair: Keyvan Nouri (Miami, United States)
D3T11.3A	14:15	Lasers of scars Christine Dierickx (Luxembourg, Luxembourg)
D3T11.3B	14:35	Scars in skin of colour Mukta Sachdev (Bangalore, India)
D3T11.3C	14:55	Fractional laser for drug delivery in scars Merete Haedersdal (Copenhagen, Denmark)
D3T11.3D	15:15	What's new in treatment? Brian Berman (Miami Beach, United States)
D3T11.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **S05**

D3T11.4		Skin tightening and rejuvenation Chair: Ines Verner Rashkovsky (Savyon, Israel)
D3T11.4A	16:00	New approaches in skin tightening and rejuvenation Ines Verner Rashkovsky (Savyon, Israel)
D3T11.4B	16:20	Emerging therapies in body contouring Lillit Garibyan (Boston, United States)
D3T11.4C	16:40	Exosome for skin rejuvenation Todd Schlesinger (Charleston, United States)
D3T11.4D	17:00	Ultrasound for aesthetic injectables Hugues Cartier (Arras, France)
D3T11.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **S06**

D3T12.1		Bacterial skin infections Chairs: Giovanni Damiani (Milan, Italy) Romain Blaizot (Cayenne, French Guiana)
D3T12.1A	08:30	Atypical mycobacteria Romain Blaizot (Cayenne, French Guiana)
D3T12.1B	08:50	Leprosy Steve Walker (London, United Kingdom)
D3T12.1C	09:10	Multi-drug resistant bacteria Giovanni Damiani (Milan, Italy)
D3T12.1D	09:30	Bacteriophage therapy Lene Bens (Heverlee, Belgium)
D3T12.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **S06**

D3T12.2		Fungal skin infections Chairs: Carlos Daniel Sánchez Cárdenas (Ciudad de Mexico, Mexico) Ditte Marie L. Saunte (Virum, Denmark)
D3T12.2A	10:15	Epidemiology Pauline Lecerf (Brussels, Belgium)
D3T12.2B	10:35	Clinical and diagnostic approaches Georgios Gaitanis (Ioannina, Greece)
D3T12.2C	10:55	Deep fungal infections Carlos Daniel Sánchez Cárdenas (Ciudad de Mexico, Mexico)
D3T12.2D	11:15	Treatment resistance Ditte Marie L. Saunte (Virum, Denmark)
D3T12.2E	11:35	Discussion, Q&A

Friday, 19 September 2025

Track: **Updates**

Room **S06**

D3T12.3		Skin microbiome Chairs: Brigitte Dréno (Nantes, France) Tilo Biedermann (Munich, Germany)
D3T12.3A	14:15	Measuring the skin microbiome in your patient: Practical applications Elisabeth Grice (Philadelphia, United States)
D3T12.3B	14:35	Role in acne and HS Brigitte Dréno (Nantes, France)
D3T12.3C	14:55	Skin microbiome transplantation for AD Tilo Biedermann (Munich, Germany)
D3T12.3D	15:15	Pre- , pro- and post-biotics to modulate the skin microbiome Giuseppe Penna (Pieve Emanuele, Italy)
D3T12.3E	15:35	Discussion, Q&A

Track: **Updates**

Room **S06**

D3T12.4		Migrant dermatology Chairs: Valeska Padovese (Msida, Malta) Aldo Morrone (Rome, Italy)
D3T12.4A	16:00	Understanding and working with traditional beliefs Federica Dassoni (Milan, Italy)
D3T12.4B	16:20	Sexually transmitted infections and migration Valeska Padovese (Msida, Malta)
D3T12.4C	16:40	Skin health in displaced persons camps: Dermatology cases from the front line Juan Ortiz-Álvarez (Verín, Spain)
D3T12.4D	17:00	Abuse, self-harm and torture signs Aldo Morrone (Rome, Italy)
D3T12.4E	17:20	Discussion, Q&A

Friday, 19 September 2025

Track: **Free communication**

Room **W05-W06**

FC05		Free Communication 5 (Hair and Nail disorders) Chairs: Jana Kazandjieva (Sofia, Bulgaria) Alexander Katoulis (Athens, Greece)
FC05.1A	08:30	Alopecia areata and ultra-high frequency ultrasound: A guide to personalized monitoring and predicting response to JAK inhibitors Flavia Manzo Margiotta (Pisa, Italy)
FC05.1B	08:40	Weight gain and menstrual irregularities during JAK inhibitor therapy for AD and AA: Real-World Evidence suggesting a common JAK2-STAT3 endocrine-metabolic pathway Luciano Ibba (Rozzano, Italy)
FC05.1C	08:50	Mechanistic investigation of the combined use of Botulinum Toxin and photothermal therapy in androgenetic alopecia Traidit Thianthanyakij (Bangkok, Thailand)
FC05.1D	09:00	Investigating the role of necroptosis in alopecia areata pathogenesis Lin Shang (Beijing, China)
FC05.1E	09:10	Mesotherapy and Iontophoresis with Dutasteride: What Do We Know So Far? Michela Starace (Bologna, Italy)
FC05.1F	09:20	Most Baricitinib responders achieved full scalp hair regrowth: Findings from adult and paediatric BRAVE-AA trials Brett King (Fairfield, United States)
FC05.1G	09:30	Rationale and design of a novel, phase 3, external and synthetic placebo-controlled clinical trial of ritlecitinib 50 mg and 100 mg for alopecia areata Brett King (Fairfield, United States)
FC05.1H	09:40	Correlation between hair thickness and follicular unit density in androgenetic alopecia: A quantitative trichoscopic study Artina Pajaziti (Prishtina, Kosovo)
FC05.1I	09:50	Sulfhydryl surge: A new lens on alopecia areata Seyfettin Mahir Koçak (İstanbul, Türkiye)

Friday, 19 September 2025

Track: **Free communication**

Room **W05-W06**

FC06		Free Communication 6 (Acne and related disorders) Chairs: Barbara Horvath (Groningen, Netherlands) Aikaterini I. Liakou (Athens, Greece)
FC06.1A	10:15	Risk of new-onset and recurrent depression and anxiety in patients with hidradenitis suppurativa: a population-based cohort study Nikolaj Holgersen (Copenhagen, Denmark)
FC06.1B	10:25	Single cell and spatial transcriptomics profiling of lesional hidradenitis suppurativa skin provides insight into disease pathogenesis Bo Bang (Basel, Switzerland)
FC06.1C	10:35	A new algorithm for analyzing the kinetics through different phases of acne lesions Pierre Gillibert (Ramonville-Saint-Agne, France)
FC06.1D	10:45	A Phase 2 multicenter, single-arm, open-label study to evaluate the safety and efficacy of Lutikizumab in biologic-naïve adult patients with moderate-to-severe hidradenitis suppurativa Alexa B. Kimball (Boston, United States)
FC06.1E	10:55	IHS4-100 responses and other IHS4 outcomes with the IL-17A- and IL-17F-inhibiting nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the phase 2 MIRA trial Brian Kirby (Dublin, Ireland)
FC06.1F	11:05	Resolution of deep dermal inflammatory lesions with the nanobody sonelokimab in moderate-to-severe hidradenitis suppurativa (HS): Preclinical results and outcomes from the phase 2 MIRA trial Martina L Porter (Boston, United States)
FC06.1G	11:15	Efficacy and safety of brivekimig (a dual-target, anti-tumour necrosis factor and anti-OX40 ligand NANOBODY®-based biologic) in participants with moderate-to-severe hidradenitis suppurativa Alexa B. Kimball (Boston, United States)
FC06.1H	11:25	The efficacy of continuous secukinumab treatment over two years, as measured by the International Hidradenitis Suppurativa Severity Scoring System (IHS4), in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials Tzellos Thrasyvoulos (Bodø, Norway)
FC06.1I	11:35	Bimekizumab efficacy on IHS4 response levels and draining tunnels by HS disease duration over 2 years: Data from BE HEARD EXT Tzellos Thrasyvoulos (Bodø, Norway)

Friday, 19 September 2025

Track: **Free communication**

Room **W05-W06**

FC07		Free Communication 7 (Inflammatory skin diseases) Chairs: Nicola Zerbinati (Pavia, Italy) Wilhelm Stolz (Munich, Germany)
FC07.1A	14:15	The novel, first-in-class IL-1R3 antagonist SAR445399 reduces skin inflammation in an innovative proof-of-mechanism study with dual immune challenge models and comparator drugs Anouk Meijs (Leiden, Netherlands)
FC07.1B	14:25	PN-881: A first-in-class oral IL-17 antagonist peptide for potential treatment of psoriatic diseases Mariana Manrique (Newark, United States)
FC07.1C	14:35	Relationship between cutaneous GVHD and COVID-19 infection in allogeneic hematopoietic stem cell transplant recipients Shahab Babakoochi (Charlotte, United States)
FC07.1D	14:45	Results from the HELIOS Study: A phase 2, open-label, long-term extension study of Bitopertin in erythropoietic protoporphyria Melanie Chin (Watertown, United States)
FC07.1E	14:55	Serological biomarkers of the basement membrane and extracellular matrix are altered in patients with hidradenitis suppurativa and associated with disease severity and treatment response Helena Port Linares (Herlev, Denmark)
FC07.1F	15:05	Chronic hand eczema is a type 2 disease: Evidence from integrated clinical trial and molecular profiling Marie Tauber (Pierre-Bénite, France)
FC07.1G	15:15	Spesolimab for the treatment of generalised pustular psoriasis flares: Preliminary analysis of the EFFISAYIL REP study Siew Eng Choon (Johor Bahru, Malaysia)
FC07.1H	15:25	Roflumilast foam 0.3% for the treatment of seborrheic dermatitis in patients with diverse skin types: Subgroup analyses of the phase 3 STRATUM trial Raj Chovatiya (Chicago, United States)
FC07.1I	15:35	Transcriptomic profiling of hyperkeratotic hand eczema skin with comparison to atopic dermatitis and psoriasis Weixin Zhou (Groningen, Netherlands)

Friday, 19 September 2025

Track: **Free communication**

Room **W05-W06**

FC08		Free Communication 8 (Atopic Dermatitis/Eczema) Chairs: David Pesqué (Barcelona, Spain) Zsuzsanna Bata-Csorgo (Szeged, Hungary)
FC08.1A	16:00	A Novel Topical JAK1 Inhibitor for atopic dermatitis: Safety and early efficacy of IN-115314 Ha-Yeon Kim (Cheongju, Korea, Rep. of South)
FC08.1B	16:10	Successful tapering of dupilumab in pediatric patients with atopic dermatitis: Daily practice results from the BioDay registry Florence Vroman (Utrecht, Netherlands)
FC08.1C	16:20	TRIV-509, a dual inhibitor of KLK5 and KLK7, normalizes epidermal hyper-proliferation, improves barrier integrity and reduces secretion of inflammatory cytokines in atopic dermatitis skin explants Elizabeth Mateer (Watertown, United States)
FC08.1D	16:30	Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial Andrew Blauvelt (Portland, United States)
FC08.1E	16:40	Efficacy and safety of OX40-receptor targeting with Rocatinlimab in moderate-to-severe atopic dermatitis: Results from the phase 3 ROCKET-Ignite trial Emma Guttman-Yassky (New York, United States)
FC08.1F	16:50	Scars of life: Unraveling skin pain in atopic dermatitis – Prevalence, severity, and psychosocial burden Delphine Kerob (Levallois Perret, France)
FC08.1G	17:00	Patients with cardiovascular risk factors and atopic dermatitis: Long-term safety of Upadacitinib for major adverse cardiovascular events, venous thromboembolism, or malignancy (excluding nonmelanoma skin cancer) Christopher Bunick (New Haven, United States)
FC08.1H	17:10	Interpretable deep learning framework for automated EASI scoring in atopic dermatitis assessment Sharif Amit Kamran (Cambridge, United States)
FC08.1I	17:20	A first-in-patient 18-week study of galvokimig, a multispecific antibody-based therapeutic targeting interleukin (IL)-13, IL-17A, and IL-17F in participants with moderate-to-severe atopic dermatitis (AD) Hamish Hunter (Salford, United Kingdom)

Friday, 19 September 2025

Track: **Miscellaneous**

Room **W03-W04**

D3T14.1		Gearing up your talents in: Presenting Chairs: Paola Pasquali (Cambrils, Spain) Sarah Walsh (London, United Kingdom)
D3T14.1A	08:30	Scientific content Sarah Walsh (London, United Kingdom)
D3T14.1B	08:33	Body language Myrto-Georgia Trakatelli (Thessaloniki, Greece)
D3T14.1C	08:39	Graphics Peter Greenhouse (Bristol, United Kingdom)
D3T14.1D	08:42	Photography Paola Pasquali (Cambrils, Spain)
D3T14.1E	08:45	Participants presentations

Track: **Miscellaneous**

Room **W03-W04**

D3T14.2		Gearing up your talents in: Writing Chairs: Sarah Walsh (London, United Kingdom) Jo Lambert (Ghent, Belgium)
D3T14.2A	10:15	Abstract and figures: The business card of your paper Carle Paul (Toulouse, France)
D3T14.2B	10:30	How to ask the right questions Johannes Ring (Munich, Germany)
D3T14.2C	10:45	Writing your paper from scratch Jo Lambert (Ghent, Belgium)
D3T14.2D	11:00	Selecting the journal. Answering reviewer's/editor's comments Sarah Walsh (London, United Kingdom)
D3T14.2E	11:15	The most common mistakes when publishing Rolland Gyulai (Szeged, Hungary)
D3T14.2F	11:30	Discussion, Q&A

Friday, 19 September 2025

Track: **Miscellaneous**Room **W03-W04**

D3T14.3		Gearing up your talents in: Photography Chairs: Paola Pasquali (Cambrils, Spain) Mayur Davda (Mumbai, India)
D3T14.3A	14:15	Tips for using images in presentations and publications Oriol Yelamos (Barcelona, Spain)
D3T14.3B	14:35	Special areas, special uses Paola Pasquali (Cambrils, Spain)
D3T14.3C	14:55	Oral cavity images Mayur Davda (Mumbai, India)
D3T14.3D	15:15	Total body photography and dermoscopy images Konstantinos Liopyris (Athens, Greece)
D3T14.3E	15:35	Discussion, Q&A

Track: **Miscellaneous**Room **E01-E03****EADV Games**

Chairs: Frederic Caux (Bobigny, France)
Dédée Murrell (Sydney, Australia)

The EADV Games bring together dermatology residents from across Europe for a thrilling, fast-paced quiz competition covering all areas of dermatology and venereology.

Whether you're looking to showcase your clinical expertise, connect with peers, or simply enjoy some friendly competition, the EADV Games 2025 are your chance to shine. Form your team, represent your country, and be part of one of the Congress's most exciting and dynamic events.

Participating countries

 Finland	 Latvia	 Spain
 France	 Poland	 Switzerland
 Germany	 Portugal	 The Netherlands
 Hungary	 Romania	 Türkiye
 Ireland	 Serbia	 United Kingdom
 Italy	 Slovakia	

Read more eadv.org/congress/scientific-programme/eadv-games/

Saturday, 20 September 2025

Programme at a glance

Plenary	12:00 – 13:00			
Paris Nord	Plenary Lectures C			
Room	08:30 – 10:00	10:15 – 11:45	14:15 – 15:45	16:00 – 17:30
Paris Nord	Acne	Acne		
Paris Sud	Itch	Chronic prurigo		
N01	Hypohidrosis and hyperhidrosis	Travel-related infectious diseases	European Society of Dermatopathology (ESDP)	
N04	Global Health	Chronic leg ulcers	Société Française des Lasers en Dermatologie (SFLD)	Société Française d'Esthétique en Dermatologie (SFED)
N02	Joint EADV/JDA - Faces of skin diseases from East to West	Photodermatology	International Peeling Society (IPS)	
N03	Botulinum Toxin II, Advanced	Aesthetic dermatology for medical indications	International Eczema Council (IEC)	
S01	Red flags and emergencies in dermatology	Actinic keratosis	European Women Dermatological and Venereological Society (EWDVS)	
S02	Paediatric dermatology: Pathogenesis	Paediatric dermatology: Management	European Society for Dermatology and Psychiatry (ESDaP)	
S03	Infectious diseases	Skin in internal medicine	Worldwide Dermatology Collaboration (WDC)	
S04	History of dermatology	Implications of climate change and environmental challenges	International Dermatology Outcome Measures (IDEOM)	
S05	Clinical cases presented by residents	The hot seat: Local residents quiz the international faculty		
S06	Impact of climate change in dermatology	Tropical dermatology interactive quiz		
W05-W06	Nutrition and Dermatology	Global skin disease atlases	Skin cancer nursing	Developing specialist nurses in dermatology
W03-W04	Task Force highlights	Task Force highlights		
W07	[Workshop] Laser treatment for beginners		[Workshop] Laser treatment for beginners	
W08	[Workshop] Use of Botulinum Toxin in Cosmetic and Medical Dermatology		[Workshop] Talk that heals: How better communication drives better patient outcomes	

Saturday, 20 September 2025

Track: **Updates**

Room **Paris Nord**

D4T1.1		Acne Chairs: Clio Dessinioti (Athens, Greece) Falk Ochsendorf (Frankfurt, Germany)
D4T1.1A	08:30	Special focus: Pre-pubertal population Clio Dessinioti (Athens, Greece)
D4T1.1B	08:50	Special focus: Adult women Aleksandra Lesiak (Lodz, Poland)
D4T1.1C	09:10	Severe forms of acne Falk Ochsendorf (Frankfurt, Germany)
D4T1.1D	09:30	Mimickers of acne Julien Lambert (Antwerp, Belgium)
D4T1.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **Paris Nord**

D4T1.2		Acne Chairs: Vincenzo Bettoli (Ferrara, Italy) Lajos Kemény (Szeged, Hungary)
D4T1.2A	10:15	Acne guidelines 2025: Critical assessment Neal Bhatia (San Diego, United States)
D4T1.2B	10:35	Is there a rationale for biologics in acne? Lajos Kemény (Szeged, Hungary)
D4T1.2C	10:55	Artificial Intelligence to score acne severity Vincenzo Bettoli (Ferrara, Italy)
D4T1.2D	11:15	Management of post-acne hyperpigmentation Jose Luis Lopez-Estebarez (Madrid, Spain)
D4T1.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Plenary**

Room **Paris Nord**

	Plenary lectures C Chairs: Marie-Aleth Richard (Marseille, France) Menno de Rie (Breukelen, Netherlands)
12:00	What's new in the treatment of scabies Olivier Chosidow (Paris, France)
12:20	ESDR Plenary Lecture: Unique insights from mosaic disorders of oncogenes Veronica Kinsler (London, United Kingdom)
12:40	René Touraine Plenary lecture: The changing landscape of understanding and treating vitiligo Markus Böhm (Münster, Germany)

Saturday, 20 September 2025

Track: **Updates**

Room **Paris Sud**

D4T2.1		Itch Chairs: Elke Weisshaar (Heidelberg, Germany) Laurent Misery (Brest, France)
D4T2.1A	08:30	Neurosensitisation in itch Laurent Misery (Brest, France)
D4T2.1B	08:50	Immune mechanisms of itch Bernhard Homey (Düsseldorf, Germany)
D4T2.1C	09:10	Pruritus of unknown origin workup Elke Weisshaar (Heidelberg, Germany)
D4T2.1D	09:30	Management of itch Emilie Brenaut (Brest, France)
D4T2.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **Paris Sud**

D4T2.2		Chronic prurigo Chairs: Sonja Ständer (Münster, Germany) Gil Yosipovitch (Miami, United States)
D4T2.4A	10:15	Understanding chronic prurigo Manuel Pereira (Berlin, Germany)
D4T2.4B	10:35	Diagnostic workup Jacek Szepietowski (Wroclaw, Poland)
D4T2.4C	10:55	Emerging biologics Sonja Ständer (Münster, Germany)
D4T2.4D	11:15	Emerging oral therapies Gil Yosipovitch (Miami, United States)
D4T2.4E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Updates**

Room **N01**

D4T3.1		Hypohidrosis and hyperhidrosis Chairs: Smail Hadj-Rabia (Paris, France) Jacob Mashiah (Tel Aviv, Israel)
D4T3.1A	08:30	Physiology of eccrine sweat glands Smail Hadj-Rabia (Paris, France)
D4T3.1B	08:50	Congenital hypohidrosis: Ectodermal dysplasias Tor Shwayder (Detroit, United States)
D4T3.1C	09:10	Non congenital hypohidrosis Laura Fertitta (Créteil, France)
D4T3.1D	09:30	Hyperhidrosis Jacob Mashiah (Tel Aviv, Israel)
D4T3.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N01**

D4T3.2		Travel-related infectious diseases Chairs: Kenneth Tomecki (Cleveland, United States) Jose Dario Martinez Villarreal (Monterrey, Mexico)
D4T3.2A	10:15	Climate-related skin disease Mark Davis (Rochester, United States)
D4T3.2B	10:35	Global journeys and STDs George Sorin Tiplica (Bucharest, Romania)
D4T3.2C	10:55	Deadly travellers' maladies Jose Dario Martinez Villarreal (Monterrey, Mexico)
D4T3.2D	11:15	Migratory skin disease Kenneth Tomecki (Cleveland, United States)
D4T3.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **N01**

	European Society of Dermatopathology (ESDP): Dermatopathology Chairs: Gürkan Kaya (Geneva, Switzerland) Carlo Francesco Tomasini (Pavia, Italy)
14:15	Welcome
14:30	European Society of Dermatopathology Gürkan Kaya (Geneva, Switzerland)
14:45	European Diploma of Dermatopathology Carlo Francesco Tomasini (Pavia, Italy)
15:00	Test yourself - Dermatopathology quiz Carlo Francesco Tomasini (Pavia, Italy)
15:15	Test yourself - Dermatopathology quiz Gürkan Kaya (Geneva, Switzerland)
15:30	Discussion - Concluding remarks

Saturday, 20 September 2025

Track: **Updates**

Room **N04**

D4T4.1		Global Health Chair: Lucinda Claire Fuller (London, United Kingdom)
D4T4.1A	08:30	Decentralising nodulectomy for podoconiosis: Improving access and outcomes in southern Ethiopia Wendemagegn Enbiale (Wageningen, Netherlands)
D4T4.1B	08:50	Accelerating early case detection of skin neglected tropical diseases: A teledermatological solution in remote areas of Indonesia Marianne Louise Grijzen (Jakarta, Indonesia)
D4T4.1C	09:10	Impact of virtual training program for Nigerian health workers on skin neglected tropical diseases Olufolakemi Cole (Lagos, Nigeria)
D4T4.1D	09:30	A global campaign to address skin cancer prevention and management amongst persons with albinism in the tropics Lucinda Claire Fuller (London, United Kingdom)
D4T4.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N04**

D4T4.2		Chronic leg ulcers Chairs: Elena Conde (Madrid, Spain) Patricia Senet (Paris, France)
D4T4.2A	10:15	Venous ulcers Elena Conde (Madrid, Spain)
D4T4.2B	10:35	Arterial ulcers Jürg Hafner (Zurich, Switzerland)
D4T4.2C	10:55	Leg ulcers in the course of systemic diseases Patricia Senet (Paris, France)
D4T4.2D	11:15	Special focus: Children and young adults Speaker TBC
D4T4.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **N04**

	Société Française des Lasers en Dermatologie (SFLD): Medical lasers in dermatology: Clinical applications and integration strategies Chairs: Muriel Creusot (Plancenoit, Belgium) Nathalie Gral (France)
14:15	CO₂ laser treatment of ingrown toenails François Will (France)
14:30	Laser management of hematomas Audrey Melin (France)
14:45	Beyond aesthetics: CO₂ and Q-switched lasers in medical dermatology Samy Fenniche (Casablanca, Tunisia)
15:00	Clinical contributions Fernando Valenzuela (Santiago, Chile)
15:15	Epigenetics and laser therapy: Emerging intersections Diala Haykal (Palaiseau, France)
15:30	Panel discussion & audience Q&A

Track: **Subspecialty**

Room **N04**

	Société Française d'Esthétique en Dermatologie (SFED): Bridging aesthetic and medical dermatology: Contemporary clinical perspectives Chairs: Muriel Creusot (Plancenoit, Belgium) Martine Baspeyras (Bordeaux, France)
16:00	Tranexamic acid injections in the management of melasma Rym Benmously (Ariana, Tunisia)
16:15	Aesthetic vigilance: Managing filler-related complications Martine Baspeyras (Bordeaux, France)
16:30	The role of hyaluronic acid in acne scar management Hans-Joachim Laubach (Geneva, Switzerland)
16:45	Photodynamic therapy for photorejuvenation Muriel Creusot (Plancenoit, Belgium)
17:00	Botulinum toxin and scarring: Finding the right balance Hugues Cartier (Arras, France)
17:15	Panel discussion & audience interaction

Saturday, 20 September 2025

Track: **Updates**

Room **N02**

D4T5.1		Joint EADV/JDA - Faces of skin diseases from East to West Chairs: Branka Marinovic (Zagreb, Croatia) Manabu Fujimoto (Osaka, Japan)
D4T5.1A	08:30	Nagashima-type palmoplantar keratosis (SERPINB7-pEDD) Akiharu Kubo (Kobe, Japan)
D4T5.1B	08:50	Darier's disease Wolfram Hoetzenecker (Linz, Austria)
D4T5.1C	09:10	Ofuji disease Kenji Kabashima (Kyoto, Japan)
D4T5.1D	09:30	Sezary syndrome Maarten Vermeer (Leiden, Netherlands)
D4T5.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N02**

D4T5.2		Photodermatology Chairs: Harvey Lui (Vancouver, Canada) Mariateresa Rossi (Brescia, Italy)
D4T5.2A	10:15	Photoprotection in 2025 Harvey Lui (Vancouver, Canada)
D4T5.2B	10:35	Solar urticaria Angelika Hofer (Graz, Austria)
D4T5.2C	10:55	Chronic actinic dermatitis Hiva Fassihi (London, United Kingdom)
D4T5.2D	11:15	Phototherapy in challenging areas Mariateresa Rossi (Brescia, Italy)
D4T5.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **N02**

	International Peeling Society (IPS): Innovations on chemical peeling Chairs: Fotini Bageorgou (Athens, Greece) Hugues Cartier (France) Ofir Artzi (Tel Aviv, Israel) Felipe Ribeiro (São Paulo, Brazil)
14:15	Chemical peeling for difficult indications Fotini Bageorgou (Athens, Greece)
14:27	The cardiac influence of Phenol Oliver Kreyden (Muttentz, Switzerland)
14:39	Optimizing outcomes: How to prevent and treat hyperpigmentation after peels Felipe Ribeiro (São Paulo, Brazil)
14:51	Chemical peels vs. laser resurfacing: Is one better than the other? Monica Darmanescu (Bucharest, Romania)
15:03	The role of chemical peels in scar revision Christina Fotiadou (Thessaloniki, Greece)
15:15	Chemical peeling of rosacea – a no-go? Claudia Borelli (Tübingen, Germany)
15:27	Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **N02**

	International Peeling Society (IPS): Innovations on chemical peeling Chairs: Fotini Bageorgou (Athens, Greece) Hugues Cartier (France) Ofir Artzi (Tel Aviv, Israel) Felipe Ribeiro (São Paulo, Brazil)
16:00	Newer skin indications for peeling for darker skins - 2025 Mukta Sachdev (India)
16:12	Peeling and LC-OCT: What happens beneath the skin? Hugues Cartier (France)
16:24	Current medical indications for chemical peels Lidia Comba Pérez Pérez (Vigo, Spain)
16:36	The pigmentation puzzle: Combining peels with precision to address melanogenesis, cellular crosstalk, and skin integrity Ofir Artzi (Tel Aviv, Israel)
16:48	The pigmentation puzzle: Combining peels with precision to address melanogenesis, cellular crosstalk, and skin integrity Peter Velthuis (Rotterdam, Netherlands)
17:00	Q&A and Panel discussion

Saturday, 20 September 2025

Track: **Updates**

Room **N03**

D4T6.1		Botulinum Toxin II, Advanced Chairs: Christopher Rowland Payne (London, United Kingdom)
D4T6.1A	08:30	Advanced BTX lifting possibilities Liliana Sytnyk (Kyiv, Ukraine)
D4T6.1B	08:50	Treatment of facial asymmetry with BTX Eckart Haneke (Freiburg im Breisgau, Germany)
D4T6.1C	09:10	BTX for androgenetic alopecia Inigo De Felipe Y Garate (Barcelona, Spain)
D4T6.1D	09:30	BTX combination treatments Hassan Galadari (Dubai, United Arab Emirates)
D4T6.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **N03**

D4T6.1		Aesthetic dermatology for medical indications Chairs: Klaus Fritz (Landau, Germany)
D4T6.2A	10:15	Lasers for rosacea and rhinophyma Hugues Cartier (Arras, France)
D4T6.2B	10:35	Lasers for the treatment of genodermatoses Albert Wolkerstorfer (Amsterdam, Netherlands)
D4T6.2C	10:55	Lasers and light treatment of hypopigmentations and vitiligo Klaus Fritz (Landau, Germany)
D4T6.2D	11:15	New and future indications of lasers in medical dermatology Dieter Manstein (Charlestown, United States)
D4T6.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **N03**

	International Eczema Council (IEC): AD versus CTCL: Challenges and novel insights Chairs: Yael Leshem (Tel Aviv, Israel) Patrick Brunner (New York, United States)
14:15	Introduction and welcome from the IEC Alan Irvine, MD, DSC (Dublin, Ireland)
14:25	Programme overview Yael Leshem (Tel Aviv, Israel) Patrick Brunner (New York, United States)
14:30	CTCL: The great eczema mimicker in adults Pietro Quaglino (TORINO, Italy)
14:50	CTCL: The great eczema mimicker in children Emmilia Hodak (Petah Tikva, Israel)
15:10	AD/CTCL: How to tell the two apart? Patrick Brunner (New York, United States)
15:30	Q&A

Track: **Subspecialty**

Room **N03**

	International Eczema Council (IEC): AD versus CTCL: Challenges and Novel Insights Chairs: Yael Leshem (Tel Aviv, Israel) Patrick Brunner (New York, United States)
16:00	Lymphomas & eczema therapeutics: Conventional systemics, JAK inhibitors Emmanuella Guenova (Lausanne, Switzerland)
16:25	Lymphomas & eczema therapeutics: Biologics Shamir Geller (New York, United States)
16:50	A pragmatic approach to complex cases Yael Leshem (Tel Aviv, Israel)
17:10	Q&A
17:25	Programme summary & concluding remarks Yael Leshem (Tel Aviv, Israel) Patrick Brunner (New York, United States)

Saturday, 20 September 2025

Track: **Updates**

Room **S01**

D4T7.1		Red flags and emergencies in dermatology Chairs: Lars E. French (Munich, Germany) Alexander Navarini (Basel, Switzerland)
D4T7.1A	08:30	Mast cell activation syndrome Frank Siebenhaar (Berlin, Germany)
D4T7.1B	08:50	Toxic epidermal necrolysis Lars E. French (Munich, Germany)
D4T7.1C	09:10	Erythroderma Alexander Navarini (Basel, Switzerland)
D4T7.1D	09:30	Necrotising fasciitis Olivier Chosidow (Paris, France)
D4T7.1E	09:50	Discussion, Q&A

Track: **Updates**

Room **S01**

D4T7.2		Actinic keratosis Chairs: Susana Puig (Barcelona, Spain) Maria Concetta Fagnoli (Rome, Italy)
D4T7.2A	10:15	Genomic and transcriptomic pathways Susana Puig (Barcelona, Spain)
D4T7.2B	10:35	Management of field cancerization Hans Christian Wulf (Vedbæk, Denmark)
D4T7.2C	10:55	Actinic cheilitis Ondřej Kodet (Prague, Czech Republic)
D4T7.2D	11:15	New treatment options Maria Concetta Fagnoli (Rome, Italy)
D4T7.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **S01**

	European Women Dermatological and Venereological Society (EWDVS): Women's dermatologic diseases, health care delivery, and socioeconomic barriers Chairs: Carmen Rodríguez Cerdeira (Vigo, Spain) Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic) Monika Fida (Tirana, Albania)
14:15	Female underrepresentation in dermatological research Carmen Rodríguez Cerdeira (Vigo, Spain)
14:25	LGBT health in dermatology Teerapong Rattananukrom (Bangkok, Thailand)
14:35	Common complications in the aesthetic and non-aesthetic use of botulinum toxin type A Monika Fida (Tirana, Albania)
14:45	Epidemiology, clinical diagnosis, and management of cutaneous infections caused by atypical Mycobacteria Leonardo Mayorga-Garibaldi (Jalisco, Mexico)
14:55	Female pattern hair loss: Beyond minoxidil – What's new? Roxanna Sadoughifar (Tehran, Iran)
15:05	Botulinum toxin type A in depression: A novel frontier in psychodermatological treatment Solange Reynoso (Dominican Republic)
15:15	Convergence of chronic infections: Molecular approach to a case of mycetoma and leprosy José Guillermo Pereira-Brunelli (San Lorenzo, Paraguay)
15:25	Tinea manuum: A comprehensive overview Roberto Arenas Guzman (Ciudad de Mexico, Mexico)
15:35	Questions and Answers Carmen Rodríguez Cerdeira (Vigo, Spain) Francisca Flores de la Cuadra-Galán (San Salvador, El Salvador)

Saturday, 20 September 2025

Track: **Training and education**

Room **S02**

D4T8.1		Paediatric dermatology: Pathogenesis Chairs: Christine Bodemer (Paris, France) Andrea Diociaiuti (Rome, Italy)
D4T8.1A	08:30	Keratinization disorders Lisa Weibel (Zurich, Switzerland)
D4T8.1B	08:50	Mosaic skin diseases Suzanne Pasmans (Rotterdam, Netherlands)
D4T8.1C	09:10	Autoinflammatory skin diseases Christine Bodemer (Paris, France)
D4T8.1D	09:30	Epidermolysis bullosa Andrea Diociaiuti (Rome, Italy)
D4T8.1E	09:50	Discussion, Q&A

Track: **Training and education**

Room **S02**

D4T8.2		Paediatric dermatology: Management Chairs: Lucero Noguera (Madrid, Spain) Juliette Mazereeuw-Hautier (Toulouse, France)
D4T8.2A	10:15	Erythroderma in children Hagen Ott (Munich, Germany)
D4T8.2B	10:35	Vulvar diseases in children Ifigenia Spanoudi Kitrimi (Woluwe Saint-Lambert, Belgium)
D4T8.2C	10:55	Skin tumours in infants Lucero Noguera (Madrid, Spain)
D4T8.2D	11:15	Hair diseases Juliette Mazereeuw-Hautier (Toulouse, France)
D4T8.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **S02**

	European Society for Dermatology and Psychiatry (ESDaP): Psychodermatology Chairs: Francoise Poot (Bruxelles, Belgium) Mohammad Jafferany (Saginaw, United States) Tanyo Tanev (Stara Zagora, Bulgaria)
14:15	A mirror of the mind? Exploring its deeper meaning Saif Najeeb (Prague, Czech Republic) Zahraa Al Hamwi (Prague, Czech Republic)
14:25	Somatosensory amplification in dermatology Razvigor Darlenski (Sofia, Bulgaria)
14:36	Skin under suggestion: Brief hypnotic approaches in psychodermatology Tanyo Tanev (Stara Zagora, Bulgaria)
14:47	Psychological aspects in occupational dermatology Elke Weisshaar (Heidelberg, Germany) Maurice Waitek (Heidelberg, Germany)
14:58	New data on stigmatization in psoriasis based on the data of the observational cross-sectional multicenter European study Adam Reich (Rzeszów, Poland)
15:09	ESDAP consensus on the management of trichotillomania Maria-Angeliki Gkini (London, United Kingdom)
15:20	Expert consensus on delusional infestation: Results from a Delphi study Patrick Kemperman (Haarlem, Netherlands)
15:31	Delusional infestation: Alleged pathogens from a large cohort Sophie Lepping (Merthyr Tydfil, United Kingdom)

Saturday, 20 September 2025

Track: **Subspecialty**

Room **S02**

	European Society for Dermatology and Psychiatry (ESDaP): Psychodermatology Chairs: Francoise Poot (Bruxelles, Belgium) Mohammad Jafferany (Saginaw, United States) Tanyo Tanev (Stara Zagora, Bulgaria)
16:00	Pediatric psychodermatological conditions Chakiri Radia (Agadir, Morocco)
16:10	Psychosocial comorbidities of atopic dermatitis in children and adolescents Mark Koh (Singapore, Singapore)
16:21	Assessing suicidality in UAE dermatology outpatients: Results from a cross-sectional study Dimitre Dimitrov (Abu Dhabi, United Arab Emirates)
16:32	Exploring the psychological burden and associated psychiatric manifestations in rosacea Mohammad Jafferany (Saginaw, United States)
16:43	Neuroimaging the itch experience: Evidence from functional brain imaging studies Wei Qiang Chng
16:54	The influence of social media on self-perception in patients with skin disease Vitaliia Popovych (Uzhhorod, Ukraine)
17:05	Psychodermatology in China: Bridging research advances and clinical practice Haiping Zhang (Beijing, China)
17:16	Beyond the mirror: Psychodermatology in the Gulf – a culturally adapted therapeutic education model for the Arab world Alia Galadari (Dubai, United Arab Emirates)

Saturday, 20 September 2025

Track: **Training and education**

Room **S03**

D4T9.1		Infectious diseases Chairs: Antoine Bertolotti (Saint Pierre, Reunion) Roni Dodiuk-Gad (Haifa, Israel)
D4T9.1A	08:30	Necrotising skin infections Nicolas de Prost (Créteil, France)
D4T9.1B	08:50	Staphylococcal scalded skin syndrome Roni Dodiuk-Gad (Haifa, Israel)
D4T9.1C	09:10	Viral skin infections Arjen Fokko Nikkels (Liege, Belgium)
D4T9.1D	09:30	Mycobacterial infections Antoine Bertolotti (Saint Pierre, Reunion)
D4T9.1E	09:50	Discussion, Q&A

Track: **Training and education**

Room **S03**

D4T9.2		Skin in internal medicine Chairs: Evangelia Papadavid (Athens, Greece) Martine Grosber (Brussels, Belgium)
D4T9.2A	10:15	Kidney disorders Luc Mouthon (Paris, France)
D4T9.2B	10:35	Diabetes Slavomir Urbancek (Banska Bystrica, Slovakia)
D4T9.2C	10:55	Thyroid disorders Martine Grosber (Brussels, Belgium)
D4T9.2D	11:15	Haematological malignancies Evangelia Papadavid (Athens, Greece)
D4T9.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **S03**

	Worldwide Dermatology Collaboration (WDC): Global dermatology in practice: cutting-edge non-surgical therapies in hair restoration, skin rejuvenation & psychodermatology Chairs: Torello M. Lotti (Rome, Italy) Patrick Treacy (Dublin, Ireland) Mohammed Jafferany (Michigan, United States)
14:15	Frontal fibrosing alopecia: Diagnosis, management, and challenges in hair restoration surgery Roxanna Sadoughifar (Tehran, Iran)
14:25	Autologous exosomes for non-surgical hair restoration Patrick Treacy (Dublin, Ireland)
14:35	Regenerative modalities in hair restoration Gulhima Arora (New Delhi, India)
14:45	Laser treatments for alopecia areata Mohammed Rachid Hamlaoui (Algiers, Algeria)
14:55	Complications of laser: Why and how to prevent Anurag Tiwari (Bhopal, India)
15:05	Psychiatric aspects of hair disorders Mohammed Jafferany (Michigan, United States)
15:15	Therapeutic education in atopic dermatitis Samira Zobiri (Algiers, Algeria)
15:25	Vascular filler complications and management Ulaş Güvenç (Mersin, Türkiye)
15:35	Beyond ablation: Exploring the non-surgical applications of cold plasma in dermatological aesthetics Fahimeh Abdollahimajd (Tehran, Iran)

Saturday, 20 September 2025

Track: **Subspecialty**

Room **S03**

	Worldwide Dermatology Collaboration (WDC): Global dermatology in practice: Cutting-edge non-surgical therapies in hair restoration, skin rejuvenation & psychodermatology Chairs: Torello M. Lotti (Rome, Italy) Patrick Treacy (Dublin, Ireland) Mohammed Jafferany (Michigan, United States)
16:00	Management of post-rejuvenation facial dyschromias in skin of colour Johannes Dayrit (Silang, Philippines)
16:10	Innovative use of 5-FU, bleomycin, and methotrexate Sweta Rambhia (Mumbai, India)
16:20	Updates in laser for hyperpigmentation Henry Foong (Ipoh, Malaysia)
16:30	Vitiligo breaking news Torello M. Lotti (Rome, Italy)
16:40	Skin rejuvenation: Techniques and realities Amit Luthra (New Delhi, India)
16:50	Rapamycin + bleomycin for AVMs Aïcha Salhi (Algiers, Algeria)
17:00	Do nails age? Can I keep them young? Eckart Haneke (Freiburg im Breisgau, Germany)
17:10	AI-assisted vascular and CO2 laser therapy: Future targets optimising parameters of personalised care Faisal Dubash (Dundee, United Kingdom)
17:20	Mind over matter: The use of nerve desensitization techniques in dermatology Sharad Paul (Auckland, New Zealand)

Saturday, 20 September 2025

Track: **Miscellaneous**

Room **S04**

D4T10.1		History of dermatology Chairs: Michael Lukas Geiges (Kloten, Switzerland) Lawrence Chukwudi Nwabudike (Bucharest, Romania)
D4T10.1A	08:30	Of rickets, sunshine, goats and the Nobel prize: History of vitamin D discovery Lawrence Chukwudi Nwabudike (Bucharest, Romania)
D4T10.1B	08:50	Skin colour and diversity in dermatology: A historical perspective Antoine David Petit (Paris, France)
D4T10.1C	09:10	Images in dermatology: From iconodiagnosis to AI-based algorithms Patricia Deps (Vitoria, Brazil)
D4T10.1D	09:30	Women in the history of dermatology: Gender and syphilis in the early 20th century Michael Lukas Geiges (Kloten, Switzerland)
D4T10.1E	09:50	Discussion, Q&A

Track: **Miscellaneous**

Room **S04**

D4T10.2		Implications of climate change and environmental challenges Chairs: Hok Bing Thio (Rotterdam, Netherlands) Dennis Niebel (Regensburg, Germany)
D4T10.2A	10:15	Climate change, skin health and disease Eva R. Parker (Nashville, United States)
D4T10.2B	10:35	Global warming and allergic diseases: Fostering climate resilience by policy making Claudia Traidl-Hoffmann (Augsburg, Germany)
D4T10.2C	10:55	Environmental footprint of dermatologic surgery Rachel Abbott (Cardiff, United Kingdom)
D4T10.2D	11:15	EADV members' attitude towards climate change David de Berker (Bristol, United Kingdom)
D4T10.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Subspecialty**

Room **S04**

	IDEOM outcome measures in dermatology Chair: Alice B. Gottlieb (New York, United States)
14:15	Welcome and introductions Alice B. Gottlieb (New York, United States)
14:20	Geriatric dermatology update Daniel Butler (San Francisco, United States)
14:25	Itch update Sonja Ständer (Münster, Germany)
14:35	IDEOM MSK-Q for psoriatic disease Joseph F. Merola (Dallas, United States)
14:40	Screening and treating to target for psoriatic arthritis using the PEST and PSAID instrument Alice B. Gottlieb (New York, United States)
14:50	Musculoskeletal (MSK) symptoms in HS and potential value of the IDEOM MSK-Q Alice B. Gottlieb (New York, United States)
15:00	Development and validation of HAF-16: A standardized digital intake form for HS management Tarannum Jaleel (Durham, United States)
15:10	Acne update Jerry Tan (Ontario, Canada)
15:20	Vitiligo update Arnon Dov Cohen (Hod Hasharon, Israel) Nanette Silverberg (New York, United States)
15:30	CTD Update Joseph F. Merola (Dallas, United States)
15:35	Q&A and closing remarks

Saturday, 20 September 2025

Track: **Miscellaneous**

Room **S05**

D4T11.1		Clinical cases presented by residents Chair: Marie-Aleth Richard (Marseille, France)
D4T11.1A	08:30	Case 1 Lionel Fourcade (Marseille, France)
D4T11.1B	08:39	Case 2 Alia Ghorfi (Marseille, France)
D4T11.1C	08:48	Case 3 Chiara Bocchi (Ferrara, Italy)
D4T11.1D	08:57	Case 4 Georgia Pappa (Athens, Greece)
D4T11.1E	09:06	Case 5 Marco Spadafora (Modena, Italy)
D4T11.1F	09:15	Case 6 Andrea Danese (Verona, Italy)
D4T11.1G	09:24	Case 7 Alexandra Dobre (Bucharest, Romania)
D4T11.1H	09:33	Case 8 Irina Struna (Bucharest, Romania)
D4T11.1I	09:42	Case 9 Beatriz Clemente Hernández (Zaragoza, Spain)
D4T11.1L	09:51	Case 10 Francisco Martins (Coimbra, Portugal)

Track: **Miscellaneous**

Room **S05**

D4T11.2		The hot seat: Local residents quiz the international faculty Chairs: Antonio Torrelo (Madrid, Spain) Faculty: Angelo Valerio Marzano (Milan, Italy) Eniko Sonkoly (Uppsala, Sweden) Maria del Mar Llamas Velasco (Madrid, Spain)
D4T11.2A	10:15	Case 1 Aljuhani Farrah (Amiens, France)
D4T11.2B	10:35	Case 2 Pauline Di Paola (Marseille, France)
D4T11.2C	10:55	Case 3 Valentine Guyomard (Paris, France)
D4T11.2D	11:15	Case 4 Rayan Selmani (Marseille, France)
D4T11.2E	11:35	Discussion, Q&A

Saturday, 20 September 2025

Track: **Miscellaneous**

Room **S06**

D4T12.1		Impact of the climate change in dermatology Chairs: Eva R. Parker (Nashville, United States) Susana Puig (Barcelona, Spain)
D4T12.1A	08:30	Climate change, medicine, and dermatology – from the AAD to EADV Mark Davis (Rochester, United States)
D4T12.1B	08:50	Impact of climate change and air pollution on skin ageing and cancer Susana Puig (Barcelona, Spain)
D4T12.1C	09:10	The environmental impact on skin care: Microplastics and more Dennis Niebel (Regensburg, Germany)
D4T12.1D	09:30	Impact of climate change on skin infections Eva R. Parker (Nashville, United States)
D4T12.2E	09:50	Discussion, Q&A

Track: **Miscellaneous**

Room **S06**

D4T12.2		Tropical dermatology interactive quiz Chairs: Antoine Bertolotti (Saint Pierre, Reunion) Lara Valeska Maul- Duwendag (Zurich, Switzerland)
D4T12.2A	10:15	Clinical cases 1 Romain Blaizot (Cayenne, French Guiana)
D4T12.2B	10:30	Clinical cases 2 Niels Horst (Edegem, Antwerpen, Belgium)
D4T12.2C	10:45	Clinical cases 3 Lara Valeska Maul-Duwendag (Zurich, Switzerland)
D4T12.2D	11:00	Clinical cases 4 Rüdiger Panzer (Rostock, Germany)
D4T12.2E	11:15	Clinical cases 5 Antoine Bertolotti (Saint Pierre, Reunion)
D4T12.2F	10:15	Discussion, Q&A

Saturday, 20 September 2025

Track: **Miscellaneous**

Room **W05-W06**

D4T13.1		Nutrition and dermatology Chairs: Jan-Christoph Simon (Leipzig, Germany)
D4T13.1A	08:30	Nutrition and psoriasis Jan-Christoph Simon (Leipzig, Germany)
D4T13.1B	08:50	Nutrition and skin cancer Alpaslan Tasdogan (Essen, Germany)
D4T13.1C	09:10	Nutrition and skin ageing Apostolos Pappas (Branchburg, United States)
D4T13.1D	09:30	Food allergies, nutrition, and atopic dermatitis Peter Lio (Chicago, United States)
D4T13.1E	09:50	Discussion, Q&A

Track: **Miscellaneous**

Room **W05-W06**

D4T13.2		Global skin disease atlases Chairs: Christopher E. M. Griffiths (Manchester, United Kingdom) Carsten Flohr (London, United Kingdom)
D4T13.2A	10:15	Introduction Christopher E. M. Griffiths (Manchester, United Kingdom)
D4T13.2B	10:20	Global psoriasis atlas Christopher E. M. Griffiths (Manchester, United Kingdom)
D4T13.2C	10:40	Global atopic dermatitis atlas Carsten Flohr (London, United Kingdom)
D4T13.2D	11:00	Global hidradenitis suppurativa atlas Gregor Borut Jemec (Roskilde, Denmark)
D4T13.2E	11:20	Global vitiligo atlas Khaled Ezzedine (Créteil, France)
D4T13.2F	11:40	Discussion and closing

Saturday, 20 September 2025

Track: Allied healthcare professionals workshop

Room W05-W06

D4T13.3		Skin cancer nursing Chairs: Arjen Fokko Nikkels (Liege, Belgium) Cathelijn den Hartog - Jorissen (Rotterdam, Netherlands)
D4T13.3A	14:15	The increasing role of dermatology nurse specialists in dermato-oncology Corinne Chapelier (Liege, Belgium) Arjen Fokko Nikkels (Liege, Belgium)
D4T13.3B	14:45	Hedgehog inhibitors for skin cancer Cathelijn den Hartog - Jorissen (Rotterdam, Netherlands)
D4T13.3C	15:15	The establishment of an Advanced Nurse Practitioner (ANP) led dermoscopy and skin cancer service in Ireland Bernie Finneran (Roscommon, Ireland)

Track: Allied healthcare professionals workshop

Room W05-W06

D4T13.3		Developing specialist nurses in dermatology Chairs: Corinne Scicluna-Ward (Msida, Malta) Lisa McGovern (Surrey, United Kingdom)
D4T13.4A	16:00	Development of the specialist nurse role Corinne Scicluna-Ward (Msida, Malta)
D4T13.4B	16:20	Specialist nursing - the Spanish experience Juana De La Torre Aboki (Alicante, Spain)
D4T13.4C	16:40	Specialist nursing - the UK experience Lisa McGovern (Surrey, United Kingdom)
D4T13.4D	17:00	Specialist nursing - the Belgian experience Elfie Deprez (Sint-Denijs-Westrem, Belgium)
D4T13.4E	17:20	Discussion, Q&A

Saturday, 20 September 2025

Track: **Miscellaneous**

Room **W03-W04**

D4T14.1		Task Force highlights Chairs: Paola Pasquali (Cambrils, Spain) Franco Rongioletti (Milan, Italy)
D4T14.1A	08:30	Teledermatology 1: Digital teledermoscopy for anogenital lesions Linda Tognetti (Siena, Italy)
D4T14.1B	08:44	Teledermatology 2: Digital teledermoscopy for palmoplantar lesions Elvira Moscarella (Naples, Italy)
D4T14.1C	08:58	Teledermatology 3: Current state of usage in Europe Paola Pasquali (Cambrils, Spain)
D4T14.1D	09:12	Dermatopathology 1: New and emerging entities in infectious dermatology Maria Teresa Fernández-Figueras (Barcelona, Spain)
D4T14.1E	09:26	Dermatopathology 2: New and emerging entities in paediatric dermatology Sylvie Fraitag (Paris, France)
D4T14.1F	09:40	Dermatopathology 3: New and emerging entities in inflammatory dermatology Franco Rongioletti (Milan, Italy)
D4T14.1G	09:54	Discussion Q&A

Track: **Miscellaneous**

Room **W03-W04**

D4T14.2		Task force highlights Chairs: Gürkan Kaya (Geneva, Switzerland) Georges Reuter (Strasbourg, France)
D4T14.2A	10:15	Skin ageing 1: Clinical, histological and pathophysiological aspects Gürkan Kaya (Geneva, Switzerland)
D4T14.2B	10:29	Skin ageing 2: Sensitive skin Joachim W. Fluhr (Berlin, Germany)
D4T14.2C	10:43	Skin ageing 3: Prevention Maria-Angeliki Gkini (London, United Kingdom)
D4T14.2D	10:57	Office management 1: Implementation of new technologies Georges Reuter (Strasbourg, France)
D4T14.2E	11:11	Office management 2: Coping with skin cancer flood Mihaela Leventer (Bucharest, Romania)
D4T14.2F	11:25	Office management 3: Role of qualified assistants Monika Gniadecka (Herlev, Denmark)
D4T14.2G	11:39	Discussion Q&A


Practical workshops

All workshops require a pre-registration and a pre-payment. Class sizes are limited, and registrants are accepted on a first-paid, first-served basis.

More info eadv.org/congress/scientific/workshops

References to brands: Commercial names of medical devices/software/equipment may appear in this content because they are linked to specific medical procedures, which are the focus of this training material. Other products in the market can be used to perform the aforementioned medical procedures. The educational provider does not endorse any particular product.

Wednesday 17 September 2025




Dermal Fillers

Room W07 8:30 – 11:45

Chair: Bertrand Richert (BE)

Instructors: Pauline Lecerf (BE), Elena Rossi (IT)



STI diagnosis and treatment

Room W08 8:30 – 11:45

Chair: Georg Stary (AT)

Instructors: Valeska Padovese (IT), Gemma Martin Ezquerro (ES)



Allergology: Skin environmental induced contact dermatitis and urticaria

Room W07 14:15 – 17:45

Chair: Ana Maria Gimenez Arnau (ES)

Instructors: Sabine Altrichter (AT), Mette Sommerlund (DK)



Basics of ultrasound imaging in dermatology

Room W08 14:15 – 17:45

Chair: Fernando Alfageme Roldan (ES)

Instructors: Ximena Wortsman (CL), Hugues Cartier (FR), Valentina Dini (IT), Antonio Martorell (ES), Armanda Onderdijk (NL), Diana Crisan (DE), Peter Velthuis (NL)

Thursday, 18 September 2025



Playing with AI in dermatology

Room W07 8:30 – 11:45

Chair: Harald Kittler (AT)

Instructors: Alexander Navarini (CH), Philipp Tschandl (AT)



Wound healing

Room W08 8:30 – 11:45

Chair: Elena Conde Montero (ES)

Instructors: George Sorin Tiplica (RO), Damien Pastor (CH), Kirsi Isoherranen (FL)




Dermoscopy – Practical and conceptual (I)

Room W07 14:15 – 17:45

Chair: Giuseppe Argenziano (IT)

Instructors: Aimilios Lallas (GR), Gabriella Brancaccio (IT), Michela Starace (IT)



Confocal Microscopy and LC-OCT

Room W08 14:15 – 17:45

Chairs: Mariano Suppa (BE), Marco Ardigò (IT), Elisa Cinotti (IT), Linda Tognetti (IT)

Instructors: Salvador González (ES), Mario Valenti (IT), Lucas Boussingault (BE)

Friday, 19 September 2025



Dermoscopy – Practical and conceptual (II)

Room W07 8:30 – 11:45

Chair: Giuseppe Argenziano (IT)

Instructors: Aimilios Lallas (GR), Gabriella Brancaccio (IT), Michela Starace (IT)




Surgery – Beginners

Room W08 8:30 – 11:45

Chair: Victoria Marmgren (SE)

Instructors: Marcus Muche (NL), Frida Appelqvist (SE), Stephanie Steeman (NL)




Phlebology for beginners

Room W07 14:15 – 17:45

Chair: Felizitas Pannier (DE)

Instructors: Laura Fischer (DE), George Sorin Tiplica (RO), Eberhard Rabe (DE)



Surgery - Intermediate

Room W08 14:15 – 17:45

Chair: Victoria Marmgren (SE)

Instructors: Marcus Muche (NL), Frida Appelqvist (SE), Stephanie Steeman (NL)

Saturday, 20 September 2025



Laser treatment for beginners

Room W07 8:30 – 11:45

Chair: Albert Wolkerstorfer (NL)

Instructors: Pablo Boixeda (ES), Keyvan Nouri (US)



Use of Botulinum Toxin in cosmetic and medical dermatology

Room W08 8:30 – 11:45

Chair: Samira Baharlou (BE)

Instructors: Armanda Onderdijk (NL), Sanjay Rajpara (UK)



Laser treatment for beginners

Room W07 14:15 – 17:45

Chair: Albert Wolkerstorfer (NL)

Instructors: Pablo Boixeda (ES), Keyvan Nouri (US)



Talk that heals: How better communication drives better patient outcome

Room W08 14:15 – 15:30

Chair: Josef De Guzman (PH), Aleksandra Lesiak (PL), Justyna Ceryn (PL)

Instructors: Catherine van Montfrans (NL), Christine Bundy (GB), Jacek Szepietowski (PL)

Patient organisations area

EADV actively works to develop a synergic action between the patient community and key healthcare providers.

We invite all Congress attendees to visit the Patient Organisations Area taking place from 17 to 20 September 2025 on level 7.2. In this dedicated area you have the opportunity to meet with leaders of the represented patient organisations, discuss activities of common interest, explore different perspectives, needs and roles and how to fit them into the larger world of European dermatology.

We acknowledge and thank the belowpatient organisations for their commitment and involvement during this year's Congress.



General information

Organiser's address and contact

European Academy of Dermatology & Venereology
Via S. Balestra 22B, 6900 Lugano – Switzerland

Website: eadv.org

Congress venue

Paris Expo Porte de Versailles
1 Pl. de la Porte de Versailles, 75015 Paris

Website: viparis.com/nos-lieux/paris-expo-porte-de-versailles

Venue opening hours

- Tuesday 16 September 14:00 – 18:00 *
- Wednesday 17 September 07:00 – 22:30
- Thursday 18 September 07:00 – 21:30
- Friday 19 September 07:00 – 20:30
- Saturday 20 September 07:00 – 19:00

*Badge pick-up area and Speaker preview room only

Destination management company

Colloquium Paris / C'accommodation

Official booking platform: <https://eadv.org/congress/about/accommodation/>

Internet access / Wi-Fi

Free Wi-Fi access will be available in the common areas of the venue and in the session rooms.

Network: EADV2025

General information

Onsite facilities and opening hours

Badge pick-up area

The badge pick-up area is located in the Hall 7.1 and it will be open as follows:

- Tuesday 16 September 14:00 – 18:00
- Wednesday 17 September 07:30 – 18:00
- Thursday 18 September 07:30 – 16:30
- Friday 19 September 07:30 – 16:30
- Saturday 20 September 07:30 – 16:00

MyEADV area

The MyEADV area is located in Hall 7.2.1.

We invite you to visit the MyEADV booth dedicated to showcasing the diverse offerings and initiatives of the European Academy of Dermatology and Venereology (EADV). Our booth is your go-to destination for comprehensive information on EADV Membership, educational opportunities, and our journals JEADV and JEACPV. Additionally, we are proud to highlight our ongoing sustainability efforts. Whether you're a current member or new to EADV, this space is designed for you to connect with our membership representatives and explore the full spectrum of benefits and resources that EADV has to offer.

Join us at MyEADV and discover how EADV is advancing the field and supporting its community.

Speaker preview room

The speaker preview room is in Hall 7.1 and will be open as follows:

- Tuesday 16 September 14:00 – 18:00
- Wednesday 17 September 07:30 – 18:00
- Thursday 18 September 07:30 – 17:00
- Friday 19 September 07:30 – 17:00
- Saturday 20 September 07:30 – 16:00

All presentations must be in English. Speakers should also verify in the online programme that the name of the room and time of session have not changed.

Speakers must upload their presentation 3 hours (minimum) before the lecture if not already uploaded.

Speakers with a presentation during the first time slot of the morning are requested to upload their PowerPoint presentation the day before.

General information

Official language

English is the official language of the EADV Congress. No simultaneous translation will be provided at any EADV scientific session.

Scientific sessions

The Scientific Session rooms for the EADV Congress are located in Hall 7.3. Please refer to the [floor plans](#) for orientation.

Seating is regulated on a first-come, first-served basis. We recommend you go to the session room well in advance of the session to ensure your place. Due to safety regulations, the organisers will close the access to the session if all seats are occupied. Delegates are not permitted to stand in the aisles of the session rooms.

Recording during scientific sessions



The use of mobile phones as well as audio and video recording devices are strictly prohibited within the scientific session rooms. Please ensure that you have your mobile phone switched off when attending a session. Photography is not permitted.

Certificates and accreditation

All registered participants will be able to download their certificates online based on their level of engagement:

- A **Certificate of Attendance** is available for all registered participants who have a valid registration badge and attended at least 1 session.
- A **CME-CPD Certificate** is available for all participants who actively attended scientific sessions, have their badge scanned and completed the online evaluation forms.
- An **ePoster Certificate** is available for all leading ePoster authors.
- An **Oral presentation Certificate** is available for all presenters of an abstract accepted for an oral presentation.
- A **Speaker presentation Certificate** is available for all presenters who have delivered a lecture in a scientific session
- A **Workshop Certificate** is available for all for all Workshop participants.

The certificates are not sent out automatically. They can be downloaded from our platform by entering the [email address and password used during the registration process](#) OR the [EADV member log-in details](#) (if a EADV member).

Platform URL: eadv.org/congress/account

General information

Abstracts and ePosters

Accepted abstracts will be made available on our website eadv.org/scientific/abstract-books/

Abstracts selected for ePosters will be published as electronic posters during the Congress and will be available for viewing in the ePoster area, located in the Hall 7.3.

30 big screens are provided and configured exclusively to display the ePosters.

The ePosters can be viewed sequentially by number, submission topic or searched individually by title, key word, or author.

The ePoster area will be open as follows:

- Wednesday 17 September 07:30 – 18.30
- Thursday 18 September 07:30 – 18.30
- Friday 19 September 07:30 – 18.30
- Saturday 20 September 07:30 – 12.00

Exhibition hall

The Congress will host an exhibition hall of more than 15.000sqm, located in Hall 7.2.2. The exhibition hall can be accessed from the Atrium 7.2 and from the internal blocks.

Please note that the exhibition hall is open to Healthcare Professionals (HCPs) only, as prescription medical products will be advertised.

According to the European Union Directive 2001/83/EC (and amended version 2010/84/EU), the promotion of prescription-only medicines should be directed solely at Healthcare Professionals or any person who is authorised to prescribe or handle them.

The National French Laws, codes and regulations are applied during the EADV Congress in Paris. Therefore, access to the Exhibition halls, Satellite Symposia and Industry expert hub sessions dealing with development, research or other related to prescription medicine will be restricted to Healthcare Professionals only.

The exhibition hall will be open during the following hours:

- Wednesday 17 September 12:00 – 17:30
- Thursday 18 September 09:00 – 17:30
- Friday 19 September 09:00 – 17:30
- Saturday 20 September 09:00 – 12:00

Exhibitors can enter the exhibition hall 1 hour before and after the opening hours except for the closing time of the last day.

More info:

[Exhibitors list](#)

[Exhibition floor plans](#)

General information

Other services

Cloakroom - The Cloakroom is in Hall 7.1 and will be open as follows:

- Wednesday 17 September 07:30 – 22.00
- Thursday 18 September 07:30 – 21.30
- Friday 19 September 07:30 – 20.00
- Saturday 20 September 07:30 – 19.00

Lost & found - Please hand in all found items and ask for lost items at the cloakroom.

Catering facilities - Lunches and coffee breaks are not included in the registration fees. Meals and snacks can be purchased within the Congress venue during the opening hours in various catering areas.

Childcare facility

An on-site professional childcare service is located in room 741A on level 4, accessible from Atrium 7.3 through the meeting rooms area.

The service is designed for children aged 6 months to 14 years old and will be overseen by a professional childcare agency to assure you that your children will receive attentive care while you actively participate in the conference activities.

The childcare service fee is 10€ for the full day.

The childcare facility will be open as follows:

- Wednesday 17 September 08:00 – 19.30
- Thursday 18 September 08:00 – 18.00
- Friday 19 September 08:00 – 18.00
- Saturday 20 September 08:00 – 18.00

More info: eadv.org/congress/childcare-facility

First aid room and emergency numbers

In case of need please visit the First aid room managed by Cispè, located in Hall 7.2.1.

Congress emergency number: +33 1 72 72 10 36

General emergency number: 112

Closest hospital: AP-HP George Pompidou, 20 Rue Leblanc, 75015 Paris

General information

Privacy

Use of private data

The data made available through the Registration Portal for Congresses and Symposia are gathered and treated by the EADV in compliance with the Swiss regulation on data protection and the General Data Protection Regulation. We advise you to read full EADV Privacy Policy on eadv.org/privacy-policy.

Transferring the data to the industry session organiser

During the EADV Congress you have the right to transfer the data collected by EADV to another controller ("the Industry session organiser", "Industry"). It might happen through scanning a badge, QR code or other means. Each participant shall consider that by accepting any scanning of the badge, QR code or other means at any industry session at the Congress, the participant gives authorization to the EADV to transfer the data of the participant to the Industry.

The EADV is obliged to make this process possible but does not take any responsibility for what happens with the data after it is transferred to the Industry session organiser. We advise to make sure that Industry presents Privacy Policy and read it carefully. It may occur that purposes described by the Industry Exhibitor might include the promotion of pharmaceutical products and similar.

Transfer of the data from the EADV to exhibiting Industry does not mean the removal of original data from EADV. If you wish for the data to be removed or have any request or questions, please contact us at any time by writing to eadvoffice@eadv.org.

Third-party registration

The EADV does not officially support or authorize any third-party organization that creates registrations for individuals or groups. We strongly advise to register accordingly to official fees and only on EADV official websites.

Liability disclaimer

The Organisers cannot be held liable for any hindrance or disruption to the EADV Congress arising from political, social or economic events or any other unforeseen incidents beyond their control. The Organisers will accept no liability for any personal injuries sustained or for loss or damage to property belonging to Symposium participants, either during or as a result of the Congress or during all tours and events. Registration of a participant entails acceptance of these conditions.

The venue


The EADV Congress 2025 will be held at the **Paris Expo Porte de Versailles – Pavillion 7**.

➔ **Pl. de la Porte de Versailles, 75015 Paris**


Session rooms are located in Hall 7.3.

level


7.1




level
7.2


















level
7.3



level 7.4



- | | | | |
|---|----------------------------------|---|-----------------------------|
|  | Session rooms |  | Lift |
|  | Workshops |  | Escalator |
|  | Exhibition |  | Stairs |
|  | Industry expert hubs |  | Cloakroom - Lost and found |
|  | Industry meeting rooms / lounges |  | Food area |
|  | Meeting rooms |  | Cafeteria |
|  | Press area |  | Childcare |
| | |  | Working area - Seating area |

Registration

Any person who wishes to make a registration for the EADV Congress can proceed online on the registration system platform available on eadv.org/congress/registration. Fees, deadlines, policies and other important information are published at the same link.

EADV Congress ticket types

The EADV Congress offers **3 ticket options** to participate with flexibility.

The EADV Congress **Full Ticket** includes:

- Admission to live Congress Scientific Sessions
- Access to the virtual Congress Platform
- Admission to the Networking Symposium on Wednesday, 17 September 2025 (No entertainment)
- Access to Subspecialty Society Meetings
- Access to the ePoster area, MyEADV booth and Patient Advocacy Booth
- For Healthcare Professionals and Non Members (INDUSTRY) access to the Exhibition Hall
- Access to Satellite Symposia Sessions and Industry Expert Hub sessions *
- Eligibility to claim ECMEC Credits for participating in the live Scientific Sessions
- Transportation pass (read more on eadv.org/congress/about/the-venue)
- **Along with all benefits of the virtual registration**

The EADV Congress **Virtual Ticket** includes:

- Access to the virtual Congress Platform with live-streamed scientific sessions
- Access to all on-demand content until 31 December 2024
- Access to the streaming of Subspecialty Society Meetings
- Access to the online library of ePosters and abstracts
- Access to the online EADV area and Patient Organisation Hub
- For Healthcare Professionals and Non Members (INDUSTRY) access to the exhibiting company profiles
- Live-streaming of selected Satellite Symposia Sessions and Industry Expert Hub *
- Eligibility to claim ECMEC Credits for participating in the live-streamed Scientific Sessions

EADV Congress **1-Day Ticket**

A 1-Day Ticket is limited to one ticket per participant and is available for on-site attendance only. To attend the Congress for more than one day, a Full Ticket valid for the whole duration of the event needs to be purchased. Transportation pass and Virtual Access after the event are not included.

** IMPORTANT: Industry Session organisers could limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the industry session. The organising company reserved the right to refuse single categories, in particular if not adequately related to the objective and purpose of the session.*

Registration

Name badge

Registered participants are invited to print out their badge at the self-printing machines on arrival to the Registration area. The name badge is the official EADV Congress identification document and should be worn at all times in order to gain entry to the various Congress areas.

The name badge is your ticket for booked activities and sessions. Admission to other areas of the venue is not permitted without badge identification.

The badge includes a QR-code containing your full address and email. It is the participant's decision to disclose these details to the Industry Session's organisers with a scanner.

Press information for journalists and media representatives

Journalists who are working for and representing recognised news organisations are encouraged to attend the Congress as Press. To register, journalists must complete the online application, upload a valid press card, and confirm adherence to the Embargo policy.

All registered Press members must adhere to the EADV Press & Media Guidelines, Embargo Policy and Filming/Photography/Recording Policy for Professionals. Registered Press can access all scientific sessions, but not the Exhibition Area, Satellite Symposia or Industry Expert Hub sessions. Only specialised press representatives can access the Exhibition area.

For further information about registration, the EADV Press and Media Guidelines and the Embargo Policy, please visit the press page on our website eadv.org/congress/press.

Healthcare professional information and definition

1. Important note to Healthcare and Non-Healthcare Professionals

Access to the different areas and sessions of the Congress depends on Healthcare Professional status.

As a multidisciplinary audience will attend the EADV Congress, the EADV will assign different classes to Healthcare Professionals (HCPs) and Non-Healthcare Professionals (non-HCPs) to ensure compliance with the French Les Entreprises du Medicament (Leem) Rules of Professional Conduct (Dispositions Deontologiques Professionnelles (DDP)).

Specifically, HCPs are classified into the following groups: medical doctors, nursing and midwifery professionals, dentists, pharmacists, professionals involved in rehabilitation, and technical paramedical professionals.

Please read the description below to ensure that you (or your delegates) comply with the regulations in place.

EADV members are not automatically considered Healthcare Professionals. Please select the correct status (HCP or non-HCP) during registration.

2. Definition

The DDP code defines HCPs as follows:

“Healthcare Professional: An individual who is a member of a healthcare profession regulated by the French Public Health Code, regardless of whether he or she is a civil servant or public official, or any other person practising in France who, in the course of his/her professional activities, may prescribe, purchase, dispense, recommend or administer a Medicinal Product. This definition does not apply to Healthcare Professionals employed by Companies, wholesalers or distributors, excluding those whose primary occupation is that of a practising Healthcare Professional.”

Medical students are not considered Healthcare Professionals under the current guidelines and will be automatically classified as Non-Healthcare Professionals.

3. Industry sessions

Satellite Symposia and Industry Hub Sessions presenting data on the development, research, or other issues related to prescription medicine is restricted to Healthcare Professionals and Industry Participants as indicated by the Industry Session Organizer.

All promotional materials and marketing aids related to these industry sessions should be strictly limited to HCPs.

Industry Session organisers can limit participation to certain representative groups independently from the EADV recommendations if deemed imperative to achieving the session's intended purpose. The organising company reserves the right to refuse single categories, particularly if they are not adequately related to the session's objective and purpose.

The industry session organiser is responsible for compliance with the session.

EA CONGRESS
DV



PARIS
17-20 SEPTEMBER 2025

Exhibition

Exhibitor list


A.D.O. MEDICAL S.R.L.	E17
AbbVie Inc.	D02
ACM Laboratoire Dermatologique	B10
Adamo Srl	A10
ALLERGIKA Pharma GmbH	A09
Almirall	D06
ALPHASCIENCE	A17
Alta Care Laboratoires	D05
Altruist	F11
Amgen	F07
AMI Inc	A07
Aniva International	A16
Apogee Therapeutics	E11
Archidemia	C18
AURORA R&D s.r.o.	G03
Beaumed	E24
Eucerin by Beiersdorf AG	D10
belle.ai	E25
Biogen	G07
Bioneer Corp.	C17
BODERM S.A.	F18
Boehringer Ingelheim	E06
Boehringer Ingelheim	E07
BR Pharmaceuticals Ltd	C12
Brera Medical Technologies	E14
Bristol Myers Squibb	E02
Brymill Criogenic Systems	E16
Canfield Scientific GmbH	C05
Cantabria Labs	B09
Caregen Co., Ltd.	F20
CATALYSIS, S. L.	D24
CEBELIA	E23
Celldex Therapeutics	F08
Celltrion, inc.	F04
CeraVe	B03C
Chaeum Pharma GmbH	D17
Codex Labs	E15
Cortex Technology	G11
Cosmed Cosmeceuticals	C11
Courage+Khazaka electronic GmbH	E20
Daavlin	D26
Damae Medical	C16
Delfin Technologies	A02
DERMACTIVE GLOBAL LLC	B11
Dermavision Solutions	E13
DERMEDIC	B19
DermLite LLC	D14
Dermofarm SAU	B08
Dermus Ltd.	D07
DocCheck Steam GmbH	A13
Dr August Wolff Arzneimittel	E22
DUBAI DERMA	A01

Eli Lilly and Company	B01
Estée Lauder Companies - CLINIQUE	E18
EXPANSCIENCE	F19
Floxia	C15
FotoFinder Systems GmbH	D14
Galderma SA	E01
GME German Medical Engineering	F14
Grand Aespio INC	E21
HD DERMOCOSMETIC EFFICIENCY	D18
HEINE Optotechnik	D13
ILLUCO CO., LTD.	F17
Incyte	D11
Indero (Formerly Innovaderm)	D28
INMODE LTD	C14
ISDIN S.A	E09
ISISPHARMA	C09
Isocell Nutra	A20
JBP Korea Co., Ltd.	B21
JOHNSON AND JOHNSON	C08
Karger Publishers	A14
Kenvue	F05
Ker Sun	D08
KERNEL MEDICAL EQUIPMENT CO.LTD	F15
KREUSSLER PHARMA	A08
Kymera Therapeutics	B14
LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE	B03B
LABORATOIRE MOULIN ROYAL COSMETICS	G01
LABORATOIRE SVR	B16
LABORATOIRES BAILLEUL	E08
Laboratoires Dermatologiques D'Uriage	B17
Laboratoires Dermatologiques Gamarde	A18
LABORATOIRES NOREVA	B18
Laboratorios Viñas	F09
LASERVISION GmbH & Co. KG	A04
LE BONBON	G05
LEO Pharma	B02
LEO Pharma	C02
Lipotype GmbH	F03
L'Oréal Dermatological Beauty	B05
L'ORÉAL PARIS	B03D
Lumo Imaging	B23
MartiDerm	A23
MDPI - Academic Open Access Publishing since 1996	A24
medac GmbH	B04
Medicines Evaluation Unit	D04

MESOESTETIC PHARMA GROUP	D12
MetaOptima - DermEngine	A15
MKL Green Nature	A19
MoonLake Immunotherapeutics	D22
NAOS	C07
NeoStrata Company, Inc.	F06
Novartis Pharma AG	E04
Novartis Pharma AG	E05
OCULO-PLASTIK, INC.	A05
Omnidoc	E12
OPATRA LONDON	D27
Oruka Therapeutics	B15
Oxford University Press	A25
Pfizer	E03
Pierre Fabre SA	C10
PIXIENCE	F16
Professional Skin Solutions Lab	F02
QuantifiCare	A22
Regeneron	F01
Replior AB	G02
Rilastil - Istituto Ganassini S.p.A. di Ricerche Biochimiche	B06
Rilastil - Istituto Ganassini S.p.A. di Ricerche Biochimiche	B07
Sanofi	C03
Sanofi Regeneron	D01
Santor Edition	G10
Sesderma S.L	D15
Skin Science Foundation	A00
Speclipse Europe GmbH	G04
SquareMind	D09
SUN Pharmaceuticals	D23
Swiss4ward	G09
Symbio	D16
Takeda Pharmaceuticals	E10
TIZO by FALLENE,LTD.	G06
TOOsonix A/S	C13
TOPICREM - Laboratoire Dermatologique	A12
TRICOPAT	A11
Tuenda	F10
UCB	C01
UCB	C06
Unilever	D20
Unilever	D21
VICHY LABORATOIRES	B03A
VivaScope GmbH	C04
Wisepress Medical Bookshop	A26
ZERO GRAVITY SKIN	B13
ZHENGZHOU BESTVIEW LASER CO., LTD	A21
Zhuhai Yasha Medical Instrument Co., Ltd	A06

Exhibition floor plan

The exhibition is located on level 7.2. You can also view the interactive floor plan on the [EADV Congress website](#) or the interactive floor plan available on the [Virtual Platform](#)



Main sponsors

Platinum sponsors

sanofi | REGENERON®



Gold sponsors

abbvie



NOVARTIS

Johnson & Johnson



L'ORÉAL
Dermatological Beauty

GALDERMA
EST. 1981

Silver sponsors

Bristol Myers Squibb®



Pierre Fabre

Eucerin®

AMGEN



NAOS

kenvue

REGENERON®

Bronze sponsors



URIAGE
EAU THERMALE

IMAGING EXCELLENCE FROM
CANFIELD
VIVASCOPE

SVR
LABORATOIRE DERMATOLOGIQUE



cantabria labs
celebrate life



SYMBIO
RESEARCH





FotoFinder®

medac
improving human health


Workshop sponsors

Wound healing	       
Confocal microscopy and LC-OCT	 
Dermoscopy – practical and conceptual	  
Basics of ultrasound imaging in dermatology	  
Allergology: skin environmental induced contact dermatitis and urticaria	  
Phlebology for beginners	 

Acknowledgements

Sponsor of the Health Care Professional Scholarship	
Sponsor of the EADV Congress Highlights	 
Contribution to shipment and logistics	

EA
DV CONGRESS



PARIS
17-20 SEPTEMBER 2025